Clinical Development
CTL019
Protocol CCTL019B2205J / [STUDY_ID_REMOVED]
A Phase II, single arm, multicenter trial to determine the 
efficac y and safety of CTL019 in pediatric patients with 
relapsed and refractor y B-cell acute ly mphoblastic 
leukemia
Authors
Document type Amended Protocol Version
EUDRACT number 2015 -003736 -13
Version number 02 (Clean )
Development phase II
Document status Final
Release date 01-Sep-2015
Property of Novartis
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Novartis
 

Novartis Confidential Page 2
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
Table of contents
Table of contents ................................................................................................................. 2
List of appendices ................................................................................................................ 6
List of figures ...................................................................................................................... 6
List of tables ........................................................................................................................ 6
List of abbreviations ............................................................................................................ 9
Glossary  of terms ............................................................................................................... 13
Amendment 2 .................................................................................................................... 14
Amendment 1 .................................................................................................................... 21
Protocol summary :
............................................................................................................. 22
1Background ................................ ................................ ................................ ........................ 28
1.1 Overview of disease pathogenesis, epidemiology and current treatment .............. 28
1.2 Introduction to investigational treatment(s) and other study  treatment(s) ............. 28
1.2.1 Overview of CTL019 ............................................................................ 28
2Rationale ................................ ................................ ................................ ............................ 33
2.1 Study  rationale and purpose ................................................................................... 33
2.2 Rationale for the stud y design ............................................................................... 34
2.2.1 Rationale for l ymphodepletion .............................................................. 34
2.3 Rationale for dose and regimen selection .............................................................. 35
2.4
Rationale for choice of combination drugs............................................................ 36
2.5 Rationale for choice of comparator drugs ............................................................. 36
3Objectives and endpoints ................................................................................................... 36
4Study  design ................................ ................................ ................................ ...................... 40
4.1 Description of stud y design ................................................................................... 40
4.1.1 Apheresis assessment ............................................................................ 41
4.2 Definition of end of the study ................................................................................ 41
4.3 Early study termination .......................................................................................... 42
5Population .......................................................................................................................... 42
5.1 Patient population .................................................................................................. 42
5.2 Inclusion criteria .................................................................................................... 42
5.3 Exclusion criteria ................................................................................................... 44
6Treatment ................................ ................................ ................................ ........................... 46
6.1 Study  treatment ...................................................................................................... 46
6.1.1 Dosing regimen ..................................................................................... 46
 

Novartis Confidential Page 3
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
6.1.2 Ancillary  treatments .............................................................................. 50
6.1.3
Rescue medication ................................................................................ 51
6.1.4 Guidelines for continuation of treatment .............................................. 51
6.1.5 Treatment duration ................................................................................ 51
6.2 Dose escalation guidelines ..................................................................................... 51
6.2.1 Starting dose rationale ........................................................................... 51
6.2.2 Provisional dose levels .......................................................................... 51
6.2.3
Guidelines for dose escalation and determination of 
MTD/RP2D/RDE .................................................................................. 51
6.2.4 Definitions of dose limiting toxicities (DL Ts) in a Phase II Study .......52
6.2.5 Criteria
for dis continuing a patient’s participa tionin the study............. 63
6.2.6 Concomitant Therap y............................................................................ 63
6.2.7 Prohibited concomitant therap y
............................................................ 64
6.3 Patient numbering, treatment 
assignment or randomization ................................. 65
6.3.1
Patient numbering ................................................................................. 65
6.3.2 Treatment assignment ........................................................................... 65
6.3.3 Treatment blinding ................................................................................ 65
6.4 Study  drug preparation and dispensation ............................................................... 66
6.4.1 Study  drug packaging and labeling ....................................................... 66
6.4.2 Drug supply  and storage ........................................................................ 66
6.4.3 Study  drug compliance and accountabilit
y ........................................... 67
6.4.4 Disposal and destruction ....................................................................... 67
7
Visit schedule and assessments ......................................................................................... 68
7.1 Study  flow and visit schedule ................................................................................ 68
7.1.1 Screening Phase .................................................................................... 84
7.1.2 Pre-Treatment Phase ............................................................................. 86
7.1.3 Treatment and Primary  Follow -Up Phase ............................................. 87
7.1.4 Secondary Follow -Up Phase ................................................................. 91
7.1.5
Survival Follow- Up Phase .................................................................... 92
7.1.6 Long -Term Follow Up .......................................................................... 92
7.2 Assessment ty pes................................................................................................... 93
7.2.1 Efficacy  assessments ............................................................................. 93
7.2.2 Safety  and tolerability  assessments ....................................................... 95
7.2.3 Pharmacokinetics .................................................................................. 99
 

Novartis Confidential Page 4
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
 
105
7.2.5 Resource utilization ............................................................................. 105
7.2.6 Patient reported outcomes ................................................................... 105
8Safety  monitoring and reporting ...................................................................................... 106
8.1 Adverse events ..................................................................................................... 106
8.1.1
Definitions........................................................................................... 106
8.1.2
Reporting............................................................................................. 106
8.1.3 Laboratory  test abnormalities .............................................................. 108
8.1.4
Adverse events of special interest....................................................... 109
8.2 Serious adverse events ......................................................................................... 109
8.2.1
Definitions........................................................................................... 109
8.2.2
Reporting............................................................................................. 109
8.3 Emergency  unblinding of treatment assignment ................................................. 111
8.4 Pregnancies .......................................................................................................... 112
8.5 Warnings and precautions .................................................................................... 113
8.6
Data Monitoring Committee................................................................................ 113
8.7 Steering Committee ............................................................................................. 113
8.8 Independent Review Committee (I RC)............................................................... 114
9Data collection and management ..................................................................................... 114
9.1 Data confidentiality ............................................................................................. 114
9.2 Site monitoring .................................................................................................... 115
9.3
Data collection..................................................................................................... 115
9.4 Database management and quality  control ................................ .......................... 115
10Statistical methods and data anal ysis.............................................................................. 116
10.1 Analy sis sets ........................................................................................................ 116
10.1.1 Screened Set ........................................................................................ 116
10.1.2 Enrolled Set ......................................................................................... 116
10.1.3 Full Anal ysis Set ................................................................................. 116
10.1.4 Safety  Set
............................................................................................ 116
10.1.5
Per-Protocol Set .................................................................................. 117
10.1.6 Pharmacokinetic anal ysis set
............................................................... 117
10.2 Patient demographics/other base line characteristics ........................................... 117
10.3 Treatments (stud y treatment, concomitant therapies, compliance) ..................... 118
10.4 Primary  objective ................................................................................................. 118
 

Novartis Confidential Page 5
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
10.4.1 Variable ............................................................................................... 118
10.4.2 Statistical hy pothesis, model, and method of analy sis........................ 120
10.4.3 Handling of missing 
values/censoring/discontinuations ..................... 121
10.4.4 Supportive analy ses............................................................................. 121
10.5 Secondary  objectives ........................................................................................... 122
10.5.1 Key secondary  objective(s) ................................................................. 122
10.5.2 Other secondary  efficacy objectives ................................................... 122
10.5.3 Safety  objectives ................................................................................. 126
10.5.4 Pharmacokinetics ................................................................................ 129
130
130
131
131
10.7 Interim anal ysis.................................................................................................... 131
10.8
Sample size calculation........................................................................................ 133
10.9 Power for anal ysis of key secondary  variables
.................................................... 133
11Ethical con siderations and administrative procedures ................................ .................... 133
11.1 Regulatory and ethical compliance ...................................................................... 133
11.2 Responsibilities of the investigator and IRB/ IEC/SRC ....................................... 133
11.3 Informed consent procedures
............................................................................... 134
11.4 Discontinuation of the study ................................................................................ 134
11.5 Publication of study  protocol and results ................................ ............................. 134
11.6 Study  documentation, record keeping and retention of documents..................... 135
11.7 Confidentiality  of study  documents and patient records ..................................... 135
11.8
Audits and inspections......................................................................................... 136
11.9 Financial disclosures ............................................................................................ 136
12Protocol adherence .......................................................................................................... 136
12.1 Amendments to the protocol ................................................................................ 136
13References ....................................................................................................................... 137
14Appendices ...................................................................................................................... 143
14.1 Appendix 1:  Guidelines for efficacy  evaluation in Acute Ly mphoblastic 
Leukemia (ALL) studies ...................................................................................... 143
Document History ........................................................................................................... 143
14.1.1 Introduction ......................................................................................... 145
14.1.2 Efficacy  evaluation .............................................................................. 145
 

Novartis Confidential Page 6
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
14.1.3 Data collection .................................................................................... 152
14.1.4 Efficacy  anal ysis definitions ............................................................... 153
14.1.5 References ........................................................................................... 158
14.2 Appendix 2: Guidelines for efficacy  evaluation in Ly mphoblastic Ly mphoma 
patients ................................................................................................................. 160
14.2.1 Introduction ......................................................................................... 160
14.2.2 Types of efficacy  assessments ............................................................ 160
14.3 Appendix 3: 
Eligibility  based on serologic markers for hepatitis B infection .... 164
14.4 Appendix 4: CTL 019 Modified Safet y Reporting ............................................... 165
14.4.1
Adverse Event (AE) and Serious Adverse Event (SAE) Reporting ... 165
14.4.2 Concomitant Medication..................................................................... 166
List of appendices
Appendix 1 : Guidelines for efficacy  evaluation in Acute Lymphoblastic Leukemia (ALL) 
studies
Appendix 2 : Guidelines for efficacy  evalu ation in Ly mphoblastic Ly mphoma patients
Appendix 3: 
Eligibility  based on serologic markers for hepatitis B infection
Appendix 4: CTL 019 Modified Safet y Reporting
List of figures
Figure 1 -1 CTL 019 chimeric antigen receptor design............................................ 30
Figure 4 -
1 Study  design .......................................................................................... 40
Figure 6 -
1 CRS Management Algorithm: ............................................................... 54
Figure 7 -
1 Potential Patient flow scenarios ............................................................ 68
List of tables
Table 3
-1 Objectives and related endpoints .......................................................... 37
Table 6
-1 CTL 019-Therap y -Associated Grading for C ytokine Release 
Syndrome: The Penn Grading Scale for C ytokine Release 
Syndrome (PGS -CRS) .......................................................................... 55
Table 6
-2 High Dose V asopressor Use .................................................................. 57
Table 6
-3 Staging & Grading of Acute Graft -Versus -Host Disease ..................... 58
Table 6-4 Definitions of Chronic Graft- Versus -Host Disease .............................. 59
 

Novartis Confidential Page 7
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
Table 6-5 Concomitant Medication Reporting b y Trial Phase .............................. 64
Table 7-1 Visit evaluation schedule ...................................................................... 69
Table 7
-2 Visit Evaluation Schedule: Treatment and Primary  follow -up 
continued (Month 15 through Month 60) .............................................. 78
Table 7
-3 Visit Evaluation Schedule: Secondary  Follow -up ................................ 81
Table 7-4 Imaging or disease assessment collection plan – Primary  follow -up 
phase ...................................................................................................... 94
Table 7
-5 Karnofsk y/Lansk y Performance Scales ................................................ 96
Table 7
-6 Local clinical laboratory  parameters collection plan ............................ 98
Table 7-7 Central clinical laboratory  parameters collection plan .......................... 99
Table 7-8 CTL 019 pharmacokinetics by q-PCR in peripheral blood collection 
log.......................................................................................................... 99
Table 7
-9 CTL 019 pharmacokinetics by flow cytometry in peripheral blood 
collection log....................................................................................... 100
Table 7
-10 CTL 019 pharmacokinetics by q-PCR in bone marrow aspirate 
collection log....................................................................................... 100
Table 7
-11 CTL 019 pharmacokinetics by  flow cytometry  in bone marrow 
aspirate c ollection log ......................................................................... 101
Table 7
-12 CTL 019 pharmacokinetics by q-PCR in CSF collection log .............. 101
Table 7-13 Immunogenicit y serum sample collection log .................................... 101
Table 7
-14 Immunogenicit y peripheral blood sample collection log .................... 101
Table 7-15 Tocilizumab, CTL 019 Pharmacoki netics (PK), and sIL6R (PD) in 
tocilizumab treated patients during CRS ............................................. 102
Table 7
-16 Anti- cytokine therapy  (other than tocilizumab) PK, CTL 019 PK 
and sIL6R (PD) in anti -cytokine therapy  treated patients during 
CRS ..................................................................................................... 102
104
Table 10
-1 Definition of CR, CRi and relapse at a given evaluation time in 
Acute Ly mphoblastic Leukemia patients  (excluding 
Lym phoblastic Ly mphoma patients) ................................................... 119
Table 10
-2 Additional definition of remission and relapse at a given evaluation 
time for Ly mphoblastic Ly mphoma patients ...................................... 120
Table 10
-3 Analy ses of duration of response (DOR) ............................................ 123
Table 10
-4 Adverse events of special interest (AESI) search criteria................... 126
Table 10-5 Noncompartmental pharmacokinetic parameters ................................ 129
Table 10-6 Simulated probabilities to claim success at the interim or final 
analysis................................ ................................ ................................ 132
 

Novartis Confidential Page 8
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
Table 14-1 Overall disease response classification at a given evaluation time .....150
Table 14-2 Data sources ........................................................................................ 152
Table 14
-3 Options for ev entdates usedinDOR, EFS andRFS........................... 157
Table 14-4 Response criteria for mediastinal disease ........................................... 162
Table 14
-5 Overall disease response classification at a given evaluation time 
for ly mphoblastic l ymphoma patients ................................ ................. 163
 

Novartis Confidential Page 9
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
List of abbreviations
AE Adverse Event
4-1 BB type 2 transmembrane glycoprotein be longing to the TNF superfamily, expressed on activated 
T Lymphocytes
AESI Adverse Event of Special Interest
ALC Absolute Lymphocyte Count
ALL Acute Lymphoblastic Leukemia
ALT Alanine Aminotransferase/Glutamic Pyruvic Transaminase/SGPT
AML Acute Myeloid Leukemia
Anti-HBc Hepatitis B core antibody
Anti-HBs Hepatitis B surface antibody
AST Aspartate Aminotransferase/Glutamic Oxaloacetic Transaminase/SGOT
ATC Anatomical Therapeutic Chemical
ATG Anti-thymocyte globu lin
AUC Area Under the Curve
AUMC Area under the first moment curve
B-ALL B cell lineage acute lymphoblastic leukemia
BCR -ABL Philadelphia Chromosome
BiPAP Bilevel Positive Airway Pressure
BM Bone Marrow
BMT Bone Marrow Transplantation
BOR Best Overall Response
BUN Blood Urea Nitrogen
CAR Chimeric Antigen Receptor
CBC Complete Blood Count
CCGs CRF Completion Guidelines
CD Cluster of Differentiation
CD137 4-1BB costimulatory molecule
CFR Code of Federal Regulations
CHOP Children’s Hospital of Philadelphia
CI Confidence Interval
CIF Cumulative Incidence Function
CLL Chronic Lymphocytic Leukemia
Cmax Maximum concentration
CMC Chemistry/ Manufacturing/ Control 
CMO Contract Manufacturing Facility Organization
CNS Central Nervous System
CPAP Continuous Positive Airway Pressure
CR Complete remission
CRF Case Report/Record Form; the term CRF can be applied to either EDC or Paper
CRi Complete remission with incomplete blood count recovery
CRO Contract Research Organization
CR p Complete remission with incomplete platelet recovery
 

Novartis Confidential Page 10
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
CRS Cytokine Release Syndrome
CSF Cerebral Spinal Fluid
CSP Clinical Study Protocol
CSR Clinical Study Report
CT Computed Tomography
CTC Common Toxicity Criteria
CTCAE Common Terminology Criteria for Adverse Events
CTL Cytotoxic T Lymphocyte
CTL019 cells CD 19 redirected autologous T cells (also called CART19 T cells )
CVPF Cell and Vaccine Production Facility
DLI Donor Lymphocyte Infusion
DLBCL Diffuse Large B Cell Lymphoma
DMC Data Monitoring Committee
DNA Deoxyribonucleic Acid
DOR Duration of Remission
EC European Commission
ECG Electrocardiogram
ECHO Echocardiogram
EDC Electronic Data Capture
EFS Event Free Survival
EOS End of Study
EOT End of Treatment and Primary Follow -Up
FAB Fragment Antigen Binding
FAS Full Analysis Set
FDA Food and Drug Administration
FFP Fresh Frozen Plasma
FISH Fluorescent in situ hybridization
FL Follicular Lymphoma
GCP Good Clinical Practice
G-CSF Granulocyte Colony Stimulating Factor
GFR Glomerular Filtration Rate
GI Gastrointestinal
GM-CSF Granulocyte Macrophage -Colony Stimulating Factor
GMP Good Manufacturing Practice
GU Genitourinary
GVHD Graft versus Host Disease
HBsAg Hepatitis B surface Antigen
HCV Hepatitis C Virus
HIV Human Immunodeficiency Virus
HLT High level term
i.v. Intravenous(ly)
IB Investigator Brochure
ICH International Conference on Harmonization
ICU Intensive Care Unit
IEC Independent Ethics Committee
 

Novartis Confidential Page 11
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
Ig Immunoglobulin
IL Interleukin
IL6R Interleukin 6 receptor
IN Investigator Notification
INR International Normalized Ratio
IRB Institutional Review Board
IRC Independent Review Committee
IRT Interactive Response Technology
ISBT International Society of Blood Transfusion
IUD Intrauterine Device
IVIG Intravenous Immunoglobulin
KM Kaplan Meier
LDH Lactate Dehydrogenase
LFT Liver Function Test
LLOQ Lower Limit of Quantification
LOQ Limit of Quantification
LP Lumbar Puncture
LPLV Last Patient Last Visit
LVEF Left Ventricular Ejection Fraction
LVSF Left Ventricular Shortening Fraction
MAP Master Analysis Plan
MAS Macrophage Activation Syndrome
MCHC Mean Corpuscular Hemoglobin Concentration
MCL Mantle Cell Lymphoma
MCV Mean Corpuscular Volume
MedDRA Medical Dictionary for Regulatory Authorities
MHC Major Histocompatibility Complex
MLL Mixed-Lineage Leukemia
MNC Mononuclear Cells
MRD Minimal Residual Disease
MRI Magnetic Resonance Imaging
MRT Mean Residence Time
MUGA Multiple Uptake Gated Acquisition
MYC A regulator gene located on chromosome 8 that is disregulated via translocations in Burkitt's 
lymphoma/leukemia
NCCN National Comprehensive Cancer Network
NE Norepinephrine Equivalent
NHL non-Hodgkin’s lymphomas 
NR No Response
O2 Oxygen
ORR Overall Remission Rate
OS Overall Survival
PAS Pharmacokinetic Analysis Set
PCR Polymerase Chain Reaction
 

Novartis Confidential Page 12
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
PE Physical examination
PGS -CRS The Penn Grading Scale for Cytokine Release Syndrome
pH Hydrogen ion concentration; a measure of the acidity or basicity of an aqueous solution
Ph+ Philadelphia Chromosome Positive
PHI Personal Health Information
PI Principal Investigator
PK Pharmacokinetics
PML Progressive Multifocal Leukoencephalopathy 
PPS Per-Protocol Set
PR Partial Remission
PT Preferred Term
PT Prothrombin Time
aPTT Activated Partial Thromboplastin Time
q-PCR Quantitative Polymerase Chain Reaction
r/r Relapsed or refractory
RAP The Report and Analysis Plan (RAP) is a regulatory document which provides evidence of 
preplanned analyses
RCL Replication Competent Lentivirus
RDC Remote Data Capture
REB Research Ethics Board
RFS Relapse Free Survival
SAE Serious Adverse Event
SC Steering Committee
scFv Single chain Fv fragment of an antibody
SCID Severe Combined Immunodeficiency
SCT Stem Cell Transplantation
sIg Surface Immunoglobulin
SOC System Organ Class
SUSAR Suspected Unexpected Serious Adverse Event
TCR T Cell Receptor
TCR-zeta Signaling domain found in the intracellular region of the TCR zeta, gamma and epsilon chains
TKI Tyrosine Kinase Inhibitor
TLH Trilineage Hematopoiesis 
TLS Tumor Lysis Syndrome
Tmax Time to peak concentration
TNF Tumor Necrosis Factor
ULN Upper Limit of Normal
UPenn University of Pennsylvania
VASST Vasopressin and Septic Shock Trial
VH Heavy Chain Variable Domain
VL Light Chain Variable Domain
VSV-G Vesicular Stomatitis Virus, Glycoprotein
WBC White Blood Cell
 

Novartis Confidential Page 13
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
Glossary  of terms
Assessment A procedure used to generate data required by the study
Cohort A group of newly enrolled patients treated at a specific dose and regimen (i.e. 
treatment group) at the same time
Dose level The dose of drug given to the patient (total daily or weekly etc .) 
Enrollment Point/time of patient entry into the study; defined as the point at which a patient 
meets all inclusion/exclusion criteria, and after which the patient’s apheresed 
product is received and accepted by Novartis Morris Plains manufacturing facility.
Investig ational drug The study treatment whose properties are being tested in the study; this definition is 
consistent with US Code of Federal Regulations (CFR )21 Section 312.3 and is 
synonymous with “investigational new drug.”
Investigational treatment Drug who se properties are being test ed in the study as well as their associated 
placebo and active treatment controls (when applicable). This also includes 
approved drugs used outside of their indication/approved dosage, or that are tested 
in a fixed combination. Investigational treatment generally does not include other 
study treatments administered as concomitant background therapy required or 
allowed by the protocol when used in within approved indication/dosage
Medication number A unique identifier on the label of each study treatment package which is linked to 
one of the treatment groups of a study
Other study treatment Any drug administered to the patient as part of the required study procedures that 
was not included in the investigational treatment
Subject Number A unique identifying number assigned to each patient who enrolls in the study
Period A subdivision of the study timeline; divides stages into smaller functional segments 
such as screening, baseline, titration, washout, etc.
Premature patient 
withdrawalPoint/time when the patient exits from the study prior to the planned completion of 
all study treatment administration and/or assessments; at this time all study 
treatment administration is discontinued and no further assessments are planned, 
unles s the patient will be followed for progression and/or survival
Stage related to study 
timelineA major subdivision of the study timeline; begins and ends with major study 
milestones such as enrollment, randomization, completion of treatment, etc.
Stage i n cancer The extent of a cancer in the body. Staging is usually based on the size of the 
tumor, whether lymph nodes contain cancer, and whether the cancer has spread 
from the original site to other parts of the body
Study treatment Includes any drug or combination of drugs in any study arm administered to the 
patient as part of the required study procedures, including active drug run -ins.
In specific examples, it is important to judge investigational treatment component 
relationship relative to a study t reatment combination; study treatment in this case 
refers to the investigational and non -investigational treatments in combination.
Supportive treatment Refers to any treatment required by the exposure to a study treatment
Variable Identifier used in the data analysis; derived directly or indirectly from data collected 
using specified assessments at specified time points
 

Novartis Confidential Page 14
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
Amendment 2
Amendment rationale
At the time of this protocol amendment, 9 sites have been initiated, 33 patients have been 
enrolled, and 27 patients have been treated.
The protocol is being amended to:
1. Ensure full alignment with the agreed binding measures detailed in the Pediatric 
Investigation Plan (PI P) opinion of the Paediatric Committee of the European Medicines 
Agency , issued on 20 March 2015, including the expansion of inclusion criteria to enroll 
patients with relapsed or refractory  B-cell ly mphoblastic ly mphoma .
2.
Address recommendations from EMA Scientific Advice letter on 25 April 2014
3.Transfer the trial sponsorship from University  of Pennsy lvania IND to Novartis IND .
Additional PK and cy tokine sample time points were added to better define cell expansion and 
CRS,  that did not impact total sample 
collection requirements.
Testing forCMV and EBV is not required at screening per current guidelines for autologous 
blood product therap y.
Other changes have been instituted for purposes of clarity and feasibility  based on experiences 
from ongoing trials as outlined below.
Key change s include:
1. The trial will be transferred under Novartis IND from UPenn IND. After the IND transfer, 
all CTL 019 products will be manufactured according to the Novartis CMC process. An 
interim analy sis is planned for patients who were treated with UPenn manu factured 
CTL 109 product and have completed 6 months from stud y day 1 infusion or discontinued
earlier. An α -spending function according to Lan -DeMets (O’Brien- Fleming) will be used 
to construct the efficacy  stopping boundaries (Lan and DeMets 1983).
2.Expand the inclusion criteria so that the trial can also enroll patients with relapsed or 
refractory  B-cell ly mphoblastic ly mphoma , and add in the primary  objective to assess 
ORR in ly mphoblastic l ymphoma patients too.
3.The final primary  anal ysis will include at least 50 patients (both acute l ymphoblastic 
leukemia and l ymphoblastic ly mphoma patients) treated using either UPenn CMC or 
Novartis CMC with at least 40 patients < 18 years. Sites will be notified once the cap of 
patients ≥ 18 y ears is reached.
4.Clarificat ion of primary  endpoint to be assessed during the first 6 months after CTL019 
administration.
5.Day 28 tumor assessment window changed from +/ -7 day s to +/ -4 day s
6.Additional analy ses have been included to assess the response at Day  28 +/ -4 day s,and 
theimpact of baselin e tumor burden on response.
 

Novartis Confidential Page 15
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
7.Minimum number of manufactured CTL 019 transduced cells for infusion has been 
removed.
8.Updated c ontraception guidelines for males and  females of childbearing potential .
In addition, other changes have been instituted for purposes of clarity and further efficacy 
follow -up, as outlined below.  Key  changes include:
1.Extension of trial follow -up duration from 12 months to 60 months.
2.Clarifications to more accuratel y define the term “refractory  ALL” in inclusion criteria #1. 
The two refractory  populations now defined have equally  poor prognosis at study  
enrollment and are not expected to negatively  impact the population homogeneity .  
3.Clarifications on adverse event reporting and apheresis collections
Changes to Protocol
1.Table 1- 1: Clarit y added for patient population on the trials
2.Section 1.2.1.2: Updated clinical experience section with currentl y available data. 
Clarification on corre lation between administration of tocilizumab and CTL019 cell 
expansion. 
3.Table 1- 2: Removed and replaced with summary  text
4.Table 2- 1: Removed and replaced with summary  text
5. Section 2.2: Replaced CVPF Penn manufacturing with Novartis manufacturing process 
will be used starting from Amendment 2
6. Section 2.3: Added “viable T” to dose.
7.Table 3- 1: Objectives a nd endpoints updated to clarify primary  endpoint to be assessed  6 
months after CTL019 administration, addition of ORR assessment in ly mphoblastic 
lymphoma patients, addition of other secondary  objectives,  
8.Section 4.1: Study  design diagram Extension of trial duration from 12 months to 60 
months. Ref erence added. 
9.Figure 4 -1: Study  design diagram updated with extension of trial duration from 12 months 
to 60 months. 
10.Section 4.1.1: Clarity  on guidelines for optimal apheresis collection
11.Section 4.1.1: Clarity  on use of CTL019 manufactured cells if GVHD experienced after 
collection of apheresis product
12.Section 4.1.1: Removed reference to Manual of Procedures.
13. Section 4.2: Updated trial design to reflect extension of trial duration from 12 months to 
60 months. 
14.Section 4.3: Replaced reference to Universit yof Pennsy lvania regulatory  and safet y 
bodies with Novartis.
15.Section 5.1: Addition of lymphoblastic l ymphomas to patient population 
16. Section 5.1: Clarification of European PIP required guidelines for primary  anal ysis and 
capping of patients ≥18 years of ag e. 
 

Novartis Confidential Page 16
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
17. Section 5.2: Clarification on the definition of refractory  ALL added to criteria # 1
18.Section 5.3: Criteria # 7 retired and replaced with criteria # 15 with extension of window 
for obtaining results within 8 weeks of screening
19.Section 5.3: Criteria # 8 retired and replaced with criteria # 16 with extension of window 
for obtaining results within 8 weeks of screening
20.Section 5.3: Criteria # 10 retired and replaced with criteria # 17 with additional Anti T -cell 
therap y guidance , and c larifications to testing time windows and chemotherapy  in 
exclusion criteria.
21. Section 6.1.1.1: Clarification on timing of ly mphodepleting chemotherapy  before CTL019 
infusion.
22.Section 6.1.1.2: Removed
reference to Universit y of Pennsy lvania manufacturing facility  
and operational procedures. Anti T -cell Therap y details added. Clarifications on patient 
pre-infusion requirements . The number of tocilizumab doses required on site prior to 
CTL 019 infusion changed to two doses. Clarification on which specific manual 
referenced.  
Minimu m release dose criteria removed. Guidance on monitori ng of patient 
temperature added.   
23.Section 6.1.3: Number of tocilizumab doses required on site prior to CTL 019 infusion 
changed to two doses.
24. Section 6.2.4.1: University  of Penns ylvania Data Safety  Monitoring Board (DSMB) 
replaced with Novartis Data Monitoring Committee (DMC).
25.Section 6.2.4.1.1: 
Replaced reference to University of Penns ylvania regulatory  and safety  
bodies with Novartis.
26.Section 6.2.4.2: CRS management algorithm to be followed b y inv estigators.
27.Sections 6.2.4.2 & 6.2.4.3: Safety  information added based on most current IB.
28.Figure 6 -1: CRF Management Algorithm further clarified
29.Table 6- 2: Adjustment of vasopressor doses corrected by  weight .
30.Section 6.2.6: Modified concomitant medication reporting better defined; clarification on 
concomitant medication recording prior to screening. Clarification on administration of 
granulocy te colon
y stimulating fac tor (G -CSF).
31.Section 6.2.7: Anti T -cell Therap y guidance added . Clarifications added. 
32. Sec tion 6.3.1: Changed “the Sponsor” to “Novartis”.
33.Section 6.4: Clarification on which specific manual referenced, and changed “the person” 
to “personnel” to ensure alignment with manuals . Changed “Regulatory  Sponsor” to 
“Novartis”. Clarification on which specific manual referenced .
34. Section 6.4.1: Added “viable T” and “transduced viable T” to dose.
35.Section 6.4.2: Clarification on which specific manual referenced .
36.Section 6.4.3: Clarifications on guidelines of product traceability  between patient’s 
autologous apheresis and CTL 019 product guidelines added. Clarification on which 
specific manuals referenced.
37.Section 6.4.3.2: Clarification on which specific manual referenced
 

Novartis Confidential Page 17
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
38. Section 6.4.4: Clarification on which specific manuals referenced . Replaced “the 
Regulatory  Sponsor” with “Novartis”
39.Section 7.1: Updated trial design to reflect extension of trial duration from 12 months to 
60 months.
40.Figure 7 -1: Added figure to reflect patient f low scenarios.
41.Table 7- 1: Day  28 window changed from +/- 7 day s to +/ -4 day s .
42.Table 7-1: Enrollment window changed from “W- 3 to D -8” to “W -8 to D -8”
43.Table 7- 1: Pre -infusion window changed from “D -1” to “D -1 +1”
44.Table 7- 1: Cy togenetics testing updated for relapsed patients
45.Table 7- 1: Added collection timepoints of antineoplastic therapies  treatment post CTL 019 
infusion
46.Table 7- 1: Separated and added “Labs of Special Interest” from Chemistry  panel
47.Table 7- 1: Deleted “Viral Serology  (CMV/ EBV)” testing
48.Table 7-1: Deleted “Flow Cy tometry  of bone marrow aspirate (B cell, tumor cell, CD19 
assessment” 
49.Table 7
-1: Added MRD assessment by bone marrow aspirate by  flow cytometry  to 
include normal B and T cell counts amd CD19 status
50.Table 7- 1: Tumor cell assessment b y flow cy tometry  of peripheral blood for clarit y 
51.Table 7- 1: “Aspirate” added to ly mph node or other involved tissue assessment
52.Table 7-1: Added Mediastinal disease assessment imaging for l ymphoblastic ly mphoma 
patients
53.Table 7- 1: Added pregnancies and men strual status
54.Table 7- 1: CRS assessment by  peripheral blood clarification
55.Table 7- 1: Added CTL019 pharmacokinetics b y flow cy tometry  (bone marrow aspirate) 
56.  
57.
58.
59.
60.Table 7- 1: Added apheresis sample for correlative studies
61.Table 7-1: Added CTL019 cell product sample for correlative studies
62.Table 7-2: Added to reflect assessments performed from 12 month to 60 month period of 
Treatment and Primary  Follow -Up.
63.Table 7- 3: Added to reflect assessments performed during Secondary  Follow -Up. 
64.Section 7.1.1: Clarifications made throughout section. “at the time of screening” added to 
performance status assessment; Standard cy togenetics results clarified to be collected “at 
the time of most recent relapse. If not available, test must be performed at screening ;
“ within 3 months of screening” added to donor chimerism; “L abs of special interest 
(  LDH, and fibrinogen)” added;   HIV testing window updated and testing 
methodology  updated; Viral serologies deleted; “test within 8 weeks of screening” added 
 

Novartis Confidential Page 18
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
to Hepatitis B/ C testing; T cell numbers added to bone marrow aspirate and biopsy   and 
peripheral blood flow cy tometry . Mononuclear cell isolation for genomic analy ses added 
to bone marrow aspirate or biopsy . Mediastinal disease assessment added for relapsed or 
refractory  B-cell ly mphoblastic ly mphoma. 
65.
7.1.1.1: Clarification to operational impact of screening and enrollment requirements from 
transfer of IND from University  of Pennsy lvania to Novartis IND. Removal of third party  
review for confirmation of clinical eligibility .
66. Section 7.1.2: Section updated with new visit windows and clarifications for pre-infusion 
criteria .
67. Section 7.1.3: Section updated with new visit windows and other clarifications :. T cells 
added for flow cy tometry; Da y 28 window changed to +- 4 day s; “aspirate” added to 
lymph node assessment . Month 12, 15, 18, 21, 24, 30, 36, 42, 48, and 54 visit assessment 
details added. 
68.7.1.3.1: Updated trial design to reflect extension of trial duration from 12 months to 60 
months.
69. 7.1.3.2: Section updated with criteria for premature patient withdrawal from Treatment 
and Primary  Follow -Up 
70.  
 
71.Section 7.1.4: Section updated and clarified.
72.Section 7.1.4.1: Section added. 
73.Section 7.2.1: Updated with Ly mphoblastic Ly mphoma efficacy  assessment reference. 
74.Table 7-2: Mandated collections added for 60 month extension of trial to peripheral 
blood , extramedullary  disease assessment by  physical exam, and flow cy tometry  of 
peripheral blood; Mediastinal disease assessment imagine for l ymphoblastic ly mphoma 
patients,  T cells added for flow cy tomet ry of peripheral blood; Deleted flow cy tometry  of 
bone marrow aspirate. 
75.Section 7.2.1.1: Updated with timepoints for extension of trial duration from 12 months to 
60 months. 
76. S ection 7.2.1.2: Updated with timepoints for extension of trial duration from 12 months to 
60 months. 
77. Section 7.2.2: Further Tanner staging not required if patient classified as Tanner stage 5
78. Section 7.2.2.4: Added Tanner Staging details .
79.Table 7
-4: Table updated for clarification. “B cell and T cell levels” added.  
80.  
81.Section 7.2.3: Enrollment window changes from “W- 3 to D -8” to “W -8 to D -8” and Day 
28 window changed to +/ -4 day s for all applicable tables.
82.Table 7- 6: Day  11 collection added; Collections added for extension of trial from 12 
months to 60 months; clarification of collection of unscheduled samples. 
 

Novartis Confidential Page 19
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
83.Table 7- 7: Table added for collection of CTL019 PK samples by  flow cytometry  of 
peripheral blood.
84.Table 7- 9: Table added for collection of CTL019 pharmacokinetics by  flow cy tometry  in 
bone marrow aspirate.
85.Table 7- 11: Collections added for extension of trial from 12 months to 60 months; 
clarification of collection of unscheduled samples.
86.Table 7- 11: Collections added for extension of trial from 12 months to 60 months; 
clarification of collection of unscheduled samples. Clarification added for primary  follow 
up only . 
87.Table 7- 13: Table added for Tociluzimab CTL 019 PK collection 
88.Table 7- 14: Table added for Anticy tokine therapy  (other than Tocilizumab) PK collection 
89. Section 7.2.3.1: Section updated for clarification.
90.
 
91.Section 7.2.4: Section added.
92. Section 8.1.2: Clarification added on adverse even t reporting while patient simultaneously  
enrolled on CTL019B2206 and extension of trial from 12 months to 60 months.
93. Section 8.2.2: Clarification added on serious adverse event reporting while patient 
simultaneously  enrolled on CTL 019B2206 and extension of trial from 12 months to 60 
months; “Regulatory Sponsor” replaced with “Novartis”.
94.Section 8.2.3: Section deleted.
95.Section 8.4: “salpingotomy ” corrected to “bilateral salpingectomy ”; “the Regulatory  
Sponsor” replaced with “Novartis”.
96.Section 8.6: Section deleted.
97.Section 8.7: Replaced reference to Universit y of Pennsylvania regulatory  and safet y 
bodies with Novartis and clarifications made
98.Section 8.8: R eplaced reference to Universit y of Pennsylvania regulatory  and safet y 
bodies with Novartis
.
99.Section 9: Cl arifications added
100. Section 9.2: R eplaced reference to Universit y of Pennsylvania regulatory  and safet y 
bodies with Novartis.
101. Section 9.4: Replaced “the Regulatory  Sponsor” with “Novartis”.
102. Section 10: Section updated with new population details and additio n of formal 
interim analy sis. 
103. Section 10.1: Section updated based on new population
104. Section 10.1.6: Clarification added.
105. Section 10.2: Primary  refractory  definition clarified
 

Novartis Confidential Page 20
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
106. Section 10.4 and subsections: Statistical analy sis updates based on changes 
implemented in protocol
107. Section 10.5.2.2: Section updated
108. Section 10.5.2.3: Clarification added.
109. Section 10.5.2.4: Section removed (CR or CRi with MRD negative bone marrow)
110. Section 10.5.2.7: Section added
111. Section 10.5.2.8: Section added
112. Section 10.5.2.9: Secti on added
113. Section 10.5.3.7: Section added
114. Section 10.5.3.9: Section updated
115. Section 10.5.4: Section update
116. Table 10- 4: Table updated with more details 
117. Section 10.6.1: Section updated
118. Section 10.6.1.3: Section updated
119. Section 10.7: Section updated to include interim analy sis. 
120. Section 10.8: Section updated
121. Section 10.6.4: Patient reported outcome section removed and moved to Section 
10.5.2.7
122. Section 10.8: Section updated
123. Section 11.2: Clarifications made for updated bod ied and r eplaced reference to 
University  of Pennsy lvania regulatory  and safety  bodies with Novartis.
124. Section 11.3: Clarifications made; replaced reference to Universit y of Pennsylvania 
regulatory  and safet y bodies with Novartis.
125. Section 11.4 and 11.5: Repl aced “the Regulatory  Sponsor” with “Novartis”.
126. Section 11.6: R eplaced reference to Universit y of Pennsylvania regulatory and safet y 
bodies with Novartis
127. Section 11.7: Replaced “the Funding Sponsor” with “Novartis”
128. Section 11.8: Replaced “the Regulatory  Sponsor” with “Novartis”.
129. Section 12: Replaced “the Regulatory  Sponsor” with “Novartis”.
130. Section 12.1: Clarifications made for updated bodied and replaced reference to 
University  of Pennsy lvania regulatory  and safety  bodies with Novartis
131. Section 13: Reference s added
132. Section 14.1 Appendix 1: Updated 
133. Section 14.2 Appendix 2: Ly mphoblastic l ymphoma assessment guidelines added
134. Section 14.3 Appendix 3: clarifications made
135. Section 14.4 Appendix 4: CTL 019 Modified Safety  Reporting guidelines added
 

Novartis Confidential Page 21
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
IRB/IEC
A copy  of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/EC approval prior to 
implementation. In addition, if the chan ges herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into 
account the changes described in this amended protocol.
Amendment 1
Amendment rationale
This protocol amendment was finalized under the UPenn IND and therefore, a rationale was 
not included at the time.  Therefore, at the time of transitioning the trial to Novartis IND, it 
has been retrospectively added. 
At the time of this protocol amendment, no sites had been initiated and first patient first visit 
(FPFV) had not occurred. All sites are to be initiated with the current protocol amendment.
The protocol was being amended in order to include additional safety  information and 
includes Health Authority  feedback regarding reporting of SAEs including CRS and deaths, 
updating CTL019 dosing, staggered -enrollment design,  follow -up time required after a live 
birth, influenza testing 10 days prior to infusion, general toxicity  management, and modified 
Serious Adverse Event (SAE) and Adverse Event (AE) reporting.
 

Novartis Confidential Page 22
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
Protocol summary :
Protocol number CCTL019B220 5J
Title A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in 
pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Brief title Study of efficacy and safety of CTL019 in pediatric ALL patients
Sponsor and 
Clinical PhaseNovartis
Phase II 
Multicenter
Investigation 
typeBiological
Study  type Interventional
Purpose and 
rationaleOutcome remains poor for patients with second or greater relapse or refractory ( r/r)pediatric 
B-cell ALL and Lymphoblastic Lymphoma . Treatment options for r/r B- cell ALL and 
Lymphoblastic Lymphoma include further treatment with salvage chemotherapy, allog eneic 
SCT or supportive care. Therapy in this population is not curative with an overall survival of 3 
to 6 months.
CD19 has emerged as an attractive therapeutic target because it is widely expressed on 
normal and malignant B -cells throughout B -cell maturation but not on pluripotent stem cells 
or non –B-cell tissues. Thedevelop ment of chimeric antigen receptor (CAR) T c ells to target 
CD19+ cells (CART19 or CTL019) provides an innovative new approach to these 
malignancies . This approach involves autologous patient -derived T cells that are genetically 
modified ex vivo via lentiviral transduction to express a CD19 antigen r ecognition domain 
attached to intracellular signaling domains that mediate T -cell activation in a MHC
independent manner. Anti-tumor efficacy has been seen in r/r adult and pediatric ALL and in 
r/r CLL.
Primary  
Objective(s) and 
Key Secondary  
ObjectiveTo evaluate the efficacy of CTL019 therapy in acute lymphoblastic leukemia patients as 
measured by overall remission rate (ORR), 6 months after CTL019 administration, which 
includes Complete Remission (CR)and CR with incomplete blood count recovery (CRi) as 
determined by independent review committee (IRC) assessment.
ORR in Lymphoblastic Lymphoma patients will be evaluated separately using local 
investigator’s assessment.
Secondary  
ObjectivesThese objectives will be assessed in the acute lymphoblastic leukemia patients and 
separately in the lymphoblastic lymphoma patients.
Objective 1 : To evaluate the percentage of patients who achieve CR or CRi at Month 6 
without SCT between CTL019 infusion and Month 6 response assessment
Objective 2 : To e valuate the p ercentage of patients who achie veCR or CRi and then 
proceed to SCT while in remission before Month 6 response assessment
Objective 3 : To e valuate the duration of remission (DOR) .
Objective 4 : To e valuate the quality of response by assessing the percentage of patients 
who achieve a best overall response (BOR) of CR or CRi with a minimal residual disease 
(MRD) negative bone marrow 6 months after CTL019 infusion and at D28 by central 
analysis .
Objective 5 : To evaluate the relapse-free survival (RFS), event -free survival (EFS) and 
overall survival (OS)
Objective 6 : Evaluate the response at Day 28+/ -4 days
Objective 7: To evaluate the impact of baseline tumor burden on response
Objective 8: To e valuate the safety of CTL019 therapy as measured by type, frequency and 
severity of adverse events and laboratory abnormalities
Objective 9: To c haracterize the in vivo cellular pharmacokinetic (PK) profile (levels, 
persistence, trafficking) of CTL019 cells in target tissues (blood, bone marrow, and other 
tissues if availa ble)
Objective 10: To describe the prevalence and incidence of immunogenicity to CTL019
Objective 11 : To describe the profile of soluble immune factors that may be key to cytokine 
 

Novartis Confidential Page 23
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
release syndrome
Objective 1 2: To d escribe the levels of  B and T cells (per ipheral blood and bone marrow) 
prior to and following CTL019 infusion
Study  design This is a single arm, open -label, multi -center, phase II study to determine the efficacy and 
safety of CTL019 in pediatric patients with r/rB-cell AL L and lymphoblastic lymphoma . The 
study will have the following sequential phases: Screening, Pre-Treatment (Cell Product 
Preparation & Lymphodepleting Chemotherapy) , Treatment and Primary Follow -up, 
Secondary Follow -up (if applicable )and Survival Follow -up. The total durati on of the study is 
5years from CTL019 cell infusion . After CTL019 infusion, efficacy will be assessed monthly 
for the first 6 months, quarterly up to 2 years, and semi -annually afterwards up to 5 years, or 
until patient relapse. Safety will be assessed th roughout the study. A post -study follow -up for 
lentiviral vector safety will continue under a separate destination protocol for 15 years post 
infusion per health authority guidelines. An interim analysis is planned when all acute 
lymphoblastic leukemia patients who were enrolled and CTL019 manufactured according to 
the UPenn manufacturing process have completed 6 months from study day 1 infusion or 
discontinues earlier.
Population The target population is comprised of pediatric patients with B-cell ALL and Lymphoblastic 
Lymphoma who are primary refractory, chemo -refractory, relapsed after allogeneic SCT, or 
are otherwise ineligible for allogeneic SCT . Approximately 67 patients will be enrolled to 
allow 50 total patients to be treated which will consist of patients with relapsed or refractory 
acute lypmphoblastic leukemia and/or lymphoblastic l ymphoma age 3 at the time of 
screening to age 21 at the time of initial diagnosis . 
In order to satisfy European PIP requirement, at least 40 patients <18 years o f age will be 
treated at the time of primary analysis.  Therefore, no more than 10 patients ≥18 years of age 
will be treated . Site swill be notified when this age cap is reached .
The number of acute lymphoblastic leukemia and lymphoblastic lymphoma patient s to be 
treated respectively will be based on the actual recruitment of the two populations. It is 
anticipated that the lymphoblastic lymphoma population is small and will represent less than 
10% of the entire population. Therefore with 50 patients treated in the study, it is assumed 
that 45 acute lymphoblastic leukemia patients will be treated.
Inclusion criteria 1. [Retired from UPenn protocol version 2.0 ]
2. For relapsed patients, documentation of CD19 tumor expression in bone marrow or 
peripheral blood by flow cytometry within 3 months of study entry
3. Adequate organ function defined as:
a. Renal function defined as:
i. Calculated c reatinine clearance or radioisotope Glomerular Filtration Rate
(GFR )> 60 mL/min/1.73 m2, OR
ii. Aserum creatinine based on age/gender as follows:
Maximum Serum Creatinine
(mg/dL)
Age Male Female
1 to < 2 years 0.6 0.6
2 to < 6 years 0.8 0.8
6 to < 10 years 1.0 1.0
10 to < 13 years 1.2 1.2
13 to < 16 years 1.5 1.4
≥ 16 years 1.7 1.4
b.Alanine Aminotransferase (ALT ) ≤ 5 times the upper limit of normal (ULN) for age
c. Bilirubin < 2.0 mg/dL
d. Must have a minimum level of pulmonary reserve defined as ≤Grade 1 dyspnea and 
pulse oxygen ation > 91% on room air
e. Left Ventricular Shortening Fraction ( LVSF)≥ 28%confirmed by echocardiogram, or 
Left Ventricular Ejection Fraction (LVEF) ≥45% confirmed by echocardiogram or MUGA
4. Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening
 

Novartis Confidential Page 24
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
5. Life expectancy > 12 weeks
6. [Retired from UPenn protocol version 2.0].
7. Karnofsky (age ≥16 years) or Lansky (age < 16 years) performance status ≥ 50 at 
screening
8. Signed written informed consent and assent forms if applicable must be obtained prior to 
any study procedures
9. Once all other eligibility criteria are confirmed, must have an apheresis product of non-
mobilized cells received and accepted by the manufacturing site. 
10. Relapsed or refractory pediatric B-cell Acute Lymphoblastic Leukemia orB-cell 
Lymphoblastic Lymp homa , AND
a.2nd or greater BM relapse OR
b.Any BM relapse after allogeneic SCT and must be > 6 months from SCT at the time of 
CTL019 infusion OR
c.Primary refractory as defined by not achieving a CR after 2 cycles of a standard 
chemotherapy regimen o r chemorefractory as defined by not achieving a CR after 1 cycle of 
standard chemotherapy for relapse leukemia OR
d.Patients with Ph+ ALL are eligible if they are intolerant to or have failed two lines of TKI 
therapy, or if TKI therapy is contraindicated OR
e.Ineligible for allogeneic SCT because of:
i.Comorbid disease
ii. Other contraindications to allogeneic SCT conditioning regimen
iii.Lack of suitable donor
iv.Prior SCT
v. Declines allogeneic SCT as a therapeutic option after documented discussion, 
including expected outcomes, about the role of SCT with a BMT physician not part of the 
study team
11. Age 3 at the time of screening to age 21 at the time of initial diagnosis.
Exclusion 
criteria1. Isolated extra -medullary disease relapse
2.Patients with concomitant genetic syndrome: such as patients with Fanconi anemia, 
Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure 
syndrome . Patients with Down Syndrome will not be excluded.
3.Patients with Burkitt’s lymphom a/leukemia (i.e. patients with mature B -cell ALL, leukemia 
with B-cell [surface Immunoglobulin (sIg)positive and kappa or lambda restricted positivity ] 
ALL, with FAB L3 morphology and /or a MYC translocation)
4. Prior malignancy , except carcinoma in situ of the skin or cervix treated with curative intent 
and with no evidence of active disease
5.Prior treatment with gene therapy product
6.Treatment with any prior anti-CD19 /anti-CD3 therapy , or any other anti-CD19 therap y
7. [Retired from UPenn protocol version 2.0 ]
8. [Retired from UPenn protocol version 2.0 ]
9.Presence of Grade 2 to 4 acute or extensive chronic graft -versus -host disease (GVHD)
10. [Retired from UPenn protocol version 2.0 ]
11.Active CNS involvement by malignancy , defined as CNS -3per National Comprehensive 
Cancer Network (NCCN) guidelines . Note: Patients with history of CNS disease that has 
been effectively treated will be eligible .
12. Patient has participated in an investigational research study using an investigational 
agent within the last 30 days prior to screening
13.Pregnant or nursing (lactating) women .NOTE: female study participants of reproductive 
potential must have a negative serum or urine pregnancy test performed within 48 hours 
before infusion
14. [Retired from UPenn protocol version 2.0 ]
15.Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any 
uncontrolled infection at screening
16. HIV positive test within 8 weeks of screening
17. The following medications are excluded:
a.Steroids : Therapeutic doses of steroids must be stopped > 72 hours prior to CTL019 
infusion. However, the following physiological replacement doses of steroids are allowed: < 
12 mg/m2/day hydrocortisone or equivalent
 

Novartis Confidential Page 25
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
b.Allogeneic cellular therapy : Any dono r lymphocyte infusions (DLI) must be 
completed > 6 weeks prior to CTL019 infusion
c.GVHD therapies : Any drug used for GVHD must be stopped > 4 weeks prior to 
CTL019 infusion (e.g. calcineurin inhibitors, methotrexate or other chemotherapy drugs, 
mycophen olyate mofetil , rapamycin, thalidomide, or immunosuppressive antibodies such as 
anti-CD20 (rituximab), anti -TNF, anti -IL6 or anti -IL6R)
d.Chemotherapy :
The following drugs must be stopped > 1 week prior to CTL019 infusion and should not be 
administered c oncomitantly or following lymphodepleting chemotherapy: hydroxyurea, 
vincristine, 6 -mercaptopurine, 6 -thioguanine, methotrexate < 25 mg/m2, cytosine arabinoside 
< 100 mg/m2/day, asparaginase (non -pegylated)
The following drugs must be stopped > 2 weeks pri or to CTL019 infusion: salvage 
chemotherapy (e.g. clofarabine, cytosine arabinoside >100 mg/m2, anthracyclines, 
cyclophosphamide), excluding the required lymphodepleting chemotherapy drugs
Pegylated -aspariginase must be stopped > 4 weeks prior to CTL019 infusion  
e.CNS disease prophy laxis :
i. CNS prophylaxis treatment must be stopped > 1 week prior to CTL019 infusion 
(e.g. intrathecal methotrexate)
f.Anti T -cell Therapy : Administration of any T cell lytic or toxic agent (e.g . alemtuzumab) 
prior to CTL019 is strongly discouraged since residual lytic levels may destroy the infused 
CTL019 cells and/or prevent their in vivo expansion. If such an agent has been administered 
within 8 weeks prior to CTL019, contact Novartis , conside r consultation with an 
pharmacology expert, and consider measuring residual drug levels, if feasible, prior to 
CTL019 infusion.
18. Women regardless of age that may have child -bearing potential (defined as all women 
physiologically capable of becoming pregnant) and all male participants, unless they are 
using highly effective methods of contraception for a period of 1 year after the CTL019 
infusion). Women are to continue contraception until CAR cells are no longer present in the 
blood by PCR. Highly effect ive contraception methods include:
a.Total abstinence (when this is in line with the preferred and usual lifestyle of the 
patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods) and withdrawal are NOT acceptable me thods of contraception)    
b.Female sterilization (have had surgical bilateral oophorectomy with or without 
hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of 
oophorectomy alone, only when the reproductive status of the woman has been confirmed by 
follow up hormone level assessment
c.Male sterilization (at least 6 months prior to screening). For female participants on the 
study the vasectomized male partner should be the sole partner for that patient
d. Use of oral, injected or implanted hormonal methods of contraception or other forms of 
hormonal contraception that have comparable efficacy (failure rate <1%), for example 
hormone vaginal ring or transdermal hormone contraception
e.Use of intrauterine devices ( IUDs) are excluded due to increased risks of infection and 
bleeding in this population
f.In case of use of oral contraception, women must be stable on the same pill for a 
minimum of 3 months before taking study treatment
Women who are not of reproductiv e potential (defined as either <11 years of age, Tanner 
Stage 1, post -menopausal for at least 24 consecutive months (i.e. have had no menses) or 
have undergone hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy) are 
eligible without requi ring the use of contraception. Women who are not yet of reproductive 
potential are to agree to use acceptable forms of contraception when they reach reproductive 
potential if within 1 year of CTL019 or if CAR cells are present in the blood by PCR. 
Acceptab le documentation includes written or oral documentation communicated by clinician 
or clinician’s staff of one of the following:
a.Demographics show age <11
b.Physical examination indicates Tanner Stage 1
c.Physician report/letter
d.Operative report or other source documentation in the patient record
 

Novartis Confidential Page 26
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
e.Discharge summary
f.Follicle stimulating hormone measurement elevated into the menopausal range
Investigational 
and reference 
therapyA dose of CTL019 transduced cells will consist of a single infusion of 2 to 5x 106CTL019 
transduced viable T cells/kgwith a maximum dose of 2.5x 108CTL0 19 transduced viable T 
cells (non-weight adjusted) .
Efficacy  
assessmentsPrimary : Overall Response Rate (ORR ),  6 months after CTL019 administration ,which 
includes Complete Remission (CR) and Complete Remission with Incomplete Blood Count 
Recovery (CRi), as determined by assessments of peripheral blood, bone marrow, CNS 
symptoms, physical exam (PE) and CSF. The primary endpoint will be based on the IRC
assessment for acute lymphoblastic leukemia patients, and based on local investigator’s 
assessment for acut e lymphoblastic lymphoma patients . The local investigator’s assessed 
results will be used for sensitivity analysis for acute lymphoblastic leukem ia patients .
Secondary : Patients with CR or CRi at Month 6 without SCT between CTL019 infusion and 
Month 6 response assessment, patients who achieve CR or CRi and then proceed to SCT 
while in remission prior to Month 6 response assessment, Minimal residua l disease, duration 
of remission , relapse -free survival, event -free survival, and overall survival
Safety  
assessmentsAdverse events and laboratory abnormalities (type, frequency and severity)
Immunogenicity assessments
a. prevalence of immunogenicity against CTL019 (pre -existing) , both humoral and cellular
b. incidence of immunogenicity against CTL019 , both humoral and cellular
c. proportion of patients with transient anti -CTL019 antibody assay titers
d. proportion of patients with sustained anti -CTL0 19 antibody assay titers
Other 
assessmentsPharmacokinetic assessments planned for this trial include:
●Detection of CTL019 transgene levels in blood, bone marrow and CSF (if available) by q-
PCR.
●Expression of CTL019 detected by flow cytometry in blood and bone marrow
●Maximum Concentration (Cmax ),Time of Peak Concentration ( Tmax), Area Under the 
Curve (AUCs ) and other relevant PK parameters of CTL019 in blood, bone-marrow, CSF (if 
available) .
● M aximum extent of expansion of CT L019 in blood
● Persist ence of CTL019 in blood , bone marrow and CSF (if available)
Data analy sis Primary  endpoints :
● The primary analysis will be carried out after 50 treated patients have completed at least 
6 months of follow -up or have discontinue ddue to any reason. Updated efficacy and safety 
data will be reported after patients have been followe d for a total of 60months within the 
study protocol.
●The primary efficacy endpoint, ORR will be assessed by IRC for Acute Lymphoblastic 
Leukemia patients and by local investigator’s assessment for Lymphoblastic L ymphoma 
patients in the full analysis set (FAS). The primary efficacy analysis will be based on 
statistical testing in acute lymphoblastic leukemia patients, descriptive analysis in 
lymphoblastic lymphoma patients, and descriptive analysis in all patients combined.
●The primary efficacy analysis in acute lymphoblastic leukemia patients will be performed 
 

Novartis Confidential Page 27
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
by testing the null hypothesis of ORR being less than or equal to 20% against the alternative 
hypothesis that the ORR is greater than 20% at overall one -sided 2.5% level of significance, 
powered f or ORR =45%. The ORR will be summarized along with the 2- sided exact 
Clopper -Pearson confidence intervals with coverage level determined by the O’Brien -
Fleming type α -spending approach according to Lan -DeMets . The study will be considered 
successful if th e lower bound of the 2 -sided exact confidence interval for ORR is greater than 
20%, so that the null hypothesis that the ORR is less than or equal to 20% can be rejected.
Sensitivity analyses will be performed on the Enrolled Set ,the per-protocol set (PPS) and 
with all patients who satisfy all clinical eligibility criteria ( defined as all inclusion/exclusion 
criteria except that which pertains to the apheresis product) using the same method as 
described above.
Secondary  endpoints :
●Analysis of secondary or exploratory endpoints will be descriptive and may include 
summary statistics such as means, standard deviations, 95% confidence intervals, if 
applicable .Cumulative Incidence Functions (CIF), Kaplan -Meier curves and median time to 
event will be presente d for time -to-event variables (DOR, RFS, EFS and OS), if appropriate.
Interim Analy sis:
●An interim analysis is planned when all acute lymphoblastic leukemia patients who were 
enrolled and CTL019 manufactured according to the UPenn manufacturing process h ave 
completed 6 months from study day 1 infusion or discontinues earlier. Approximately 30 
patients will be included in the interim analysis. An α-spending function according to Lan -
DeMets (O’Brien -Fleming), as implemented in East 6.1, will be used to cons truct the efficacy 
stopping boundaries (Lan and DeMets 1983). If the interim analysis is performed exactly with 
30 patients, the lower bound of the 2 -sided 98.79% exact CI of the ORR will need to be 
greater than 20% to declare statistical significance
Sample size :
● In a previous study of clofarabine in pediatric patients with r/r B -cell ALL who have had 2 
or more prior regimens, the reported ORR was 20%. Based on the null hypothesis of ORR ≤ 
20% and alternative hypothesis of ORR = 45%, 50 patients in the F AS will provide 95% 
power to demonstrate statistical significance using a 2 -look Lan -Demets group sequential 
design with O’Brien -Fleming type boundary at one -sided 2.5% level of significance. 
Assuming 20% to25% enrolled patients will not be infused due to reasons such as product 
manufacturing issues , worsening of patient’s condition, etc., at least 63 to67 patients need to 
be enrolled respectively to ensure 50 acute lymphoblastic leukemia or lymphoblastic 
lymphoma patients are treated using either UPenn or Novartis CMC process and hence will 
be used for the primary analysis
Key words Relapsed/refractory ALL or Lymphoblastic Lymphoma , relapsed ALL, post allogeneic SCT, 
CTL019
 

Novartis Confidential Page 28
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
1 Background
1.1 Overview of disease pathogenesis, epidemiology  and current 
treatment
B cell malignancies comprise a heterogeneous group of neoplasms including acute 
lymphoblastic leukemia’s (ALL), chronic lymphocy tic leukemia’s (CLL), and a vast majorit y 
of non-Hodgkin's lymphomas (NHL). An estimated 91,000 new cases oflymphocy tic 
leukemia and NHL were diagnosed in the US in 2012 (National Cancer Institute 2013 ). There 
were 66,371 l ymphoid malignancies registered in 2000 -2002 by  44 European cancer registries
(Sant et al 2010 ). The majority  of these malignancies are of B cell origin ( Mitchell et al 2012 ).
ALL is more commonl y seen in children although can occur at any age. ALL repres ent 75% 
to 80% of acute leukemias among children, therefore, making it the most common form of 
childhood leukemia (The Leukemia & Lym phoma Society  2009). The median age at 
diagnosis for ALL is 13 y ears; 60% of patie nts are diagnosed at younger than 20 years of age, 
whereas 23% are diagnosed at 45 years or older. Among children, B
-cell lineage ALL 
constitutes approximately 88% of leukemia cases.
Current treatment for B cell malignancies include combination sof chemotherap y, radiation 
therap y, bone marrow transplantation, or peripheral blood and cord blood stem cell 
transplantation (SCT) . Despite these treatment modalities, many relapsed patients remain 
incurable. Initial chemo therap y istypicall yadministered over a 2 to 3 year period. With 
current multi
-agent treatment regimens, the cure rate among children with ALL is >80%. 
Most patients (>85%) with relapsed ALL will achieve a second remission (Ko et al 2010 ); 
however, the challenge remains to maintain remission. Most children who relapse once will 
relapse again, and will ultimately  succumb to the ir disease . Leukemia is still the leading cause 
of death in pediatri c oncology  (Talle n et al 2010). Refractory  ALL [never achieving a 
complete remission (CR)] in adults or children hasa dismal prognosis and these are not 
candidates for SCT. Thus relaps edor refractory (r/r) ALL patients, both adult and pediatric, 
have significant unmet medical needs.
1.2 Introduction to investigational treatment(s) and other study  
treatment(s)
1.2.1 Overview  of CTL019
Immunotherap y is a treatment that involves activating or enhancing the immune system to 
help fight disease sincluding cancer. Adoptive immunotherap ywith allogeneic donor 
leukocy tes(e.g. donor lymphocy te infusion) has potent anti-leukemic effects, however the 
benefit is confined largely  to patients with myeloid leukemia’s
, as B-ALL has a durable 
remission rate of less than 10% (Kolb et al 1995 ), and often at the cost of substantial 
morbidity  due to GVHD (Appelbaum 2001, 
Sullivan et al 1989).
 

Novartis Confidential Page 29
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
Adoptive T-cell therap y is one particular approach that involves engineering T-cell receptors 
(TCRs) to bind to specific antigens present on tumor cells. These modified TCRs, known as 
chimeric antigen receptors (CARs), allow the immune system to specifically  target and 
destroy  tumor cells in a MHC independent manner ( Mellman et al 2011 ).
A very promising potential target antigen for B cell malignancies is CD19, a cell-surface 
protein whose expression is restricted to B cells and their precursors (Sadelain et 
al 2003, 
Brentjens et 
al 2010, Porter et al 2011 ). CD19 is not expressed on hematopoietic stem cells or 
non-B cell tissues. It is a member of the immunoglobulin (Ig) superfamily  and a component of 
a cell surface signal transduction complex that regulates signal transduction through the B cell 
receptor (Ledbetter et 
al 1988, Stamenkovic and Seed 1988, Fearon and Carroll 2000). Mice 
lacking CD19 have decreased number of B cells in periphe ral lymphoid tissues, decreased B 
cell response to oral vaccines and mitogens, and decreased serum Ig levels (Ledbetter et 
al 
1988, Stamenkovic and Seed 1988 , Tedder and Isaacs 1989 , Fearon and Carroll 2000).
First generation CARs contain the TCR activation signal domain consisting of TCRζ. Second 
generation CARs contain costimulatory  signaling domains as well: either CD28 or 4-1BB. 
The 3rd generation CARs contain further advancements such asdouble costimulatory 
modules com prised of CD28, 4
-1BBplus TCRζ ( June 2007, June et al 2009 ,Kohn et al 2011 ).
CTL 019 ( CART -19) is anadoptive cellular immunotherapy  that uses the autologous
peripheral blood T cells that have been genetically  modified ex vivo to target CD19 on the 
surface of B cells. As shown in Figure 1-1, the CAR approach uses genetically  programmed 
lymphocy tes transduce dwith chimeric receptor genes to combine the effector functions of T 
lymphocy tes with the ability  of antibodies to recognize predefined 
surface antigens with high 
specificit y in a non-MHC restricted manner (Gross et al 1989 , Pinthus et al 2003). These 
receptors have the ability  to recognize intact membrane proteins independent of antigen
processing .The tumor antigen binding function of CAR is usually  accomplished by the 
inclusion of a single chain variable 
fragment (scFv) antibody , containing theheavy chain 
variable domain (VH)and light chain variable domain (VL)chains joined by a peptide linker 
of about 15 residues in length (Mullaney  et al 2001 ).
 

Novartis Confidential Page 30
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
Figure 1-1 CTL019 chimeric antigen receptor design
Early results from ongoing clinical trials of CTL019 in r/rCLL and r/r ALL have shown 
promising and durable anti-tumor efficacy  (Porter et al 2011, Grupp et al 2013, Maude 2014 ).
It is anticipated that CTL019 may offer a therapeutic alternative for patients with r/r B cell 
malignancies who are either SCT ineligible or who have relapsed after SCT, which may offer 
a greater durability  of remission than current salvage therapies. In the future, CTL 019 may 
also have the potential to replace SCT as a therapeutic choice, expanding patient eligibility  by 
obviating the need for matched donors along with potentially  lower rates of upfront mortalit y 
and morbidity .
1.2.1.1 Non
-clinical experience
Extensive literature supports the use of engineered T cells for tumor immunotherapy  in rodent 
tumor models (Calogero et al 2000, Clay et al 2002 , Hombach et al 2002, Pule et al 2003, 
Sadelain 2003). Others have used electroporation or retroviral vectors to create CAR T cells 
and have shown in vivo safety  and efficacy  of adoptively  transferred T cells in 
immunodeficient mouse models (Willemsen et al 2000, Roessig et al 2002 , Brentjens et al 
2003, Cooper et al 2003 , Serrano et al 2006). The incorporation ofcostimulatory signaling 
modules such as CD28 and 4-1BB in second generation CARs increases potency of the 
engineered T cells in pre-clinical studies (Finney  et al 1998, Krause et al 1998 , Eshhar et al 
2001, Maher et al 2002, Finney  et al 2004, Friedmann -Morvinski et al 2005 , Brentjens et al 
2010). The pre-clinical data supporting CAR T cell persistence, expansion and anti-tumor 
efficacy havebeen published ( Gross and Eshhar 1992 , Milone et al 2009 ).
 

Novartis Confidential Page 31
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
1.2.1.2 Clinical experience
For a summary  of ongoing human studies with CTL 019 (patients treated, disease indication, 
CTL 019 dosing), please refer to the Investigator Brochure. 
Initial dosing in adults and children, for safet y reasons, used a split infusion schedule of 
escalating doses . However, the majorit y of patients in the two phase I studies received 
CTL 019 as a single one time infusion or two sequential infusions due to the onset of fevers 
and other clinical events precluding further infusions . For pediatric patients, cells are dosed 
per kg bod y weight where dosing in adults does not consider bod y weight .
Safety
Pediatric r/r Acute Lymphpblastic Leukemia
Toxicities seen in pediatric r/r ALL patients includ eexpected chemotherapy  related adverse 
events (AE) and CTL019 related events of tumor ly sissyndrome (TLS) and CRS /macrophage 
activation syndrome (MAS) (Grupp et al 2013, Maude 2014). TLS and CRS /MAS in ALL 
patients typicall y occurred within days to a week following CTL 019 infusion and correlated 
with peak in vivo CTL019 cellexpansion
. TLS complications were managed as per standard 
of care includ ingproph ylactic allopurinol (in patients with elevated uric acid or high tumor 
burden) and fluids, and rasburicase as needed. CRS/MAS has been managed in pediatric ALL 
patients with supportive care and when needed, tocilizumab (anti-IL-6 receptor monoclonal 
antibody )therapy . Since CRS mechanistically is believed to be arequired part of the 
antitumor mechanism of in vivo CTL019 cell expansion and tumor killing, tocilizumab was 
administered for CRS only after symptoms became moderate or severe. This included
worsening respiratory  distress, pulmonary  infiltrates, increasing oxygen requirement (defined 
as high-flow oxy gen and/or need for mechanical ventilation ),hemody namic instability  despite 
intravenous fluids and moderate /high dose vasopressor support , and/or rapid clinical 
deterioration. Preliminary  data supports that management with tocilizumab does not appear to 
diminish CTL019 cell expansion, therefore tocilizumab should be administered for CRS when 
symptoms warrant treatment per the CRS management algorithm (Figure 6-1). Steroids 
following CTL019 infusion were avoided and given only under life threatening situations due 
to their know
nlympholy tic effects. Clinical responses do not appear to correlate prior 
relapsed or refractory  status of the patient . CRS severity  appears to correlate with pre -infusion 
tumor burden in pediatric ALL but not with CTL019 transduced cell numbers within the range 
of cell doses studied. More severe CRS is associated with earlier clinical onset of CRS related 
symptoms in pediatric r/r ALL p
atients. Refer to Section 6.2.4.2 for guidance related to CRS 
management and the [I nvestigator Brochure] for additional safety  information.
As of May 2015 51 pediatric r/r ALL patients were treated on the CHP959 Phase I  study with 
either one, two, or three doses of CTL 019 with split dosing (10%, 30%, 60%) .The age range 
of patients was4to 22 years. CRS of v ariable severity  was seen in 46 pediatric patients out of 
the 51. Of the 46 patients with CRS, 24 patients had Grade 3 or 4 CRS (47.1 %). Median tim e 
to CRS onset was three days (day 1 to 11) and median time to CRS resolution was 11 days 
(day 6 to 24). CRS that developed into severe Grade 4 (defined as hypotension requiring the 
 

Novartis Confidential Page 32
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
use of two or more vasopressors or respiratory  failure requiring mechanical ventilation) had
an initial onset at median of d ay 2 after infusion, whereas CRS that did not develop into Grade 
4 (non-severe) had an initial onset at a median of day 5  a fter infusion. Fifteen patients (33%) 
required tocilizumab (one to three doses) in addition to supportive care for management of 
CRS which resulted in rapid defervescence and stabilization of blood pressure, with 
improvement (weaning from vasopressor support) over a period of 1 to 3 days. Nine teen 
(42%) patients required admission to the intensive care unit (ICU) with 5 patients requiring 
high dose vasopressor support and 6 patients requiring mechanical ventilation. Disseminated 
intravascular coagulation requiring blood product support was seen in 5 patients and
reversib le encephalopathy  was seen in 16 patients. CRS seen in pediatric patients was 
manageable with supportive care, and, when needed, tocilizumab. All pediatric patients 
recovered fullywith complete reversal of sy mptoms and a normalization of laborato ry results . 
Patients achieving a CR also experienced B-cell aplasia and hypogammaglobulinemia, which 
was supported with periodic intravenous immune globulin infusions as per local guidelines . 
GVHD was not seen in the patients who had previously  undergone an allogeneic SCT with 
known donor chimerism. No acute fatalities were observed in this phase I study .
Maude et al (2014) reported that 13/30 CTL019 treated patients (25 pediatric and 5 adult) in 
the Phase I trials as of March 2014 had neurologic toxic effects, which ranged from delirium 
during the period of high fevers to global encephalopathy  with one or more of the follow ing: 
aphasia, confusion, delirium, and hallucinations. Six patients had delay ed encephalopath y that 
occurred after high fevers had resolved and was independent of the severity  of the CRS and 
whether the patient had received prior tocilizumab therap y. Symptoms were self-limiting 
(lasting 2 to 3 days and resolving over 2 to 3 days), and they resolved fully  without further 
intervention or apparent long-term sequelae. One patient with encephalopathy  had two 
seizures that may  have been caused by  concomitant elec troly te abnormalities. Several patients 
had normal computed tomographic or magnetic resonance imaging of the head and lumbar 
puncture that was negative for infection or leukemia.
Responding CLL and ALL patients demonstrated detectable and prolonged persist ence of
CTL 019 transduced cells in the setting of CR; over 2 years in one ALL patient, and over 4 
years in two CLL patients ( Porter 2011, Grupp 2013, Maude 2014). 
Pediatric r/r Lymphoblastic Lymphoma 
Patients with relapse/refractory  B-cell lymphoblastic lymphoma are a very rare patient 
population with no curative therapies other than allogeneic SCT. To date, patients with B cell 
lymphoblastic ly mphoma have yet to be treated with CTL019. 
Adult r/r ALL
As of May 2015, 21 adult r/r ALL patients have been treated on a phase I trial (UPCC04409 
protocol, [STUDY_ID_REMOVED]) or phase II trial (UPCC21413 protocol, [STUDY_ID_REMOVED]) under the 
Penn IND. The age range is 20 to 71years. CRS was seen in 20 of 21patient s. Seventeen 
patients (81% ) had Grade 3 or 4 CRS and 17 (85%) of these patients required anti-cytokine 
therap y with tocilizumab.
 

Novartis Confidential Page 33
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
The phase II adult r/r ALL UPCC21413 trial utilized a single infusion of a higher dose of 
CTL 019 cells. Among the first six patients treated, three deaths were attributable to Grade 5 
refractory  CRS in the setting of significant concomitant infections. The subsequent six 
patients on this trial were then treated with a reduced cell dose of CTL019. Two early deaths 
out of these six subsequent patients were seen with the lower dose of CTL019 cells, however, 
CRS in these two cases was deemed not to be refractory  to intervention. The cause of death 
was cerebral hemorrhage in one patient and sepsis in the other patient. The last three patients 
treated with the same reduced cell dose of CTL019 using a split dosing model. No early 
deaths were observed. 
Other institutions have also reported fatal SAEs in adult patients associa ted with the use of 
CD19 CARs. In one of these fatal SAEs, death occurred 44 hours post-CD19 CAR T cell 
infusion. The investigators concluded that concomitant sepsis was the most likely  cause of 
death and attributed the etiology  of the death as “possibly  related” to CAR T cell infusion 
(Brentjens 2010). Two other fatal SAEs in adult patients have been reported by other 
institutions outside the University  of Penns ylvania. Each of these deaths occurred within the 
firsttwo weeks of CAR infusion.
Efficacy
As of May 2015, of the 51r/r pediatric ALL patien ts treated in the CHP959 Phase I study ,
46/51 (90%) achieved complete remission (CR or CRi). Similar response rates were seen in 
patients with or without prior allogeneic stem cell transplant . All responding patients 
developed B-cell aplasia. The admini stered dose range per kg was 1.0 x 106to 17.3 x 106
transduced CTL 019 cells/kg . The total transduced CTL 019 cells administered was 0.3 
x 108to 
9.1x 108CTL019 c ells. 
2 Rationale
2.1 Stud y rationale and purpose
Outcome remains poor for patients with r/r pediatric B-cell lineage acute lymphoblastic
leukemia (B-cell ALL). Treatment options for r/r B-cell ALL include further treatment with 
salvage chemotherap y, second allogeneic stem cell transplantation (SCT) or supportive care.
Therap y in this population is not curative with an overall survival of 3to 6 months (Smith 
2010, Tallen 2010 ,Martin 2012 ,Ko 2010 ,Duval 2010 ,Oudot 2008 ).As an example, 
clofarabine was approved by the Food and Drug Administration (FDA )for the treatment of 
pediatric patients with r/r ALL after at least 2 prior therapeutic regiments. The overall 
remission rates were 30% for ALL and 38% for Acute Myeloid Leukemia (AML )in Phase I 
studies (Jeha et al 2004 ); 30% (20% CR or complete remission with incomplete platelet 
recovery [CR p]and 10% Partial Remission [PR]
)for ALL and 26% for AML  inPhase II 
studies (Jeha etal 2006 ).The median duration of remission for patients with ALL who 
achieved at least a partial remission was 9.7 weeks (range 7 to 335 days) in the Phase II study .
CD19 has emerged as an attractive therapeutic target because it is widely  expressed on normal 
andmalignant B-cells throughout B-cell maturation but not on pluripotent stem cells or non–
 

Novartis Confidential Page 34
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
B-cell tissues. The development of CAR T cells to target CD19+ cells (CART19 or CTL 019)
provides an innovative new approach to these malignancies . This approach involves recipient -
derived T cells that are geneticall y modified exvivo via lentiviral transduction to express a 
CD19 antigen recognition domain attached to intracellular signaling domains that mediate T-
cell activation in an MHC independent mann er. Encouraging anti-tumor efficacy  has been 
seen in r/r adult and pediatric ALL and in r/r CLL.
2.2 Rationale for the study  design
This is a single arm, multi -center, phase II study  to determine the efficacy  and safet y of 
CTL 019 in pediatric patients with relapsed or refractory  B-cell ALL and B-cell lymphoblastic 
lymphoma . A single arm study  design is supported by the absence of effective therapies in 
thissetting ,and high unmet medical needs. This study  will enroll approximately  67patients to 
allow 50 pa tients treated . After assessment of eligibility , patients qualify ing for the study  will 
be enrolled and start lymphodepleting chemotherapy  as indicated per protocol , followed by a 
single dose of CTL 019 transduced cells.
The initial 30 patients were treated with the University  of Penns ylvania manufacturing 
process . The remainin gpatients to be treated on this trail will utilize product manufactured by
theNovartis manufacturing process.
The efficacy  of CTL019 will be evaluated through the primary  endpoint of ORR (ORR = CR 
+ CRi) as determined by Independent Review Committee (IRC) assessment, including CR 
and CRi. The choice of ORR as the primary  endpoint is based on evidence that ORR: 1) Is a 
standard outcome measurement in ALL and lymphoblastic lymphoma ; and 2) the established 
correlation with long-term outcome (Cheson et al 2003 , Appelbaum et al 2007, NCCN v1 
2013).
2.2.1 Rationale for ly mphodepletion
Adoptive immunotherapy  strategies may be able tocapitalize on homeostatic T cell 
proliferation (Dummer et al 2002 )
, a recent finding that naive T cells begin toproliferate and 
differentiate into memory -like T cells when total numbers of naive T cells arereduced below 
a certain threshold (Goldrath and Bevan 1999, Surh and Sprent 2000). Host lymphodepletion 
may enhance the effectiveness of adoptivel y transferred T cells (Dummer et al 2002
). 
Homeostatic T cell proliferation can lead to activation of certain immune cell subsets (King et 
al 2004), providing a clue to improved anti-tumor responses .T cells can undergo up to seven 
rounds of cell division after being deprived of contact with antigen presenting cells (Kaech 
and Ahmed 2001, van Stipdonk et al 2001) . Lympho depletion eliminates regulatory  T-cells 
and other competing elements of the immune system that act as “cytokine sinks”, enhancing 
the availabilit y of cytokines such as IL-7 and IL-15 ( Klebanoff et al 2005 ). This hypothesis 
has been tested clinically in patients with metastatic melanoma refractory  toconventional 
treatments (Dudley  et al 2002 ). The patients received a l ymphodepleting conditioning regimen 
consisting ofcyclophosphamide (60mg/kg x 2 days) and fludarabine (25 mg/m2x 5 days) 
prior to adoptive transfer of T cells. Patients with myeloma have been treated with CARs and 
lymphopenia after lymphodepleting chemotherapy , and observed improved engraftment
 

Novartis Confidential Page 35
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
(Laport et al 2003 , Rapoport et al 2005). In this protocol , it ispropose dto infuse CTL 019 T 
cells into patient s that are rendered lymphopenic as a result of cytotoxic chemotherapy. 
Recent data indicates that the increased antitumor efficacy  of adoptive 
transfer following host 
conditioning is more than simply  “making room” because the quantitative recovery  of 
adoptively  transferred T cells in mice reveals that in vivo proliferation following adoptive 
transfer is identical in mice with or without previous irradiation (Palmer et al 2004)
.
In ongoing CTL 019 pediatric ALL  studies, 13 out of the first 16 patients infused with 
CTL 019 cells received a ly mphodepleting conditioning regimen prior to adoptive transfer of T 
cells. Six patients received a lymphodepleting conditioning regimen consisting of 
cyclophosphamide and fludarabine, five patients received cyclophosphamide and etoposide, 
one patient received etoposide and cytarabine and one patient received cyclophosphamide 
alone. Of the three patients who did not receive a lymphodepleting conditioning regimen, two 
patients presented with Absolute Ly mphocy te Count ( ALC) < 1000 at the time of infusion.
2.3 Rationale for dose and regimen selection
Animal studies support a threshold dose of CTL019 cells and therefore the initial clinical dose 
selection was within the range of 1 x 107to 1 x109CTL019 transduced cells (Milone et al 
2009). Please see IB for further information on preclinical studies . For safety  reasons, initial 
phase Icelldosing was divided among three split infusions (10%, 30% and 60% of the total 
cell dose) .Of the 26 pediatric ALL patients that had a complete remission, seven patients 
received a single infusion due to the onset of fevers, yet CRs were observed with either 1to 3
infusions .
In phase I CLL studies, patients have shown responses after a single infusion or multiple 
infusions. I n the p hase II CLLtrial, the dose has been given as a single infusion of 1 to 5 x 107
or 1 to 5 x 108CTL019 transduced cells to study  dose optimization . This single infusion was 
clinically  well tolerated
. No significant differences have been seen inresponses or toxicity  
between these two doses. In responding CLL patients with CR or lasting PR,the CTL0 19 
transduced cell numbers infused have ranged from 1.4 x 107to 1.1x 109cells.
From the data collected to date in patients with CLL and ALL , there does not appear to be a
discernible dose-response relationship with CTL 019 transduced cell numbers infused. This is 
likely  the result of CTL019 transduced cells ability  to proliferate and expand extensively (e.g.
1000 to >
10,000 fold) in vivo. Thus, the administered dose may underestimate the number of 
CTL019 cells in vivo following engraftment and expansion and will vary from patient to 
patient. Additional considerations in this dose selection take into account the manufac turing 
feasibility  of producing adequat
e numbers of CTL019 transduced cells.
In pediatric ALL patients who were treated in the CHP959 study , patients received one, two 
or three CTL019 infusions. Tumor responses were seen with each of these dosing schedules. 
Nineteen patients within the CHP959 study received only a single infusion of CTL 019 due to 
the onset of fever with a cell range of 1.1 x 106to 6.3 x106CTL019 cells per kgwith an 
acceptable safet y profile . At the lower endof this dose range there is concern that doses less 
 

Novartis Confidential Page 36
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
than 2 x 106CTL 019 cells/kg may beassociated with a lack of respon se or CR with an early 
relapse.
Several patients received total CTL 019 cell dose of over 5 x 108cells (e.g. 6.8, 7.8 and 9.1 x 
108total CTL019 cells). Since the experience with these higher doses is more limited, a cut 
off of 2.5 x 108cells as a maximum dose, based upon a weight ≥50 kg, is proposed. 
Manufacturing consideration and practicalit y were also considered in the dosing selection.
Therefore, the targeted CTL 019cell dose for pediatric ALL patients is2to 5x 106CTL019 
transduced viable T cells per kg body  weight with a maximum dose of 2.5x 108CTL019 
transduced 
viable T cells (non-weight adjusted) .
2.4 Rationale for choice of combination drugs
Not applicable .
2.5 Rationale for choice of comparator drugs
Not applicable .
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3-1below. These objectives will be 
assessed in the acute lymphoblastic leukemia patients and separatel y in the lymphoblastic 
leukemia patients.
If there are no more than 5 lymphoblastic lymphoma patients 
treated, data for these patients 
will be summarized primarily  via listings.
 

Novartis Confidential Page 37
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
Table 3-1 Objectives and related endpoints
Objective Endpoint Anal ysis
Primary
Evaluate the efficacy of CTL019 therapy as measured by overall 
remission rate (ORR) 6 months after CTL019 administration , which 
includes CR and CR with incomplete blood count recovery (CRi) as 
determined by IRCassessment for acute lymphoblastic leukemia 
patients ..
ORR in Lymphoblastic Lymphoma patients will be evaluated separately 
using local investigator’s assessment.● ORR (= CR + CRi) per IRCassessment in ALL patients ; See 
Appendix 1 for response definition
● ORR (= CR + CRi) per local investigator’s assessment in 
lymphoblastic lymphoma  patients; See Appendix 2 for response 
definitionRefer to Section 10.4
Key secondary
Not applicable Not applicable
Other secondary
Evaluate the percentage of patients who achieve CR or CRi at M onth 6 
without SCT between CTL019 infusion and Month 6 response 
assessment● Percentage of patients who achieve CR or CRi at M onth 6 
without SCT between CTL019 infusion and Month 6 response 
assessmentRefer to Section 10.5.2.1
Evalua te the percentage of patients who achieve CR or CRi and then
proceed to SCT while in remission before Month 6 response 
assessment● Percentage of patients who achieve CR or CRi and then 
proceed to SCT while in remission prior to Month 6 response 
assessment
● In addition, all patients that proceed to SCT after CTL019 
infusion will be describedRefer to Section 10.5.2.2
Evaluate the duration of remission (DOR) ● DOR , i.e. the time from achievement of CR or CRi ,whichever 
occurs first ,to relapse or death due to ALL
● Site of involvement of subsequent relapse will be summarizedRefer to Section 10.5.2.3
Evaluate the quality of response by assessing the percentage of 
patients who ach ieve a best overall response (BOR) of CR or CRi with 
aminimal residual disease (MRD) negative bone marrow 6 months after 
CTL019 infusion and at D28 by central analysis● Percentage of patients with BOR of CR or CRi with MRD 
negative bone marrow 6 months after CTL019 infusion, among all 
patients who are infused 
● MRD status before treatment, at day 28 +/- 4 days after 
treatment will also be describedRefer to Section 10.5.2.4
Evaluate the rel apse -free survival (RFS) ● RFS, i.e. the time from achievement of CR or CRi wh ichever 
occurs first to relapse or death due to any cause during CR or C RiRefer to Section 10.5.2.5
Evaluate the event -free survival (EFS) ● EFS, i.e. the time from date of CTL019 infusion to the earliest of 
death, relapse or treatment failureRefer to Section 10.5.2.6
 

Novartis Confidential Page 38
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
Objective Endpoint Anal ysis
Evaluate the overall survival (OS) ● OS,i.e. the time from date of CTL019 infusion to the date of 
death due to any reasonRefer to Section 10.5.2.7
Evaluate the response at Day 28 +/ -4 days ● Proportion of patients attaining CR or CRi at Day 28 +/ -4 days 
post CTL019 infusionRefer to Section 10.5.2.8
Evaluate the impact of baseline tumor burden on response ● Response as a function of baseline tumor burden (tumor load) 
(MRD, extramedull ary disease, etc)Refer to Section 10.5.2.9
Evaluate the safety of CTL019 therapy ● Type, frequency and severity of adverse events and laboratory 
abnormalitiesRefer to Section 10.5.3
Characterize the in vivo cellular pharmacokinetic (PK) profile (levels, 
persistence, trafficking) of CTL019 cells in target tissues (blood, bone 
marrow, CSF, and other tissues if available)● CTL019 transgene levels b y qPCR in blood, bone marrow and 
CSF if available
● Expression of CTL019 detected by flow cytometry in blood and 
bone marrow
● Cmax, Tmax, AUCs and other relevant PK parameters of 
CTL019 in blood, bone -marrow, CSF if a vailable
● Maximum extent of expansion of CTL019 in blood (Cmax/
Cpost-infusion ,hr)
● Persistence of CTL019 in blood ,bone marrow , and CSF (based 
on Time > Limit of Quantification [ LOQ ], Time >other threshold 
CTL019 levels, Mean Residence Time [MRT]last)Refer to Section 10.5.4
Describe the prevalence and  incidence of immunogenicity to CTL019 ● Prevalence and incidence of immunogenicity and anti -CTL019 
assay titers Refer to Section 10.5.3.4
Describe the profile of soluble immune factors that may be key to 
cytokine release syndrome ● Frequent monitoring of c oncentrations of soluble immune factors 
in bloodRefer to Section 10.5.3.6
Describe the levels of B and T cells (peripheral blood and bone 
marrow ) prior to and following CTL019 in safety monitoring● Lymphocyte subsets of B and T cells and description of 
associated  safety eventsRefer to Section 10.5.3.7
 

Novartis Confidential Page 39
Oncology Amended Protocol Version 02 (Clean) Protocol No. CCTL019B2205J
 

Novartis Confidential Page 40
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
4 Study  design
4.1 Description of study  design
This is a single arm, multi -center, phase II study  to determine the efficacy  and safet y of 
CTL 019 in pediatric patients with relapsed or refractory  B-cell ALL and B-cell lymphoblastic 
lymphoma . The study  will have the following sequential phases for all patients: Screening
(Section 7.1.1), Pre-Treatment ( Cell Product Preparation and Lymphodepleting 
Chemotherap y; Section 7.1.2), Treatment andPrimary  Follow -up ( Section 7.1.3), Secondary 
Follow -
up (if applicable ; Section 7.1.4), and Survival Follow - up (Section 7.1.5). The total 
duration of the study  is 5 years. After CTL019 
infusion, efficacy  will be assessed monthly  for 
the first 6 months, then quarterl y up to 2 years and semi -annuall y afterwards up to 5 years, or 
until patient relapse. Efficacy  assessments will be based on the Novartis guidelines for 
response assessment in ALL (Appendix 1), which isbased on NCCN version 1.2013 
guidelines , Cheson et al (2003) and Appelbaum et 
al (2007) .Safety  will be assessed 
throughout the study .A post-study  follow -up (Section 7.1.6) for lentiviral vector safet y will 
continue under a separate destination protocol perthe following health authority guidelines :
FDA (2006a) , FDA (2006b) , European Medicines Agency  (EMA) (2008) andEMA (2009) .
For sites wit
h no prior CTL019 experience , a staggered treatment design will be implemented
at each site for the first two patients for logistical and safety  purposes. The first patient will be 
treated and a 14 day follow -upperiod must be completed before the second patient can be 
treated . Then a second patient may be treated and a 14 day follow up period completed .After 
completing this staggered treatment design for the first two patients, subsequent patients may 
proceed with treatment of patients without stagger ing.
Figure 4-1 Study  design
 

Novartis Confidential Page 41
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
4.1.1 Apheresis assessment
Cryopreserved apheresis products collected from the patient prior to study  entry (historical) 
may beusable for CTL019 manufacturing if collected at anappropriatel y certified apheresis 
center and the product is accepted by the manufacturing facility . If a historical apheresis 
product is not available, an apheresis procedure will be scheduled for cell procurement prior 
to study  enrollment .It is strongl y recommended that apheresis be scheduled prior to any 
planned chemotherap y or non-physiologic dose of steroid administration as an absolute 
peripheral blood T
-cell count. Subjects with an absolute lymphoc yte count (ALC) < 500/µ L 
during screening, should have a CD3 count of ≥150/ µL to be eligible for leukapheresis 
collection.
For guidelines on optimal patient timing of apheresis collection, please refer to the 
Leukapheresis Key Requirements within the [Leukapheresis, Cryopreservation & Scheduling 
Manual].For patients developing grade 2to 4 acute GVHD or extensive chronic GVHD 
following the collection of an apheresis product, such an apheresis product cannot be used for 
CTL 019manufacturing or infusion due to concerns of auto- reactive T cells with an increased 
risk for inducing or exacerbating GVHD by  the manufactured product .
During the screening phase , informed consent /assent forms will be signed and all clinical 
eligibility  criteria (defined as all inclusion/exclusion criteria except that which pertains to the 
apheresis product) will be assessed. Only  following informed consent /assent and confirmation 
of all clinical eligibility  criteria will the patient’s apheresis product be shipped to the 
manufacturing facilit y. The manufacturing facility  will then evaluate the patient’s apheresis 
product for acceptance. Enrollment is defined as the point at which the patient meets all 
clinical inclusion/exclusion criteria, and the patients’ apheres isproduct is received and 
accepted b y the manufacturing facility .
 
 
4.2 Definition of end of the study
The end of study  is defined as the last patient’s last visit (LPLV), which is the last patient’s 
Month 60 evaluation, or the time of premature withdrawal.
Patients who discontinue the “Treatment and Primary  Follow -Up Phase” before month 60 will 
continue to be followed in the secondary  follow -up phase in order to collect health authorit y 
requested data (e.g. delay ed adverse events) up to5 years after CTL019 infusion. It is 
anticipated that patients may leave the primary  follow -up and move to secondary  follow -up 
due to reasons including: treatment failure, relapse after remission, pursuing SCT while in 
remission, or withdrawal from the pr imary  follow -up.
In addition, semiannual and annual evaluations will be performed for up to 15 years on all 
patient s under a separate destination protocol as recommended by health authority  guidance
for patients treated with gene therapies. All patients who either complete the study  or 
prematurel y discontinue from the study  will be enrolled in this destination protocol at the time 
of study  completion/discontinuation (separate informed consent/assent forms will be provided 
for this protocol; Section 7.1.6).
 

Novartis Confidential Page 42
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Patients may continue to be followed under the current protocol for survival as defined above 
or until they choose to enroll into the 15 year long term follow -up protocol
([CCTL 019A2205B]) , whichever occurs first. The survival follow -ups can be conducted in 
the form of telephone contact.
4.3 Early study  termination
The study  can be terminated at any time for any reason by Novartis or if any of the stopping 
criteria described in Section 6.2.4.1.1 are met. The investigator may  be informed of additional 
procedures to be followed in order to ensure that adequate consideration is given to the 
protection of the patient’s interests. For patients who have received a CTL019 infusion, along 
term post-study  follow -up for lentiviral vector safet y will still continue under a separate 
destination protocol for 15 years post infusion per health authority guidelines. The 
investigator will be responsible for informing Institutional Review Boards (IRBs)and/or 
Independent Ethics Committee s (IECs) of the early termination of the trial and any other 
regulatory  committee as applicable.
5 Population
5.1 Patient population
The primary target population consists of pediatric patients with B-cell ALL and 
lymphoblastic lymphoma who are primary  refractory , chemo -refractory , relapsed after
allogeneic SCT, or are otherwise ineligible for allogeneic SCT.Approximately  67 patients 
will be enrolle dto allow 50 total patients to be treated.
The primary  analysis will be comprised of at least 50 acute lymphoblastic leukemia or 
lymphoblastic ly mphoma patients treated .
In order to satisfy  European PIP requirement, at least 40 patients <18 years of age will be 
treated at the time of primary  analysis.  Therefore, no more than 10 patients’ ≥18 years of
age will be treated . Site will be notified when this cap is reaching.
The investigator or designee must ensure that only patients who meet all the following 
inclusion and none of the exclusion criteria are offered treatment in the study .
5.2 Inclusion criteri a
Patients eligible for inclusion in this study  must meet allof the following criteria:
1. [Retired from UPenn protocol version 2.0 ]
2. For relapsed patients, CD19 tumor expression demonstrated in bone marrow or peripheral 
blood by  flow cy tometry  within 3 months of study  entry
3.Adequate organ function defined as:
a.Renal function defined as:
Calculated c reatinine clearance or radioisotope GFR > 60 mL /min/1.73 m2OR
 

Novartis Confidential Page 43
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
A serum creatinine based on age/gender as follows:
Maximum Serum Creatinine
(mg/dL)
Age Male Female
1 to < 2 years 0.6 0.6
2to < 6 years 0.8 0.8
6 to < 10 years 1.0 1.0
10 to < 13 years 1.2 1.2
13 to < 16 years 1.5 1.4
≥ 16 years 1.7 1.4
b.ALT < 5times the ULN for age
c.Bilirubin < 2.0 mg/dl
d.Must have a minimum level of pulmonary  reserve defined as ≤ Grade 1 d yspnea and 
pulse ox ygen ation > 91% on room air
e.LVS F ≥ 28% confirmed by  echocardiogram, or LVEF ≥ 45% confirmed by 
echocardiogram or MUGA
4.Bone marrow with ≥ 5% ly mphoblasts by morphologic assessment at screening
5.Life expectancy  > 12 weeks
6. [Retired from UPenn protocol version 2.0 ]
7.Karnofsk y (age ≥16 y ears) or Lansk y (age < 16 years) performance status ≥ 50 at 
screening
8.Signed written informed consent and assent forms if applic able must be obtained prior to 
any study  procedures
9.Once all other eligibility  criteria are confirmed, m ust have an apheresis product of non -
mobilized cells received and accepted by the manufacturing site . Note: Apheresis product 
will not be shipped to or assessed for acceptance by the manufacturing site until 
documented confirmation of all other eligibility  criteria is received
10. Relapsed or refractory  pediatric B -cellAcute Ly mphoblastic Leukemia and 
Lym phoblastic L ymphoma
a.2nd or greater BM relapse OR
b.Any BM relapse after allogeneic SCT and must be > 6 months from SCT at the time 
of CTL 019 infusion OR
c.Primary  refractory  as defined by  not achieving a CR after 2 cy cles of a standard 
chemotherap y regimen or chemorefractory  as defined by  not achieving a CR afte r 1 
cycle of standard chemotherapy  for relapse leukemia OR
d.Patients with Ph+ ALL are eligible if they are intolerant to or have failed two lines of 
TKI therap y, or if TKI therap y is contraindicated OR
e.Ineligible for allogeneic SCT because of:
Comorbid dise ase
Other contraindications to allogeneic SCT conditioning regimen
Lack of suitable donor
Prior SCT
 

Novartis Confidential Page 44
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Declines allogeneic SCT as a therapeutic option after documented discussion, 
including expected outcomes, about the role of SCT with a BMT ph ysician not 
part of the stud y team
11.Age 3 at the time of screening to age 21 at the time of initial diagnosis.
5.3 Exclusion criteria
Patients meeting an y of the following criteria must be excluded from the study :
1. Isolated extra- medullary  disease relapse
2.Patients with conc omitant genetic sy ndrome: such as patients with Fanconi anemia, 
Kostmann sy ndrome, Shwachman s yndrome or any other known bone marrow failure 
syndrome . Patients with Down Sy ndrome will not be excluded.
3. Patients with Burkitt’s lymphoma/leukemia (i.e. patien ts with mature B -cell ALL, 
leukemia with B -cell [ sIg positive and kappa or lambda restricted positivity ] ALL, with
FAB L3 morphology  and /or a MYC translocation )
4.Prior malignancy , except carcinoma in situ of the skin or cervix treated with curative 
intent and with no evidence ofactive disease
5. P rior treatment with gene therap yproduct
6. H as had treatment with any  prior anti-CD19/anti -CD3 therap y, or any  other anti -
CD19 therap y
7. [Retired from UPenn protocol version 2.0 ]
8. [Retired from UPenn protocol version 2.0 ]
9.Presence of G rade 2 to 4 acute or extensive chronic graft -versus- host disease (GVHD)
10. [Retired from UPenn protocol version 2.0 ]
11.Active CNS involvement by  malignancy , defined as CNS-3 per NCCN guidelines. Note: 
Patients with history  of CNS disease that has been effectivel y treated will be eligible
12. Patient has participated in an investigational research study  using an investigational agent
within the last 30 day s prior to screening
13.Pregnant or nursing (lactating) women .NOTE: female study  participants of reproductive 
potential must have a negative serum or urine pregnancy  test performed within 48 hours 
before infusion
14. [Retired from UPenn protocol version 2.0 ]
15.Active or l atent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any  
unco ntrolled infection at screening
16.HIV positive test within 8 weeks of screening
17.The following medications are excluded:
a.Steroids : Therapeutic doses of steroids must be stopped > 72 hours prior to CTL 019 
infusion. However, the following phy siological replacement doses of steroids are 
allowed: 
<12 mg/m2/day hy drocortisone or equivalent
b.Allogeneic cellular therapy: Any donor l ymphocy te infusions (DLI) must be 
completed > 6 weeks prior to CTL 019 infusion
c.GVHD therapies: Any drug used for GVHD must be stopped > 4 weeks prior to 
CTL 019 infusion (e.g. calcineurin inhibitors, methotrexate or other chemotherapy  
 

Novartis Confidential Page 45
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
drugs, m ycophenol yate, rapam ycin, thalidomide, or immunosuppressive antibodies 
such as anti -CD20 (rituximab), anti -TNF, anti- IL6 or anti -IL6R)
d.Chemotherapy:
The following drugs must be stopped > 1 week prior to CTL 019 infusion and 
should not be administered concomitantl y or following l ymphodepleting 
chemotherap y: hydroxy urea, vincristine, 6 -mercaptopurine, 6- thioguanine , 
methotrexate < 25 mg/m2, cy tosine arabinoside < 100 mg/m2/day , asparaginase
(non-pegy lated)
The fol lowing drugs must be stopped > 2 weeks prior to CTL 019 infusion: 
salvage chemotherap y (e.g. clofarabine, cy tosine arabinoside >100 mg/m2, 
anthracyclines, cyclophosphamide), excluding the required l ymphodepleting 
chemotherap y drugs
Pegy lated -aspariginase must be stopped >4 weeks prior to CTL 019 infusion 
e.CNS disease prophylaxis :
CNS prophy laxis treatment must be stopped > 1 week prior to CTL019 infusion 
(e.g. intrathecal methotrexate) 
f.Anti T -cell Therapy: Administration of any  T cell ly tic or toxic agent (e.g. 
alemtuzumab) prior to CTL 019 is strongl y discouraged since residual l ytic levels may  
destroy  the infused CTL019 cells and/or prevent their in vivo ex pansion. I f such an 
agent has been administered within 8 weeks prior to CTL 019, contact Novartis , 
consider consultation with an pharmacology  expert, and consider measuring residual 
drug levels, if feasible, prior to CTL 019 infusion.
18.Women of child- bearing potential (defined as all women phy siologicall y capable of 
becoming pregnant) and all male participants, unless they  are using highl y effective 
methods of contraception for a period of 1 year after the CTL019 infusion).  Women are to 
continue contraception until CAR cells are no longer present in the blood by  PCR. Highl y 
effective contraception methods include:
a.Total abstinence (when this is in line with the preferred and usual lifest yle of the 
patient. Periodic abstinence (e.g., calendar, ovulation, sy mpto thermal, post -ovulation 
methods) and withdrawal are NOT acceptable methods of contraception
b.Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) or tubal ligation at least six weeks before taking stud y treatment. I n 
case of oophorectom y alone, only  when the reproductive status of the woman has 
been confirmed b y follow up hormone level assessment
c.Male sterilization (at least 6 months prior to screening). For female patients on the 
study  the vasectomized male partner should be the sole partner for that patient.
d.Use of oral, injected or implanted hormonal methods of contraception or other forms 
of hormonal contraception that have comparable efficacy  (failure rate <1%), for 
example hormone vaginal ring or transdermal hor mone contraception
e.Use of IUDs are excluded due to increased risks of infection and bleeding in this 
population.
f.In case of use of oral contraception, women must be stable on the same pill for a 
minimum of 3 months before taking stud y treatment
 

Novartis Confidential Page 46
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Women who a re not of reproductive potential (defined as either <11 years of age, Tanner 
Stage 1, post -menopausal for at least 24 consecutive months (i.e. have had no menses) or 
have undergone h ysterectomy , bilateral salpingectomy , and/or bilateral oophorectom y) are 
eligible without requiring the use of contraception. Women who are not yet of 
reproductive potential are to agree to use acceptable forms of contraception when they  
reach reproductive potential if within 1 y ear of CTL019 or if CAR cells are present in the 
blood by  PCR. Acceptable documentation includes written or oral documentation 
communicated b y clinician or clinician’s staff of one of the following: 
a.Demographics show age <11
b.Physical examination indicates Tanner Stage 1
c.Physician report/letter 
d.
Operative report or other source documentation in the patient record 
e.Discharge summary  
f.Follicle stimulating hormone measurement elevated into the menopausal range
6 Treatment
6.1 Study  treatmen t
CTL 019 is an autologous cellular immunotherapy  product that is comprised of CD3+ T cells 
that have undergone ex vivo T cell activation, gene modification, expansion and formulation 
in infusible cryomedia. The transgene to be expressed via lentiviral vector transduction is a 
CAR targeted against the CD19 antigen. The CAR contains a murine scFv that targets CD19 
linked to a transmembrane region derived from the CD8 receptor, which is linked to an 
intracellular bipartite signaling chain of TCR -ζ (or CD3- ζ) and 4-1BB intracellular signaling 
domains. The extracellular scFv with specificity  for CD19 is derived from a murine
monoclonal antibody .T cells are enriched from a patient leukapheresis unit are 
expanded ex 
vivo using commercially available magnetic beads that are coated with anti-CD3 and anti-
CD28 monoclonal antibodies. The cells are transduced with the CD19 CAR lentiviral vector .
The residual non-integrated vector is washed away  during the process. CTL 019 cells 
generall y areexpanded ex vivo for up to 10 day sor may  be more depending on manufacturing 
conditions. At theend of the culture, the CTL019 cells are depleted of magnetic beads, 
washed, concentrated, and cryopreserved. The product must pass all relea se criteria prior to 
infusion.
Adose of CTL019 transduced cells for pediatric patients will consist of asingle infusion of 2 
to 5x 106CTL019 transduced cells per kg body  weight with a maximum dose of 2.5x 108
CTL019 cells (non-weight adjusted) .
6.1.1 Dosing regimen
6.1.1.1 Lymphodepleting chemotherapy
When given, lymphodepleting chemotherap y should be started before CTL 019 infusion so 
that CTL 019 cells will be given 2to14days after completion of the lymphodepleting 
chemotherap y.The chemotherapy  start date will vary based on the selected chemotherapy . 
 

Novartis Confidential Page 47
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
The purpose ofthis chemotherap y is to induce lymphopenia in order to facilitate engraftment 
and homeostatic expansion of CTL 019 cells. For lymphodepleting chemotherap y,
cyclophosphamide -based regimens are the agents of choice as there is the most experie nce 
with the use of these agents in facilitating adoptive immunotherapy .The required
lymphodepleting reg imen is:
Fludarabine (30 mg/m2intraven ously [i.v.]daily  for 4 doses) 
andcyclophosphamide 
(500 mg/m2i.v. daily  for 2 doses starting with the first dose of fludarabine )
If there was previous Grade 4hemorrhagic cystitis with cyclophosphamide, or the patient 
demonstrated resistance to a previous cyclophosphamide -containing regimen, then the 
following will be used :
Cytarabine (500 mg/m2i.v. daily  for2 day s ) and etoposide (150 mg/m2i.v. daily  x 3 
daysstarting with the first dose of cy tarabine )
If patients have a White Blood Cell (WBC )count ≤ 1,000 cells/ µL within one week prior to 
CTL 019 infusion, ly mphodepleting chemotherapy is NOT required.
6.1.1.2 CTL019 infusion
The CTL019 cell product will beprepared andreleased by the manufacturing facilit y to the 
study  site approximately  3 to 4 weeks after manufacturing has commenced, provided all 
required safet y and quality release criteria have been met.
Prior to CTL019 infusion : the following criteria must be met:
1.Influenza Testing: All patients must undergo a rapid influenza diagnostic test (only  
during the months of October through May )within 10 day s prior to the planned CL T019 
infusion. I f the patient is positive for influenza, oseltamivir phosphate or zanamivir should 
administered for 10 day s as preventative treatment (see Tamiflu® or Relenza® package 
insert for dosing).The patient must complete their 10 day preventative treatment course 
prior to receiving CTL019. The test does not need to be repeat ed prior to CTL 019 infusion 
however if flu-like or respiratory  sign sand s ymptoms are present, CTL 019 infusion 
should be delay ed until patient is asy mptomatic. 
2.Performance Status : Patient should not experience a significant change in clinical or
performan ce status compared to initial eligibility  criteria that would, in the opinion of the 
treating ph ysician, increase the risk of adverse events associated with experimental cell 
infusion.
3.Laboratory Abnormalities: P
atients experiencing laboratory  abnormalities after 
enrollment, that in the opinion of the treating investigator or PI may  impact subject safet y 
or the subjects’ abilit y to receive the CTL019 infusion, may have their infusion delayed 
until it is determined to be clinically  appropriate to proceed with the CTL 019 infusion
4.Leukemia Disease Status: Prior to CTL 019 infusion and following l ymphodepleting 
(LD) chemotherap y patients must not have accelerating disease, as this will put them at 
unacceptable risk for severe CRS.  Patients should not receive CTL019 infusion if they  
exhibit significant progression of disease during or following LD chemotherapy  as 
evidenced b y:
Significant and increasing circulating blasts 
 

Novartis Confidential Page 48
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Significant increases in organomegal y
Clinical evidence of new CNS di sease
5.Chemotherapy Toxicity :Patientsexpe rie nc ingtoxicities from th eirprece d ing
lymphodepleting che mot her apywill h a vetheir infusion sched uledelaye d until these
toxicities have been resolved (to G rade 1 or baseline) . The spec ific tox icitieswarranting
delay of CTL019 cellinfusion includ e :
a.Pulmonary : Re quirement forsuppl ement al oxyge n tokeep satura tion gr eater than
91% or presence o f progressive ra di ogra phic abno rma lities on che stx -ray
b.Cardiac : New cardiac ar rhythmia not control led wi th medical management . Prior to 
infusion ECG also required ( Table 7 -
1).
c.Hypotension :requiring vasopressor suppor t
6.Infection: CTL 019 infusion must be delay ed if there is an uncontrolled active infection, 
as evidenced by positive blood cultures for bacteria, fungus, or PCR positivity  for new 
viral DNA within 72 hours of CTL 019 cell infusion, or clinical or radiographic evidence 
of active infection. Following the treatment of a recent infection, significant improvement 
must be established either clinically  and/or radiographicall y, prior to CTL019 infusion
7.GVHD Status: Patients should not be infused if they  develop Grade 2 -4 acute or 
extensive chronic GVHD since the time of screening.
8.Concomitant Medications: If patients aretaking any  of the following medications, their 
infusion must be delay ed until the medications have been stopped according to the 
following :
a.Steroids : Therapeutic doses of steroids must be stopped > 72 hours prior to CTL 019 
infusion. However, the follow ing ph ysiological replacement doses of steroids are 
allowed: 
<12 mg/m2/day hy drocortisone or equivalent
b.Allogeneic cellular therapy : Any  donor l ymphocy te infusions (DLI) must be 
completed > 6 weeks prior to CTL 019 infusion
c.GVHD therapies : Any  drug used fo r GVHD must be stopped > 4 weeks prior to 
CTL 019 infusion (e.g. calcineurin inhibitors, methotrexate or other chemotherapy  
drugs, m ycophenol yate, rapam ycin, thalidomide, or immunosuppressive antibodies 
such as rituximab, anti -TNF, anti -IL6 or anti -IL6R)
d.Chemotherapy :
The following drugs must be stopped > 1 week prior to CTL 019 infusion and 
should not be administered concomitantl y or following lymphodepleting 
chemotherap y: hydroxy urea, vincristine, 6 -mercaptopurine, 6- thioguanine, 
methotrexate < 25 mg/m2, cytosine arabinoside < 1 00 mg/m2/day, asparaginase
(non-pegy lated)
The following drugs must be stopped > 
2weeks prior to CTL 019 infusion: 
salvage chemotherap y (e.g. clofarabine, cy tosine arabinoside > 100 mg/m 2, 
anthracy clines, cy clophosphamide) , excluding the required l ymphodepleting 
chemotherap y drugs
Pegylated-
aspariginase must be stopped >4 weeks prior to CTL 019 infusion 
e.CNS disease prophylaxis :
 

Novartis Confidential Page 49
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
1.CNS prophy laxis treatment must be stopped > 1 week prior to CTL019 
infusion ( e.g. intrathecal methotrexate ).
f.Anti T -cell Therapy : Administration of any  T cell ly tic or toxic agent (e.g. 
alemtuzumab) prior to CTL 019 is strongl y discouraged since residual l ytic levels may  
destroy  the infused CTL019 cells and/or prevent their in vivo expansion. I f such an 
agent has been administered within 8 weeks prior to CTL 019, contact Novartis , 
consider consultation with an pharmacology  expert, and consider measuring residual 
drug levels, if feasible, prior to CTL 019 infusion.
1.Stem Cell Transplant : Reconfirm that patient is > 6 months from SCT at the time of 
CTL019 infusion (if applicable).
9.Lymphodepleting Chemotherapy Timing: Ifthere is a delay  of 4 or more weeks
between completion of lymphodepleting chemotherap yand the scheduled infusion, the 
WBC > 1000/µL , the patient will need to be re -treated with ly mphodepleting 
chemotherap y.
10.Cardiac Evaluations: In the event that the time between screening cardiac 
ECHO/MUGA and CTL019 infusion exceeds 6 weeks
, cardiac imaging must be repeated 
to confirm a LVSF ≥ 28% by  echocardiogra m, or L VEF ≥ 45% b y echocardiogram or 
MUGA.
11.Pregnancy: Patient must undergo a pregnancy  test (urine or serum) within 48 hours prior 
to infusion (Table 7 -1)
Additional safety procedures prior to administration :The risk of tumor lysis syndrome 
(TLS)is dependent 
on disease burden . Patients will be closely  monitored both before and 
after lymphode pleting chemotherap y and CTL019 infusions including blood tests for 
potassium and uric acid. Patients withelevated uric acid or high tumor burden should receive 
prophy lactic allopurinol, or a non-allopurinol alternative (e.g. febuxostat) .Infection 
prophy laxis should follow local guidelines dictated only by the preceding lymphodepleting 
chemotherap y
. Infection prophy laxis per se for CTL 019 is not recommended. The on-site 
pharmacy must confirm that two dose sof tocilizumab (Section 6.1.3) is on site prior to 
CTL019 infusion and available for administration in order 
to manage severe suspected 
toxicities.
Premedication: Side effects from T cell infusions can include fever, chills and/or nausea. All 
patients should be pre -medi cated with acetaminophen or paracetamol and diphenhy dramine or 
an H1 antihistamine. These medications can be repeated every 6  h ours asneeded. Non-
steroi dal anti -inflammatory  medication may be prescribed if the patient continues to have 
fever not relieved with acetaminophen or paracetamol. Steroids should NOT be used for 
premedication. It is recommended that patients NOT receive systemic corticosteroids other 
than physiologic replacement of hydrocortisone at any time, except in the case of life 
threatening emergency , since this may have an adverse effect onCTL 019 cell expansion and 
function.
Cell thawing and infusion of CTL019 product
:
A study  physician MUST evaluate the patient just prior to infusion to ensure the patient meets 
CTL 019 infusion criteria. Trained study  staff will administer theCTL019 infusion using 
precautions for immunosuppressed patients. Protective isolation should follow institutional 
 

Novartis Confidential Page 50
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
standards and policies. Emergency  medical equipment should be available during the infusion 
in case the patient hasasignificant reaction to the infusion such as anaphy laxis or severe 
hypotension. A single dose of 2to 5 x 106autologous CTL 019 transduced viable Tcells per 
kgbody  weight, with a maximum dose of 2.5 x 108autologous CTL019 transduced viable T 
cells will be administered .For patients with manufactured cell numbers falling below the 
above recommended dose ranges, CTL 019 therapy  will still be administered
if product meet s
all other manufacturing release criteria.
Depending on the volume of the CTL019 product, it will be given either as an IV infusion
through a latex freei.v. tubin gWITHOUT a leuko cytefilter (approximately  10 – 20 mL per 
minute adjusted as appropriate for smaller children and smaller volumes) or as an IV push via 
a syringe (for smaller volumes). It is recommended that the infusion/I V push be completed 
within 30 minutes of thawing the cry opreser ved product. The tubing setup should also contain 
a Y-arm with an attached supplemental saline bag to be used after the initial infusion is 
completed.  This will allow any  remaining product left behind within the bag and tubing to be 
recovered and infused.   Vital signs (temperature, respiration rate, pulse , pulse oximetry ,and 
blood pressure) will be taken prior to, during and immediately  after the infusion and then 
approximately  
every 15 minutes for one hour and repeated at 2 hours. If vital signs are 
unsatisfactory  and unstable, continue to monitor the patient until vital sign stabilization.
All used infusion supplies, including the infusion bag and tubing, must be disposed of 
according to local institutional standard operating procedures. For further details, please refer 
to the specific guidance provided in the [I nvestigational Product Handling Manual].
Following CTL019 infusion: Should emergency treatment be required in the event of life-
threatening hypersensitivity  or other acute infusion- related reaction, supportive therap y such 
as oxygen, bronchodilators, epinephrine, antihistamines, and corticosteroids should be given 
according to local institutional guidelines. Patients should be evaluated and carefully 
monitored until complete resolut ion of signs and symptoms. Patient or patient’s caregiver 
should monitor the patient’s temperate twice daily  for the first 14 day s post CTL 019 infusion. 
The patient or patient’s caregiver should be instructed to call the investigator promptly  with 
any signs offever for possible hospitalization. 
Supportive care: Local guidelines will be followed for the supportive care of 
immunosuppressed and chemotherap y treated patients including infection management . All 
blood products administered should be irradiated. Immunosuppressive medications, including 
steroids, should not be administered unless life threatening circumstances arise.
6.1.2 Ancillary  treatments
As side effects from T cell infusions can include fever, chills and/or nausea , all patients 
should be pre-medicated with acetaminophen or paracetamol and diphenhy dramine or an H1 
antihistamine , as described above in Section 6.1.1.2 .If fever develops please follow your 
institutional guidelines for patie nts with fever/neutropenia and strongl y recommend admission 
for close observation.
 

Novartis Confidential Page 51
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
6.1.3 Rescue medication
Rescue medications are medications given for severe CRS due to CTL019 cells. Please see 
Figure 6-1. CTL019 administration may require tocili zumab (recommended label dose 8 
mg/kg for patients weighing ≥
30kg, and 12mg/kg for patients weighing < 30 kg) or other 
anti-cytokine therap y for the treatment of suspected CRS toxicities as described below in 
Section 
6.2.4.2. The on-site pharmacy  must confirm that twodosesof tocilizumab areon site 
and available for administration prior to CTL019 infusion . All rescue medications (except 
for tocilizumab or other cytokine therapy  administration ), including steroids given to treat 
CRS, must be listed on the concomitant medication CRF. Tocilizumab or anti-cytokine 
therap y administration should be reported on the “Tocilizumab Dose Administration” or 
“Concomi tant Medication ” eCRF, respectivel y.
6.1.4 Guidelines for continuation of treatment
Not applicable .
6.1.5 Treatment duration
A single dose of CTL019 transduced viable T cells will be given.
6.2 Dose escalation guidelines
Not applicable .
6.2.1 Starting dose rationale
Not applica ble.
6.2.2 Provisional dose levels
Not applicable.
6.2.3 Guidelines for dose escalation and determination of MTD/ RP2D /RDE
Not applicable.
6.2.3.1 Implementation of Dose Escalation Decisions
Not applicable .
6.2.3.2 Intra -Patient dose escalation
Not applicable .
6.2.3.3 Use the following text for i ntra-patient dose escalation for 
combinations
Not applicable .
 

Novartis Confidential Page 52
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
6.2.4 Definitions of dose limiting toxicities (DLTs) in a Phase II Study
There are no dose-limiting toxicities in this protocol; however criteria for stopping or pausin g 
the trial are detailed be low.
6.2.4.1 Toxici tyManagemen t,Stopping Rulesand Study Termin ation
Itisexpected that AEs w ill occur frequently inthispopulation based on theunderlying
a
dvanced he matolo gicmalig nancy and that these can be S AEs. Therefore,thereisno
specificoccurrenc e of SAEs that define a st opping rule, but thereview of S AEs will for m
the ba sisforpotentia l early stopping ofthestudy. Only unexpected S A Esthatarerelatedto
theCTL019 transduced cells would de fine astopping rule. The re view ofthese adverse
events,a nd any dec isiontopremature lystop patient enrollment, will be de ter mined by the
Data Monitoring Committee ( DMC )
and re viewed by theIRB.
Premature termination of the clinical trial may also occur because of a regulatory  authorit y 
decision, change in opinion of the IRB, the DMC , or determination that there are problems in 
the cell product generation or safet y at the discretion of the study  investigators. Additionally , 
recruitment may be stopped at Novartis ’ discretion and may include reasons such as low 
recruitment, protocol violations, or inadequate data recording.
6.2.4.1.1 Criteria for stopping or pausing the study
The studywill be pa used pending notification of the health authorities and the DMC for 
investigation and possible protocol amendment if any  patient experiences any  of the following 
events within three weeks of the CTL 019 cell infusion:
Life- threatening (Grade 4) toxicity att ribut able to p rotocol the rapythat is unmanag eable, 
unexpected and unre l ated to chemotherapy and att ributa bleto protocol the rapy.High
fevers, hypotension, hy poxia, disseminated intravascular coagulation, encephalopathy
(e.g. lethargy, confusion, aphasia, seizures), ICU admis sion, dialy sisand m echanica l 
ve
ntilati on are expected. The expected side effec ts can also r e sultin Grade 4 l iver tox icity, 
nephroto xicity and other organ invo lvement
Death suspected to be related to CTL 019 therapy
Theoverall 
studywillbepaused and health authorities notified if:
Any patient deve lops uncontrol led Tcellproliferation beyond 8 weeks from CTL 019 cell 
product infusion thatdoes n ot respond to man agement
Any patient develops detectable replication competent lentivirus ( RCL )during the study
Novartis or health authorities decides for an y reason that patient safet y may be 
compromised by  continuing the study
Novartis decides to discontinue the development of the intervention to be used in this 
study
 

Novartis Confidential Page 53
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
6.2.4.2 General toxicity  management considerations
Acute Infusion reaction
Acetaminophen/paracetamol and diphenhy dramine /H1 antihistamine may be repeated every  6 
hours a s needed. A course of non -steroi dal anti -inflammatory  medication may  be prescribed if 
the patient continues to have fever not relieved by acetaminophen /paracetamol . It is 
recommended that patients not receive corticosteroids at any time, except those alread y on 
physiologic replacement therapy , or in the case of a life threatening emergency , since this may 
have an adverse effect on C TL019cells.
Febrile reacti on
In the event of febrile reaction, an evaluation for infection should be initiated, and patients 
managed appropriatel y with antibiotics, fluids and other supportive care as medicall y 
indicated and determined by the treating physician. Inpatient treatment is recommended 
initially .
Inthe event tha t thepatient develops sepsis or systemic b acteremiafollowing
CTL 019cellinfusion, appropriatec ultu res and medi calmanagement should be initiated.Ifa 
contaminat ed C TL019cellproduct issuspe cted,theproduct ca n be rete sted forsterility using 
archived samples that are stored at the manufacturing site.Consideration of a cy tokine release 
syndrome (see below) should be given.
Cytokine Release Syndrome (CRS) / Macrophage A ctivation Syndrome (MA S)
Data from CTL019 treated patients experiencing CRS show marked elevations in IL6 and 
IFN-g. The symptoms occur in patients with ALL 1-14 days after cell infusion and may 
include high fevers, 
rigors, myalgia/arthralgias, nausea/vomiting/anorexia, fatigue, headache,
encephalopath y,hypotension, dyspnea, tachy pnea and hypoxia. Supportive care and 
tocilizumab have been used for effective management of CRS . Prompt responses to 
tocilizumab have been seen in most patients. S everal patients with a suboptimal response to 
the first dose of tocilizumab have received a second dose of tocilizumab (within 3-5 days) 
with CRS resol ution. One fatal outcome associated with CRS has been observed in an adult 
ALL patient .
Other anti-cytokine 
therapies may also be considered if the patient does not respond to 
tocilizumab. If the patient experiences ongoing CRS despite administration of anti-cytokine 
directed therapies, anti-T-cell therapies such as cyclophosphamide , anti-thymocy te globulin 
(ATG ) or alemtuzumab may be considered and need to be captured in case report forms .
A detailed treatment algorithm has been established with clear criteria for CRS management 
and guidance on when to administer tocilizumab and ispresented below in Figure 6-1. This 
approach was designed to avoid life-threatening toxicities, while attempting to allow the 
CTL 019 transduced cells to establish a proliferative phase which appears to correlate with 
tumor response. Patients will be required to remain near to the treating site for the first 21
days.
The management of CRS is based solely  upon clinical parameters as described in Figure 6-1
and must be followed by the investigator .  
 

Novartis Confidential Page 54
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Amodific ation of theCommon Terminology Criteria for Adverse Events (CTCAE ) CRS 
grading scale has also been established to better reflect CTL 019-therapy -associated CRS as 
presented in Table 6 -1.
Specific CRFs have been developed for the capture of CRS elements, severity, management 
and response to intervention.
Figure 6
-1 CRS Management A lgorithm:
Pretreatment
Acetaminophen/paracetamol and diphenhydramine /H1 anti -histamine
Prophylaxis for complications of TLS as appropriate
CTL019 infusion
Prodromal syndrome: low grade fevers, fatigue, anorexia (hours to days)
Observation, rule out infection (surveillance cultures)
Antibiotics per local guidelines (febrile neutropenia)
Symptomatic support
Symptom progression: High fevers, hypoxia, mild hypotension
1st Line Management:
Oxygen, fluids, low dose vasopressor support, antipy retics
Monitor/manage complications of TLS
Further symptom progression:
 Hemodynamic instability despite intravenous fluids and moderate to “high dose” vasopressor 
support OR
 Worsening respiratory distress, including pulmonary infiltrates increasing oxygen requirement 
including high-flow Oxygen (O2) and/or need for mechanical ventilation OR
 Rapid clinical deterioration
2nd Line Management:
Tocilizumab:
 Patient weight < 30 kg: 12 mg/kg i.v.
 Patient weight > 30 kg: 8 mg/kg i.v. (max dose 800 mg)
Hemodynamic and respiratory support
Lack of clinical improvement while awaiting tocilizumab response
3rdLine Management:
Steroids ( plan rapid taper )
Starting dose 2 mg/kg methylprednisolone as an initial dose, then 2 mg/kg per day
 

Novartis Confidential Page 55
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
If no response to steroids, consider 2nd dose of Tocilizumab (dose as above)
Hemodynamic and respiratory support
Lack of clinical improvement while awaiting response to 3rdline management
4thLine Management : 
Consider other diagnosis causing clinical deterioration (i.e. sepsis) 
If no response to steroids and 2nd dose of Tocilizumab, consider other anti -cytokine therapies
Hemodynamic and respiratory support
Lack of clinical improvement while awaiting response to 4thline management
5th Line Management:
Consider other diagnosis causing clinical deterioration (i.e. sepsis) 
If ongoing CRS despite prior therapy, consider anti -T cell therapies such as cyclophosphamide, anti-
thymocyte globulin, or alemtuzumab
Hemodynamic and respiratory support
Table 6-1 CTL019 -Therapy -Associated Grading for Cy tokine Release Sy ndrome: 
The Penn Grading Scale for Cy tokine Release Sy ndrome (PGS -CRS)
1 2 3 4
Mild reaction: 
Treated with 
supportive care 
such as anti -
pyretics andanti-
emetics .Moderate reaction: 
Requiring intravenous 
therapies or parenteral 
nutrition; some signs of 
organ dysfunction (i.e. 
Grade 2 creatinine or 
Grade 3 l iver function 
tests [LFTs ])related to 
CRS and not attr ibutable 
to any other condition. 
Hospitalization for 
management of CRS 
related symptoms 
including fevers with 
associated neutropenia.More severe reaction: Hospitalization 
required for management of symptoms 
related to organ dysfunction including 
Grade 4 LFTs or Grade 3 creatinine
related to CRS and not attributable to any 
other conditions ;this excludes 
management of fever or myalgias. 
Includes hypotension treated with 
intravenous fluid s*or low dose pressors, 
coagulopathy requiring fresh frozen 
plasma ( FFP) or cryoprecipitate, and 
hypoxia requiring supplemental oxygen 
(nasal cannula oxygen , high flow oxygen , 
Continuous Positive Airway Pressure 
[CPAP ]or Bilateral Positive Airway 
Pressure [BiPAP ]). Patients admitted for 
management of suspected infection due 
to fevers and/or neutropenia may have 
Grade 2 CRS.Life-threatening 
complications such 
as hypotension 
requiring high dose 
pressors (see Table 
6-2) or hypoxia 
requiring 
mechanical 
ventilation .
*Defined as:  multiple fluid boluses for blood pressure support
Marked elevations in IL -6, interferon gamma and less intensely  TNF
Symptoms occur 1 to 14 day s after cell infusion in ALL
Symptoms may  include: High fevers, rigors, my algia, arthralgia, nausea, vomiting, 
anorexia, fatigue, headache, hy potension, encephalopathy , dyspnea, tach ypnea, and 
hypoxia
The start date of CRS is a retrospective assessment of the date of onset of persistent fevers 
and/or my algia consistent with CRS and not explained b y other events (i.e. sepsis). The 
 

Novartis Confidential Page 56
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
stop date of CRS is defined as the date when the patient has been afebrile for 24 hours and 
off vasopressors for 24 hours.
 

Novartis Confidential Page 57
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Table 6-2 High Do se Vasopressor Use
Definition of “High -Dose” Vasopressors
Vasopressor Dose for ≥ 3 hours
Norepinephrine monotherapy ≥ 0.2 mcg/kg/min
Dopamine monotherapy ≥ 10 mcg/kg/min
Phenylephrine monotherapy ≥ 200mcg/min
Epinephrine monotherapy ≥ 0.1 mcg/ kg/min
If on vasopressin High-dose if vaso + Norepinephrine Equivalent (NE) of ≥0.1 mcg/ kg/min 
(using VASST formula)
If on combination vasopressors (not 
vasopressin)Norepinephrine equivalent of ≥ 20 mcg/min (using VASST formula)
VASST Trial Vasopressor Equivalent Equation:
Norepinephrine equivalent dose = [norepinephrine (mcg/min)] + [dopamine (mcg/kg/min) ÷ 2] + [epinephrine 
(mcg/min)] + [phenylephrine (mcg/min) ÷10]
Criteria from Russell et al , NEJM 2008 .
Note : Pediatric weight adjustments should be taken into consideration .
Tumor lysissyndrome
Close monitoring for TLS before and after chemotherapy  and CTL019 infusions, including 
blood tests (potassium, uric acid, etc.) will be done as follows:
Screening phase :
Prophy lactic all opurinol , or a non -allopurinol alternative (e.g. febuxostat), and 
increased oral /IVhydration prior to lymphodepleting chemotherap y and CTL 019 
infusion should be given in patients with elevated uric acid or high tumor burden
Early and prompt implementation of supportive care in case of s ymptoms of acute 
TLS (i.v. hydration and rasburicase as clinicall y indicated, when uric acid continues 
to rise despite allopurinol/febuxostat and fluids)
Post-infusion Monitoring phase :
Frequent monitoring of the following laboratory  tests (2 to 3 times/week for 3 weeks
from start of l ymphodepleting chemotherapy , then weekl y): potassium, phosphorus, 
calcium, creatinine, and uric acid
Encourage oral h ydration
Laboratory  and clinical TLS is defined as follows :
Laboratory TLS is defined as two or more of the following values within three day s 
before or in the day s following CTL019 infusion.
Uric acid ≥ 8 mg/dL or 25% increase from baseline
Potassium ≥ 6 mEq/L  or 25% increase from baseline
Phosphorus ≥ 6.5 mg/dL (children) or ≥ 4.5 mg/dL (adults) or 25% increase from 
baseline
Calcium ≤ 7 mg/dL  or 25% decrease from baseline
If zero or one of the laboratory values above are abnormal , continue to manage with 
allopurinol or a non- allopurinol alternative (e.g. febuxos tat) and oral hy dration. Consider 
 

Novartis Confidential Page 58
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
IV fluids and rasburicase if uric acid levels remain elevated, and consider in hospital 
monitoring
If Laboratory TLS exists , manage with i.v.fluids, laboratory  blood tests every  6 to 8 
hours and inpatient care. Cardiac mo nitoring should be considered, and rasburicase should 
be considered if uric acid levels remain elevated
Clinical TLS is defined as the presence of laboratory TLS plus ≥ 1 of these criteria in the 
absence of other causes.
Serum creatinine ≥ 1.5 times the upper limit of the age -adjusted normal range
Symptomatic hy pocalcemia
Cardiac arrh ythmia
If Clinical TLS exists , manage with IV fluids, laboratory blood tests every 6 to 8 
hours, cardiac monitoring, rasburicase /allopurinol /febuxostat and inpatient care 
(cons iderICU)
Criteria modified from Cairo and Bishop (2004).
Graft-
Versus -Host D isease (GVHD)
The chance of GVHD occurring is low, but it is a potential risk with CTL 019 therapy . A prior 
study  of activated donor lymphocy te infusions (ex vivo activated cells collected from the 
donor and grown in the same fashion as CTL 019 but without the CAR introduction) did not 
show high rates of GVHD (2/18 patients with Grade 3 GVHD and none with Grade 4) (Porter 
et al 2006). Ten ALL patients have been treated to date with autologous CTL019 therapy  who
have
had prior allogeneic hematopoietic SCT with residual donor chimerism. None of these 
patients developed GVHD after CTL019 infusion.
As part of the exclusion criteria for this protocol regarding GVHD , the grading & staging 
assessment of acute GVHD will follow the criteria described below in Table 6-3, and the 
definition of chronic GV HD will follow the criteria described in Table 6
-4.
Table 6-3 Staging & Grading of A cute Graft -Versus -Host Disease
Exten t of organ involvement
Skin Liver Gut
Stage
1 Rash on < 25% of skinaTotal bilirubin 2 -3mg/dLbDiarrhea > 500mL/daycor 
persistent nausead
2 Rash on 25 -50% of skin Total bilirubin 3 -6mg/dL Diarrhea > 1,000 mL/day
3 Rash > 50% of skin Total bilirubin 6 -15mg/dL Diarrhea > 1,500 mL/day
4 Generalized erythroderma with 
bullous formationTotal bilirubin > 15mg/dL Severe abdominal pain with or 
without ileus
Gradee
I Stage 1 -2 None None
II Stage 3 or Stage 1 or Stage 1
III Stage 2 -3 or Stage 2 -4
IVfStage 4 or Stage 4
 

Novartis Confidential Page 59
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Exten t of organ involvement
Skin Liver Gut
a. Use “rule of nines” or burn chart to determine extent of rash.
b.Range given as total bilirubin. Downgrade by 1 stage if an additional cause of elevated bilirubin has been 
documented.
c. Volume of diarrhea applies to adults. For pediatric patients, the volume of diarrhea should be based on body 
surface area. Gut staging for pediatric patients was not discussed at the Consensus Conference. Downgrade by 1 
stage if an additional cause of diarrhea has been documented.
d.Persistent nausea with histologic evidence of GVHD in the stomach or duodenum.
e. Criteria for grading given as a minimum degree of organ involvement required to confer that grade.
f. Grade IV may also include lesser organ involvement but with extreme decr ease in performance status.
Chronic GVHD is an immune -mediated disorder that may occur following allogeneic SCT.
Manifestations include scleroderma, dry  eyes, dry  mouth, lichenoid oral changes, bronchiolit is 
obliterans, vanishing bile ducts, or weight loss. It is to be diagnosed specifically  rather than 
diagnosed when acute GVHD -like syndromes develop late (beyond day +100) after any 
transplant or donor leukocy te infusion.
Table 6-4 Definitions of Chronic Graft -Versus -Host Disease
Definite and Possible Manifestations of Chronic GVHD
Organ Sy stem Definite Manifestations of Chronic GVHDPossible Manifestations of Chronic 
GVHD
Skin Scleroderma (superficial or fasciitis), lichen 
planus, vitiligo, scarring alopecia, 
hyperkeratosis pilaris, contractures from skin 
immobility, nail bed dysplasiaEczematoid rash, dry skin, 
maculopapular rash, 
hyperpigmentation, hair loss
Mucous membranes Lichen planus, non -infectious ulcers, corneal 
erosions/non -infectious conjunctivitisXerostomia, keratoconjunctivitis sicca
Gastrointestinal (GI )
tractEsophageal strictures, steatorrhea Anorexia, malabsorption, weight loss, 
diarrhea, abdominal pain
Liver None Elevation of alkaline phosphatase, 
transaminitis, cholangitis, 
hyperbilirubinemia
Genitourinary (GU) Vaginal str icture, lichen planus Non-infectious vaginitis, vaginal 
atrophy
Musculo -
skeletal/SerosaNon-specific arthritis, myositis, myasthenia, 
polyserositis, contractures from joint 
immobilizationArthralgia
Hematologic None Thrombocytopenia, eosinophilia, 
autoimmune cytopenias
Lung Bronchiolitis obliterans Bronchiolitis obliterans with organizing 
pneumonia, interstitial pneumonitis
1.At any time point post -transplant, if there are ANY definite symptoms (column 2) then the symptoms should be 
identified as chronic GVHD.
2.At any time point post -transplant, if there are any possible symptoms (column 3) but no definite symptoms, 
then it is at the physicians’ discretion to identify as either acute or chronic GVHD.
3.Acute and chronic GVHD cannot be present at the same time. Thus if #1 is fulfilled, then all manifestations of 
GVHD should be identified as chronic GVHD.
Limited Chronic GVHD
Localized skin involvement and/or liver d ysfunction OR
 

Novartis Confidential Page 60
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Involvement of onl y one target organ
Extensive Chronic GVHD
Generalized skin involvement ≥ 50% of bod y surface area OR
Localized skin involvement and/or liver d ysfunction plus at least one of the following:
Liver histology  showing chronic aggressive hepatitis, bridging necrosis, or cirrhosis
Eye involvement (Schirmer’s test with < 5 mm wetting)
Involvement of minor salivary  glands or oral mucosa on lip biopsy
Involvement of an y other target organs OR
Involvement of at least two target organs
Bcelldepletion
Transient or permanent B cell depletion is a risk with CTL019 therapy , since normal B cells 
express CD19. This is expected to resolve if and when the CTL 019 cells are cleared.
Depletion of B cells with resulting hypogammaglobulinemia is expected as a result of 
CTL 019 on target effects in patient with sustained tumor response . CTL 019 related 
hypogammaglobulinemia is typically  managed with immunoglobulin replacement therapy 
dependent upon age sp ecific, disease specific and local institutional guidelines. 
Immunoglobulin replacement during the study  period will be recorded. In general B cell 
aplasia and hypogammaglobulinemia, of various causes, can be associated with increased 
rates of infection. Such infections are typicall y sinopulmonary  but other sites and types of 
infections have also been reported. 
Other potential complications of B cell aplasia include progressive multifocal 
leukoencephalopath y (PML ) and reactivation of hepatitis B virus. Neither PML nor 
reactivation of hepatitis B virus have been seen yet with CTL019, however, other therapies 
associated with B cell aplasia have seen these complications.
For the first 12 months following CTL019 infusion, data on all significant infections will be 
collected for patients in the primary follow -up. After 12 months following CTL019 infusion 
or if patients move to the secondary  follow -upprior to month 12, data on infections will only 
be collected when they  are opportunistic or serious and requiring intervention as defined: 
1.Requires anti -infective treatment
2.Leads to significant disability  or hospitalization
3.Needs surgical or other intervention
6.2.4.3 Potential toxicities
Progressive Multifocal Leukoencephalopathy (PML)
PML  israre but well described with antibod y therapies causing B cell aplasia (Weissert 
2010). Itis a demy elinating disease of the central nervous system, resulting from infection of 
oligodendrocy tes and astrocy tes, mostly  with JC virus. PML  classicall y has a subacute clinical 
presentation with focal neurologic deficits, such as weakness, speech difficulties, unstead y 
gait and hemiparesis. Ophthalmic symptoms are relativel y common, occurring as 
 

Novartis Confidential Page 61
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
homony mous hemianopia which progresses to cortical blindnes s. Seizure and headache are 
uncommon. Dementia manifesting as mental deficits in cognition, personality  changes, and 
memory  impairment are also common, but it is almost invariabl y associated with the focal 
neurologic deficits of PML . By CT or MRI radiograp hic assessment, lesions are confined to 
the white matter, most commonly  of the occipitoparietal lobe and without mass effect. 
In general, patients with known B cell aplasia are at increased risk for PML . Therefore 
patients in the study  will be monitored a t regular intervals for any new or worsening 
neurological sy mptoms or signs that may  be suggestive of PML . The clinician should evaluate 
the patient to determine if the symptoms are indicative of neurological dysfunction, and if so, 
whether these symptoms are possibly  suggestive of PML . Consultation with a neurologist 
should be considered as clinicall y indicated. Please see current guidelines for work up and 
treatment for PML (NINDS Progressive Multifocal Lekoencephalopath y 2015).
Hepatitis B reactivation
Reactivation of hepatitis B refers to the abrupt increase in hepatitis B virus (HBV) replication 
in a patient with inactive or resolved hepatitis B. Reactivation can occur spontaneously , but 
more typicall y is triggered by immunosuppressive therap y of cance r, autoimmune disease, or 
organ transplantation. Reactivation can be transient and clinicall y silent, but often causes a 
flare of disease that can be severe resulting in acute hepatic failure. Most instances of 
reactivation resolve spontaneously , but if immune suppression is continued, re-establishment 
of chronic hepatitis occurs which can lead to progressive liver injury  and cirrhosis. 
Reactivation is defined as increase of one log in HBV -DNA relative to baseline HBV -DNA or 
new appearance of measurable HBV -DNA ( Hoofnagle 2009 ).
In general, the risk of hepatitis B reactivation is increased in patients with B cell depletion. 
Patients with latent or active hepatitis B are typically  excluded from CTL 019 treatment 
protocols; however infection could potentially  occur following the treatment trial completion 
or early withdrawal. Therefore, patients with a history  of hepatitis B should be closel y 
monitored for clinical and laboratory  signs of active HBV infection. Standard guidelines 
should be followed for the treatment of active/reactivated hepatitis B ( Hoofnagle 2009).
Immunogenicity
Immunogenicit y of the CAR polypeptide has been described in several studies (Park et al 
2007, Lamers et al 2006 , Lamers et al 2007, Lamers et al 2011 ) Host immune responses may 
result from prese ntation of CAR transgene expressed immunogenic epitopes including murine 
sequences in the scFV extracellular binding domain (derived from a murine monoclonal 
antibody ) or novel epitopes arising at junctions between components of the CAR fusion 
polypeptide. Transgene and vector specific B and T cell immune responses have been 
previously  observed in CAR modified autologous T 
cell therapies even when 
lymphodepleting regimens were used prior to infusion. If an immune response to the CTL019 
cells occurs, it is possible that the cells might be rejected. Such immune responses could also 
have effects such as attenuating the responsiveness of CTL019 cells by causing an immune 
mediated deletion of the CTL 019 cells.  Six of 7 evaluable patients had evidence of human 
anti
-CAR antibody  directed to the murine monoclonal antibody  derived scVF in CAIX 
specific CAR T therapy  for renal cell carcinoma (Lamers et al 2011 ). A single patient 
 

Novartis Confidential Page 62
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
experienced an anaphy lactic reaction after multip le, repeated injections of a CAR with a 
murine based scFv ( Maus et al 2013 ). Impaired function of CEA -targeting autologous T cells 
has been observed in vitro following exposure to receptor specific IgG obtained from treated 
patients. ( Parkhurst et al 2011).
Immunogenicit y (hum oral and cellular) will be measured following CTL019 infusions as 
indicated in the Visit Evaluation Schedule
.
Replication -competent lentivirus (RCL) testing
An RCL  may be generated during CTL 019 manufacturing or subsequently  after introduction 
of vector transduced cells into the patient. However, an RCL  resulting from manufacturing is 
highl y unlikel y since elements are incorporated in the design of thevector system that 
minimize vector recombination and generation of RCL . Furthermore, the vector used to 
transduce the product undergoes sensitive assay s for detection of RCL before it can be 
released to a patient. Thus patients will only receive cell products that meet RCL  release 
criteria (as detected by Vesicular Stomatitis Virus/Gly coprotein (VSV -G) qPCR, for 
example) . Nevertheless, generation of an RCL following infusion of the vector product 
remains a theoretical possibility . The development of RCL could pose a risk to both the 
patient and their close contact(s), and therefore, monitoring for RCL  will be conducted during 
the course of the trial (see Manual of Procedures for a description of the assay s). If a positive 
RCL assay  result is obtained from apatient blood specimen, the Investigator will be informed 
and the patient rescheduled for a retest of the DNA test. Regulatory  agencies and the gene 
therap y community  have previousl y discussed measures to be taken should an RCL  be 
confirmed in a patient. However, because the probability  and characteristics of an RCL  are 
unknown, no guidelines have been put in place. Nevertheless, all agree that the patient must 
be isolated until an understanding of how to manage the patient becomes clear. Some 
considerations are:
Intensive follow -up of the patient in consultation with gene therap y experts, study  
investigators, and Health Authorities
Inform local and country  specific public health officials
Identify  sexual partners and provide appropriate counseling and inte rvention
Clonali ty and inse rtiona l oncogene sis
Four of nine treated patients in a gene therapy  trial for X-linked Severe Combined 
Immunodeficiency  (SCID) developed T cell leukemia 31-68 months post-treatment. The T 
cell leukemias were attributable to clona l expansion conferred by gammaretroviral vector 
integration sites in the CD34+ bone marrow stem cell modification
(Hacein -Bey-Abina et al 
2008). This represents the most severe adverse event caused by vector integration. However, 
there is also evidence for retroviral vector integration site dominance in a gene therapy  trial of 
-thalassaemia without malignancy (Cavazzana -Calvo et al 2010 ). The lentiviral vector used 
for CTL019 manufacturing is part of a vector class that may have a lower risk for integration 
in or near oncogenic regions than onco -retroviral vectors (Montini E et al 2009) . As of March 
2014, none of the patients treated with CTL 019 have developed a new malignancy , T cell or 
otherwise, related to 
lentiviral vector integration. Subjects will be monitored for evidence of 
unexpected CTL 019 expansion by CTL019 transgene quantitation by qPCR and clinical 
 

Novartis Confidential Page 63
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
monitoring for malignancy  by complete blood count (CBC) as part of the study  design. If an 
unexpected pattern of CTL 019 expansion is observed (i.e. CTL 019 expansion in the absence 
of CD19+ target), subjects will be closely  monitored clinically  for new malignancies, 
particularl y T cell, and further studies, including insertion site analy sis, will be considered to 
investigate the molecular basis of the expansion. Investigators should consult Novartis if an 
unexpe cted pattern of CTL 019 expansion and/or a new malignancy  arises. Subjects will be 
similarly  monitored for clonality  and insertional oncogenesis when enrolled on the long term 
follow up protocol.
Uncontroll ed T cellproliferation
CTL 019 transduced cells c ould theoretically proli feratewithout the control of norm a l
homeostatic mecha nisms.In pre-clinical studies (Milone et al 2009) and clinical experience to 
date (Porter et al2011, Grupp et al 2013 ),CTL019transduced c ells have onl y proliferated in 
response to physiologic signals or upon exposure to CD19 antigen . In the context of 
CTL 019 therap y, it is expected that the T cells will proliferate in response to signals from 
the CD19 expressing malignant tumor and normal B cells. This could be beneficial or 
harmful depending on the extent of proliferation. 
I
f unc ontrol l ed T cellproliferation occurs ( e.g. expansion of T cells in the absence of CD19 
antigen) ,patients m
aybetreated with cortic osteroids such as methylpred nisolone (2 mg/kg/d 
i.v.) or chemotherap y, such as high dose cyclophosphamide. Investigators should further 
discuss this with Novartis . Toxicity associa ted with allogene icor a utologousT cell infusions
has been managed with a courseo f pha rma c ologic immunosuppr ession.Tcell associ ated 
toxicity hasbeenreporte dtorespond tosystem ic cort icoster oi ds (Lamers et al 2006 ).This 
theoretical toxicity  is distinct from the toxicity  associated with a CRS that develops during T 
cell proliferation upon exposure to CD19 expressing cells. CRS associated with T cell 
expansion is managed with anti-cytokine therapy , not immunosuppressants, and is addressed 
in Section 6.2.4.2.
6.2.5 Criteria for
discont inuing a patient’s p articipa tionin the study
If apatient deve lops a condit ion thatprecludes CTL019infusion afte r enrollment but b efore 
infusion, thepatient will be pre matu relydiscont inued. This will be done at the jud gment of
the Investigator , and c ould include forexample,theoccurrence ofa nintercurrent il lness
r
equiring the institution ofsystem ic im munosuppr ession.
6.2.6 Concomitant Therapy
Clinically  significant prescription and nonprescription medication, excluding vitamins, and 
herbal and nutritional supplements, taken by the patient during the 30 days prior to screening 
will be 
recorded. At every  visit following the screening visit up to the month 60 visit,
concomitant medications will be recorded in the medical record and on the appropriate CRF. 
During selected trial phases, concomitant medication collection will be modified as outlined 
in the Modified Data Reporting document and CRF Completion Guidelines (CCGs) (Table 6-
5andAppendix 4). Modified collection of concomitant medications during these trial phases 
are designed to capture CTL 019
-related toxicity , severity , interventions and 
 

Novartis Confidential Page 64
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
response/resolution following intervention. Any additions, deletions, or changes of these 
medications will be documented. 
Table 6-5 Concomitant Medication Reporting by  Trial Phase
Trial phase Inpatient/ICU Outpatient
Pre-treatment period (ICF to LD chemo/pre -infusion) Modified Modified
Treatment period (LD chemo/pre -infusion through M12) Modified All concomitant medications
Post-treatment period ( after M12 through M60 ) Modified Modified
See Appendix 4 for further details. 
The following guidelines must be adhered to during the stud y:
Granulocy te macro phage -colony  stimulating factor ( GM- CSF)should be avoided due to 
the 
potential to worsen CRS symptoms. 
Short acting granulocy te colony  stimulating factor (G -CSF) should n ot be given within 72 
hours of CTL 019 infusion and until CRS is resolved. L ong acting G -CSF should not be 
given within 10 day s of CTL 019 infusion and until CRS is resolved. Theeffects of 
granulocyte colon y stimulating factor ( G-CSF,are unknown.
Steroids or other immunosuppressant drugs should NOT be used as pre -medication for 
CTL019therapy  (refer to Section 6.1.1.2) or fo llowing CTL019 infusion , except as
required for ph ysiological glucocorticoid replacement therap y, or under life threatening 
circumstances. Use of steroids with blood product administration should be eliminated just 
prior to and following CTL 019if possible or at least minimized .
Patients with moderate to severe signs and s ymptoms attributable to CRS should be 
managed with 
supportive care and administration of tocilizumab as defined in Figure 6-1
and Section 6.2.4.2.
6.2.7 Prohibited concomitant therapy
Concurrent use of systemic steroids or immunosuppressant medications are prohibited under 
this protocol except as required for physiologic replace ment of hydrocortisone , 
orin the case 
of a life threatening emergency , since this may have an adverse effect of CTL019 cell 
expansion and function.
Specificall y, the following medications are excluded:
a.Steroids: Therapeutic doses of steroids must be stopped > 72 hours prior toCTL 019
infusion. However, the following phy siological replacement doses of steroids are allowed: 
< 12 mg/m2/day hydrocortisone or equivalent
b.Allogeneic cellular therapy: Any donor l ymphocy
te infusions (DLI ) must be 
completed > 6 weeks prior to CTL 019 infusion
c.GVHD therapies: Any drug used for GVHD must be stopped >4 weeks prior to CTL 019
infusion (e.g. calcineurin inhibitors, methotrexate or other chemotherap y drugs, 
mycophenoly ate, rapam ycin, thalidomide, or immunosuppressive antibodies such as 
rituximab, anti- TNF, anti -IL6 or anti-IL6R)
d.Chemotherapy :
 

Novartis Confidential Page 65
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
The following drugs must be stopped > 1 week prior to CTL 019 infusion and should 
not be administered concomitantly  or following lymphodepleting chemotherap y: 
hydroxyurea, vincristine, 6 -mercaptopurine, 6 -thioguanine, methotrexate < 25 mg/m2, 
cytosine arabinoside < 1 00 mg/m2/day, asparaginase (non-pegy lated)
The following drugs must be stopped > 
2weeks prior to CTL 019 infusion: salvage 
chemotherap y (e.g. clofarabine, cytosine arabinoside ≥ 100 mg/m2, anthracy clines, 
cyclophosphamide), excluding the required l ymphodepleting chemotherapy drugs
Pegy lated -aspariginase must be stopped > 4 weeks prior to CTL 019 infusion
e.CNS disease prophylaxis:
CNS prophy laxis treatment must be stopped > 1 week prior to CTL019 infusion ( e.g. 
intrathecal methotrexate)
f.Anti T -cell Therapy :Administration of any  T cell ly tic or toxic agent (e.g. alemtuzumab) 
prior to CTL 019 is strongl y discouraged since residual lytic levels may destroy the infused 
CTL 019 cells and/or prevent their in vivo expansion. If such an agent has been 
administered wi thin 8 weeks prior to CTL 019, contact Novartis , consider consultation 
with an pharmacology  expert, and consider measuring residual drug levels, if feasible, 
prior to CTL 019 infusion.
6.3 Patient numbering, treatment assignment or randomization
6.3.1 Patient numberin g
Upon informed consent /assent completion, the patient will initiate screening. Each patient is 
identified in the study  database by a seven digit Subject Number (Subject No.), that is 
assigned sequentially  at each site by the site investigator or designate d staff when the patient 
is first enrolled for screening and is retained as the primary  identifier for the patient 
throughout his/her entire participation in the trial. The Subject No. consists of the four digit 
Center Number (Center No.) (as assigned by Novartis to the investigative site) with a 
sequential three digit IDnumber suffixed to it, suchthat each patient is numbered uniquel y 
across the entire database.
Once assigned, the Subject No. must not be reused for any other patient and the Subject No. 
for that individual must not be changed, even if the patient is re -screened. If the patient fails to 
start treatment for any reason, the reason will be documented and entered onto the appropriate
Disposition CRF page .
6.3.2 Treatment assignment
This is a single -arm open -label study .Patients will be enrolled and assigned to treatment upon 
confirmation of all clinical eligibility , and receipt and acceptance of the apheresed product by 
the manufacturing facility .
6.3.3 Treatment blinding
This is an open -label stud y.
 

Novartis Confidential Page 66
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
6.4 Stud y drug preparation and dispensation
Upon release from the manufacturing facility , the cryopreserved CTL019 cell product is
shipped to the investigator. Upon receipt of the cryopreserved CTL019 cell product , an 
inventory  must be performed and a drug receipt log filled out and signed by personnel 
accepting the shipment. It is important that designated study  staff counts and verifies that the 
shipment contains all the items noted in the shipment inventory .Any damaged or unusable 
CTL 019 cell product in a given shipment will be documented in the study  files. The 
investigator must notify  Novartis of any damaged or unusable CTL 019 cell product that was 
supplied to the investigator’s site.
After logging the CTL019 cells, they will be stored safel y and properly ( Section 6.4.2 ).Please 
note the time between product thawing and completion of the infusion should not exceed 30 
minutes to maintain maximum product viability. Therefore, to ensure this timefr ame, the 
product should be thawed in close proximity  to the patient’s bedside. Additionally , after cell 
thawing the CTL019 cell product should NOT be washed prior to infusion, all contents will 
be infused. If the CTL019 cell product appears to have a damag ed or leaking bag, or 
otherwise appears to be compromised, it should not be infused, and should be returned tothe 
manufacturing facility .This issue should be documented properl y and the manufacturing 
facility  notified on handling of compromised product. For further preparation and 
administration, see Section 6.1.1.2 and the [Investigational Product Handling Manual] (e.g. 
option of sy ringe -based administration for pediatric patients with small product v olumes).
6.4.1 Study drug packaging and labeling
Each infusion bag will typically  contain 10
– 50 m L of cells containing a cell dose of 2 to 10 x 
106CTL019 transduced viable T cells per kgbody  weight with a maximum dose of 2.5 x 108
CTL 019 transduced viable T cells (non-weight adjusted) .Higher volumes may occasionall y 
be necessary  depending on transduction efficiency . Each infusion bag will have affixed to it a 
label containing the following: A product identifier , theproper name of the product, and 
appropriat e product modifiers (see Manual of Procedures ).The study  number and the wording
“FOR AUTOLOGOUS USE ONLY” will be included in the label. In addition the label will 
have at least two unique identifiers such as the patient’s alphanumeric identifier and birth date
according to applicable regulations .Additional label elements required by local regulatory 
guidelines will also be included. Prior to the infusion, two individuals will verify  allofthis 
information and confirm identity  according to local institut ional guidelines , to ensure that the 
information is correctly matched to the patient, and that the patient receives only their 
autologous product .
6.4.2 Drug supply  and storage
CTL 019 cell product must be received by designated person nelat the study  site, handled and 
stored safel y and properly , and kept in a secured location to which only the investigator and 
designated site personnel have access. Upon receipt, the CTL019 cell product should be 
stored according to the instructions specif ied on the product labels and in the [Investigational 
Product Handling Manual] .
 

Novartis Confidential Page 67
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
6.4.3 Study drug compliance and accountability
Novartis has established methods to ensure full traceability  between the patient’s autologous 
apheresis and the CTL 019 product in line with the requirements outlined in 21 CFR 1271.250, 
21CFR 1271.290, Regulation (EC) 1394/2007, the Directive 2004/23/EC as well as the rules 
and principles of the EU “Detailed guidelines on good clinical practice specific to advanced 
therap y medicinal products.” The data contributing to the full traceability of the cells are 
stored for a minimum of 30 years. Any product quality  complaints are documented by the 
clinical site and reported to the Novartis Clinical Supplies Quality Assurance (QA) 
Department. A unique patient identifier will be used in order to maintain the chain of identit y 
between the autologous apheresis product and the CTL 019 batch, and the link between patient 
identity  and unique patient identifier will be confirmed prior to infusion. The [Investigational 
Product Handling Manual], [Leukapheresis, Cryopreservation & Scheduling Manual], and 
[Investigational Product Transport Manual] provides an overview of how the compan y 
ensures that the cells which are procured, processed, stored, and distrib uted by  or on behalf of 
the Novartis can be traced from donor to recipient and vice versa.
6.4.3.1 Study drug compliance
As a single administration study , compliance will be assessed by  the investigator and/or stud y 
personnel andcaptured in the Drug Accountability Form.
6.4.3.2 Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of CTL 019 cell product in a drug accountability  log. Drug accountability  will be reviewed by 
the field monitor during site visits and at the completion of the study .
The investigator will dispose used and unused CTL019 cell product , packaging, and product
labels . Acopy of the completed drug accountability  logwill then be collected by the study
monitor. Please refer to [Investigational Product Handling Manual] for specific details on 
product destruction.
6.4.3.3 Handling of other study  treatment
Not applicable.
6.4.4 Disposal and destruction
CTL 019 cell product may require disposal for a variet y of reasons, including but not limited 
to: 1) Mislabeled product; 2) Condition of patient prohibits infusion, and/or3) Patient refuses 
infusion
. Any unused product and all used infusion supplies, including the infusion bag and 
tubing be disposed of according to local institutional standard operating procedures. 
Additional guidance is provided in the Investigational Product Handling Manual .
In the event that CTL 019 study  drug manufactured by Novartis or University  of Penns ylvania 
was not shipped to the site for infusion, it will be managed per manufacturing facility  process. 
The CTL 019 product will either be utilized for research purposes or it will be destroy ed.
Reconciliation of CTL 019 cell product shipped, administered , and remaining, is performed by 
Novartis (or designee) .This information is submitted on an annual basis to the health 
 

Novartis Confidential Page 68
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
authorities in annual reports. All CTL019 cell product disposition will be documented in the 
study  files. Refer to [Investigational Product Handling Manual] for details on product 
reconc iliation .
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7-1 (Screening to Month 12) and Table 7-2 (Month 15 to Month 60) list all of the 
assessments through the end of the Treatment and Primary  Follow-up phase (Section 7.1.3). 
For patients who discontinue early from the Treatment and Primary  Follow -Up Phase prior to 
Month 60, the patient will enter a Secondary  Follow -Up Phase to collect health authority 
requested data (e.g. delay ed adverse events, etc.). The first visit in the Secondar y Follow -Up 
Phase is determined according to the time since CTL 019 infusion when the patient 
discontinued from the Treatment and Primary  Follow -Up Phase. For example, if the patient 
discontinued from the Treatment and Primary  Follow -Up phase at Month 10, 
the first visit in 
the Secondary  Follow -Up Phase will be Month 12. Table 7-3lists all of the assessments 
through the end of the Secondary  Follow -up phase (Section 7.1.4). 
It is anticipated that 
patients may leave the primary  follow -up and move to secondary follow -up due to reasons 
including: treatment failure, relapse after remission, pursuing SCT while in remission, or 
withdrawal from the primary  follow -up (See Figure 7-1 below ).
In each table, required assessments are indicated with an “X, and the visits when they are 
performed. All data obtained from these assessments must be supported in the patient’s source 
documentation. No CRF will be used as a source document.
Figure 7-1 Potential Patient flo w scenarios
 

Novartis Confidential Page 69
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Table 7-1 Visit evaluation schedule
Phase
Category
Protocol Reference 
Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Visit Name
Enrollment/Pre -
chemotherapy 
evaluation
Lymphodepleting 
Chemotherapy
Pre infusion
InfusionPost Infusion
Study  day
W-8 to W-4
W-8to D-8
W-2 to W-1
D-1 +1d
D1
D2
D4 ±1d
D7 ±1d
D11 ±1d
D14 ±3d
D17±3d
D21 ±3d
D28 ±4d
M2 ±14d
M3 ±14d
M4 ±14d
M5 ±14d
M6 ±14d
M9 ±14d
M12 ±14d
Obtain Informed
ConsentD 7.1.1 X
Historical Apheresis D 4.1.1 X
IWRS/IRT S 7.1.1.1 X X X X X X X X X X X X
Patient history
Demography D 7.1.1 X
Inclusion/exclusion 
criteriaD 5.2
5.3X
Medical History 
(including GVHD 
assessment)D 7.1.1
6.2.4.2X X X X X X X X X X X X X X X X X X X
Diagnosis and extent 
of cancerD 7.1.1 X
Cytogenetics / FISH/ D 7.1.1 X For patients who relapse post infusion, this assessment will be performed on relapsed BM 
evaluation
Donor chimerism D 7.2.2.5 X
Prior antineoplastic 
therapyD 7.1.1 X
 

Novartis Confidential Page 70
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Phase
Category
Protocol Reference 
Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Visit Name
Enrollment/Pre -
chemotherapy 
evaluation
Lymphodepleting 
Chemotherapy
Pre infusion
InfusionPost Infusion
Study  day
W-8 to W-4
W-8to D-8
W-2 to W-1
D-1 +1d
D1
D2
D4 ±1d
D7 ±1d
D11 ±1d
D14 ±3d
D17±3d
D21 ±3d
D28 ±4d
M2 ±14d
M3 ±14d
M4 ±14d
M5 ±14d
M6 ±14d
M9 ±14d
M12 ±14d
Donor chimerism 
(prior allogeneic SCT 
patients only)D 7.2.2.5 X
Prior/concomitant 
medicationsD 6.2.6 X X X X X X X X X X X X X X X X X X X X
Antineoplastic 
therapies after 
CTL019 infusion or 
study discontinuationD 7.1.1 X X X X X X X X X X X X X X X
Physical examination S 7.2.2.1 X X X X X X X X X X X X X X X
Performance status D 7.2.2.4 X X X X X X X X X X X X X X
Height D 7.2.2.3 X X X
Tanner staging D 7.1.1 X X X
Weight D 7.2.2.3 X X X X X X X
Vital signs D 7.2.2.2 X X X X X X X X X X X X X X X X X X
Pulse oximetry D 7.2.2.2 X X
Intervention
Lymphodepleting
ChemotherapyD 6.1.1.1 X
Other chemotherapy 
while on studyD 6.2.6 As clinically indicated
 

Novartis Confidential Page 71
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Phase
Category
Protocol Reference 
Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Visit Name
Enrollment/Pre -
chemotherapy 
evaluation
Lymphodepleting 
Chemotherapy
Pre infusion
InfusionPost Infusion
Study  day
W-8 to W-4
W-8to D-8
W-2 to W-1
D-1 +1d
D1
D2
D4 ±1d
D7 ±1d
D11 ±1d
D14 ±3d
D17±3d
D21 ±3d
D28 ±4d
M2 ±14d
M3 ±14d
M4 ±14d
M5 ±14d
M6 ±14d
M9 ±14d
M12 ±14d
CTL019 infusion 
prerequisite 
assessmentS 6.1.1.2 X
CTL019 transduced 
cell infusionD 6.1.1.2 X
Laboratory  assessments
Hematology D 7.2.2.5 X X X X X X X X X X X X X X X X X X
Chemistry D 7.2.2.5 X X X X X X X X X X X X X X X X X X
Lab tests of special 
interest  (  
,  LDH, 
fibrinogen)D 7.2.2.5 X X X X X X X X X X X
Serum pregnancy 
testD 7.2.2.5 X
Urine pregnancy test D 7.2.2.5 X
HIV test D 7.2.2.5 X
Hepatitis B and C D 7.2.2.5 X
Coagulation factors 
(PT, aPTT, INR, 
fibrinogen, D -dimer) D 7.2.2.5 X X X X X
 

Novartis Confidential Page 72
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Phase
Category
Protocol Reference 
Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Visit Name
Enrollment/Pre -
chemotherapy 
evaluation
Lymphodepleting 
Chemotherapy
Pre infusion
InfusionPost Infusion
Study  day
W-8 to W-4
W-8to D-8
W-2 to W-1
D-1 +1d
D1
D2
D4 ±1d
D7 ±1d
D11 ±1d
D14 ±3d
D17±3d
D21 ±3d
D28 ±4d
M2 ±14d
M3 ±14d
M4 ±14d
M5 ±14d
M6 ±14d
M9 ±14d
M12 ±14d
Serum 
immunoglobulin 
levels (IgG,IgA, IgM)D 7.2.2.5 X X X X X X X
MUGA/ECHO D 7.2.2.6.2 X
Electrocardiogram 
(ECG)D 7.2.2.6.1 X X
Urinalysis D 7.2.2.5 X
Pulse oximetry D 7.2.2.1 X X
Disease Assessments
Bone marrow biopsy 
and aspirate 
morphologyD 7.2.1 X X If patient is not in CR/CRi at D28, then 
required at time of disease remission at all 
other sites. For patients in CR/CRi, Month 3 
and 6 recommended but not required 
 

Novartis Confidential Page 73
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Phase
Category
Protocol Reference 
Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Visit Name
Enrollment/Pre -
chemotherapy 
evaluation
Lymphodepleting 
Chemotherapy
Pre infusion
InfusionPost Infusion
Study  day
W-8 to W-4
W-8to D-8
W-2 to W-1
D-1 +1d
D1
D2
D4 ±1d
D7 ±1d
D11 ±1d
D14 ±3d
D17±3d
D21 ±3d
D28 ±4d
M2 ±14d
M3 ±14d
M4 ±14d
M5 ±14d
M6 ±14d
M9 ±14d
M12 ±14d
Tumor cell 
assessment by flow 
cytometry of 
peripheral blood 
(includes normal B 
cell, count and, CD19 
status)D 7.2.1 X X X X X X X X X
Lymph node or other 
involved tissue 
biopsy or aspirateD 7.2.1 As clinically indicated
CSF assessment / 
lumbar punctureD 7.2.1 X X If patient is not in CR/CRi at D28, then 
required at time of disease remission at all 
other sites. Otherwise, as clinically 
indicated by the presence of neurologic 
symptoms.
CNS Brain Imaging 
(MRI / CT)D 7.2.1 As clinically indicated
Mediastinal disease 
assessment (chest 
CT scan or MRI) only 
for lymphoblastic 
lymphoma patientsD 7.2.1 X X If patient is not in CR/CRi at D28, then 
required at the first time clinical evidence 
of remission is seen by blood and PE. 
Otherwise, as clinically indicated.
 

Novartis Confidential Page 74
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Phase
Category
Protocol Reference 
Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Visit Name
Enrollment/Pre -
chemotherapy 
evaluation
Lymphodepleting 
Chemotherapy
Pre infusion
InfusionPost Infusion
Study  day
W-8 to W-4
W-8to D-8
W-2 to W-1
D-1 +1d
D1
D2
D4 ±1d
D7 ±1d
D11 ±1d
D14 ±3d
D17±3d
D21 ±3d
D28 ±4d
M2 ±14d
M3 ±14d
M4 ±14d
M5 ±14d
M6 ±14d
M9 ±14d
M12 ±14d
Extramedullary 
Disease assessment 
(physical exam and 
CNS symptom 
assessment)D 7.2.1 X X X X X X X X X
Safety
Adverse events D 8.1
8.2X X X X X X X X X X X X X X X X X X X
Pregnancies and 
menstrual statusD 7.2.2 X X X X X X X
Immunogenicity 
(serum)D 7.2.3 X X X X X X
Immunogenicity 
(peripheral blood)D 7.2.3 X X X X X X
RCL by VSV-G Q -
PCR (peripheral 
blood)D 6.2.4.3 X X X X
 

Novartis Confidential Page 75
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Phase
Category
Protocol Reference 
Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Visit Name
Enrollment/Pre -
chemotherapy 
evaluation
Lymphodepleting 
Chemotherapy
Pre infusion
InfusionPost Infusion
Study  day
W-8 to W-4
W-8to D-8
W-2 to W-1
D-1 +1d
D1
D2
D4 ±1d
D7 ±1d
D11 ±1d
D14 ±3d
D17±3d
D21 ±3d
D28 ±4d
M2 ±14d
M3 ±14d
M4 ±14d
M5 ±14d
M6 ±14d
M9 ±14d
M12 ±14d
 

Novartis Confidential Page 76
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Phase
Category
Protocol Reference 
Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Visit Name
Enrollment/Pre -
chemotherapy 
evaluation
Lymphodepleting 
Chemotherapy
Pre infusion
InfusionPost Infusion
Study  day
W-8 to W-4
W-8to D-8
W-2 to W-1
D-1 +1d
D1
D2
D4 ±1d
D7 ±1d
D11 ±1d
D14 ±3d
D17±3d
D21 ±3d
D28 ±4d
M2 ±14d
M3 ±14d
M4 ±14d
M5 ±14d
M6 ±14d
M9 ±14d
M12 ±14d
 

Novartis Confidential Page 77
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Phase
Category
Protocol Reference 
Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Visit Name
Enrollment/Pre -
chemotherapy 
evaluation
Lymphodepleting 
Chemotherapy
Pre infusion
InfusionPost Infusion
Study  day
W-8 to W-4
W-8to D-8
W-2 to W-1
D-1 +1d
D1
D2
D4 ±1d
D7 ±1d
D11 ±1d
D14 ±3d
D17±3d
D21 ±3d
D28 ±4d
M2 ±14d
M3 ±14d
M4 ±14d
M5 ±14d
M6 ±14d
M9 ±14d
M12 ±14d
Survival follow -up D 7.1.7 For all patients who prematurely discontinue from primary follow -up (regardless of remission 
status), follow -up for survival every 3 months until end of study or enrolling into the 15 year long 
term follow -up, whichever comes first
 

Novartis Confidential Page 78
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Phase
Category
Protocol Reference 
Section
ScreeningPre-Treatment Treatment and Primary  Follow -up
Visit Name
Enrollment/Pre -
chemotherapy 
evaluation
Lymphodepleting 
Chemotherapy
Pre infusion
InfusionPost Infusion
Study  day
W-8 to W-4
W-8to D-8
W-2 to W-1
D-1 +1d
D1
D2
D4 ±1d
D7 ±1d
D11 ±1d
D14 ±3d
D17±3d
D21 ±3d
D28 ±4d
M2 ±14d
M3 ±14d
M4 ±14d
M5 ±14d
M6 ±14d
M9 ±14d
M12 ±14d
End of Phase 
DispositionD N/A X X
Table 7-2 Visit Evaluation Schedule: Treatment and Primary  follo w-up continued (Month 15 through Month 60)
Phase
Category
Protocol Reference 
SectionTreatment and Primary  Follow -up
Visit Name Post infusion
End of  
treatment & 
primary 
follow -up
Survival 
follow -up
Study  DayM15
±14dM18
±14dM21
±14dM24
±14dM30
±14dM36
±14dM42
±14dM48
±14dM54
±14dM60
±14dq3m 
±14d 
Prior/concomitant medications D 6.2.6 X X X X X X X X X X
Physical examinations (PE) S 7.2.1.1 X X X X X X X X X X
Performance status assessment D 7.2.2.3 X X X X X X X X X X
Height D 7.2.2.2 X X X X X X X X
Tanner Staging D 7.1.1 X X X X X X X X
Weight D 7.2.2.2 X X X X X X X X
Vital signs D 7.2.2.1 X X X X X X X X X X
Hematology D 7.2.2.4 X X X X X X X X X X
 

Novartis Confidential Page 79
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Phase
Category
Protocol Reference 
SectionTreatment and Primary  Follow -up
Visit Name Post infusion
End of  
treatment & 
primary 
follow -up
Survival 
follow -up
Study  DayM15
±14dM18
±14dM21
±14dM24
±14dM30
±14dM36
±14dM42
±14dM48
±14dM54
±14dM60
±14dq3m 
±14d 
Chemistry D 7.2.2.4 X X X X X X X X X X
Antineoplastic therapies after CTL019 infusion or 
study discontinuation D 6.2.6 X X X X X X X X X X
Bone marrow biopsy and aspirate D 7.2.1 As clinically indicated
Tumor cell assessment by flow cytometry of 
peripheral blood (includes normal B cell, count 
and, CD19 status)D 7.2.1 X X X X X
Lymph node or other involved tissue biopsy or 
aspirateD 7.2.1 As clinically indicated
CSF assessment / lumbar puncture D 7.2.1 As clinically indicated
CNS Brain Imaging (MRI / CT) D 7.2.1 As clinically indicated
Extramedullary Disease assessment (physical 
exam)D 7.2.1 X X X X X X X X X X
Safety
Adverse events D 8.1 X X X X X X X X X X
Pregnancies and menstrual status D 7.2.2 X X X X X X X X X X
Immunogenicity (serum) D 7.2.2.4
10.5.3.4X X
Immunogenicity (peripheral blood) D 7.2.2.4
10.5.3.4X X
DNA RCL by VSV-G q -PCR (peripheral blood) D 6.2.4.3 X X X X
 

Novartis Confidential Page 80
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Phase
Category
Protocol Reference 
SectionTreatment and Primary  Follow -up
Visit Name Post infusion
End of  
treatment & 
primary 
follow -up
Survival 
follow -up
Study  DayM15
±14dM18
±14dM21
±14dM24
±14dM30
±14dM36
±14dM42
±14dM48
±14dM54
±14dM60
±14dq3m 
±14d 
Survival Follow -up D 7.1.5 For all patients who receive a CTL019 infusion, follow-up for survival every 3 months until 
end of study or enrolling into the long term fo llow-up, whichever comes first. If a patient 
misses a quarterly scheduled visit where survival status is required, or if the time -point 
does not align with a scheduled visit, survival status can be obtained via phone contact.X
End of phase disposition D N/A X
 

Novartis Confidential Page 81
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Table 7-3 Visit Evaluation Schedule: Secondary  Follow -up
Phase
Category
Protocol Reference 
SectionSecondary  Follow -up
Survival 
Follow -up
Visit Name Post Infusion
End of 
Secondary 
Follow -up
Study  DayM2
±14dM3
±14dM6
±14dM9
±14dM12
±14dM15
±14dM18
±14dM21
±14dM24
±14dM30
±14dM36
±14dM42
±14dM48
±14dM54
±14dM60
±14dq3m 
±14d 
Patient History
Concomitant 
medications 
(selected)D 6.2.6 X X X X X X X X X X X X X X X
Antineoplastic 
therapies after 
CTL019 infusion or 
study 
discontinuationD 6.2.6 X X X X X X X X X X X X X X X
Height D 7.2.2.2 X X X X X X X X X X
Weight D 7.2.2.2 X X X X X X X X X X X X
Tanner Staging D 7.2.2 X X X X X X X X X X
Vital signs D 7.2.2.1 X X X X X X X X X X X X X X X
Laboratory  assessments
Hematology D 7.2.2.4 X X X X X X X X X X X X X X X
Chemistry D 7.2.2.4 X X X X X X X X X X X X X X X
Efficacy  assessments
Relapse 
information (only 
when patient is in 
remission)D 7.1.4 X X X X X X X X X X X X X X X
 

Novartis Confidential Page 82
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Phase
Category
Protocol Reference 
SectionSecondary  Follow -up
Survival 
Follow -up
Visit Name Post Infusion
End of 
Secondary 
Follow -up
Study  DayM2
±14dM3
±14dM6
±14dM9
±14dM12
±14dM15
±14dM18
±14dM21
±14dM24
±14dM30
±14dM36
±14dM42
±14dM48
±14dM54
±14dM60
±14dq3m 
±14d 
Safety  assessments
Protocol defined 
adverse events, 
including new 
malignanciesD 8.1 X X X X X X X X X X X X X X X
Pregnancies and 
menstrual statusD 7.2.2 X X X X X X X X X X X X X X X
Physical 
examination (PE)S 7.2.1.1 X X X X X X X X X X X X X X X
Performance status D 7.2.2.3 X X X X X X X X X X X X X X X
Serum 
(immunogenicity,
cytokines) D 7.2.4 X X X
CTL019 transgene 
persistence 
(peripheral blood)D 7.2.3 X X X X X X X X X X X X
Flow Cytometry of 
peripheral blood (B 
cell, T cell levels –
local assessment)D 7.2.1 X X X X X X X X
DNA RCL by VSV-
G q-PCR 
(peripheral blood)D 6.2.4.3 X X X X X X X
Survival follow -up D 7.1.5 For all patients who receive a CTL019 infusion, follow-up for survival every 3 months until end of study or enrolling into the 
long term follow -up, whichever comes first. If a patient misses a quarterly scheduled visit where survival status is required, 
or if the time -point does not align with a scheduled visit, survival status can be obtained via phone contact.X
 

Novartis Confidential Page 83
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Phase
Category
Protocol Reference 
SectionSecondary  Follow -up
Survival 
Follow -up
Visit Name Post Infusion
End of 
Secondary 
Follow -up
Study  DayM2
±14dM3
±14dM6
±14dM9
±14dM12
±14dM15
±14dM18
±14dM21
±14dM24
±14dM30
±14dM36
±14dM42
±14dM48
±14dM54
±14dM60
±14dq3m 
±14d 
End of phase 
dispositionD N/A X
 

Novartis Confidential Page 84
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
7.1.1 Screening Phase
After informed consent is obtained, blood tests and assessments to determine eligibility  as 
outlined below are performed.
Anti- microbial proph ylaxis treatment in these immunosuppressant relapsed/ refractory  ALL 
and LBL patients should be considered per local institutional guidelines at study  entry  or prior 
to lymphodepleting chemotherapy . 
Patients should not be enrolled if they are unable to be followed up long-term i.e. 5 years on 
treatment protocol and  10 additional yearsfollow up as required by the health authorities for 
cell and gene therap y products.
Only  following confirmation of all clinical eligibility  criteria (defined as all 
inclusion/exclusion criteria except that which pertains to the apheresis product) will the 
patient’s apheresis product be shipped to the manufacturing facility . The manufacturing 
facility  will then evaluate t he patient’s apheresis product for acceptance.
Patient s who have signed an informed consent /assent form will undergo a routine leukemia 
and ly mphoma staging workup including:
a.Demograph y
b.Medical history (including diagnosis and extent of cancer) and prior/c oncomitant 
medications and antineoplastic therapies
c.Physical Examination (PE) including height, weight, GVHD assessment, Tanner staging 
and vital signs , extramedullary  disease assessment and CNS sy
mptom assessment
d.Performance status ( Karnofsky  [age ≥16 y ears]or Lansk y [age < 16 years] )at the time of 
screening
e.Standard ALL cytogenetics, FISH,  by flow cy tometry
analysis required ( at the time of most recent relapse). If not available, test must be 
performed at screening.
f.Donor Chimerism (within 3 months of screening ), only if previously  received allogeneic 
SCT)
g.Complete Blood Count, Differential
h.Chemistry  Panel
i.Labs of Special Interest (  LDH
, and fibrinogen)
j.Coagulation panel
k.Urinaly sis
l.Serum pregnancy  test (if fe male of childbearing potential) HIV testing (test within 8 
weeks of screening) - If an initial HI V screening test is positive then a confirmatory  HIV 
test is required to be performed as per current local guidelines.
m.Hepatitis B and Hepatitis C test (test w ithin 8 weeks of screening. S ee Appendix 3for 
interpretation of Hepatitis B results)
n. Serum immunoglobulin levels (IgG, IgA, IgM)
o.MUGA and/or ECHO (performed within 6 weeks of infusion) for LVSF /LVEF
p. ECG
 

Novartis Confidential Page 85
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
q.Pulse oximetry
r.
 
s.Peripheral blood collection for flow cy tometry  (B-celland T- cellnumbers, tumor cell 
numbers, and CD19 assessment)
t.Lym ph node or tissue aspirate or biops y (if clinically indicated)
u.  
v.
CNS Brain Imaging (MRI/CT) (if clinicall y indicated )
w.Adverse events
x.Mediastinal disease assessment  (chest CT scan or MRI ); onl y with history of mediastinal 
disease i.e. in patients with r/r ly mphoblastic l ymphoma 
7.1.1.1 Eligibility  Screening & Enrollment
For detailed enrollment procedures, including use of Interactive Response Technology  (IRT), 
please refer to the [IRT User Manual ].
Once clinical eligibility  has been confirmed, only then can the patient’s apheresis product be 
shipped to the manufacturing facility . The manufacturing facility  will then evaluate the 
patient’s apheresis product for acceptance and notify  the site. Enrollment is defined as the 
point at which a patient meets all clinical inclusion/exclusion criteria and the patient’s 
apheresis product is received and accepted by the manufacturing facility . The patient is then 
enrolled using the same Patient No. assigned at screening by the site investigator or 
designated staff. Once assigned, the Patient No. must not be reused for any other patient and 
the Patient No. for that individual must not be changed .. If a screened patient is not enrolled
for an y reason, the 
specific reason will be entered into the clinical database .
IRT Registration : To document screening and enrollment into the study , IRT will be 
contacted initially  after informed consent /assent is obtained and again after eligibility  is 
confirmed.
7.1.1.2 Information to be collected on patient not enrolled
The reason for not being enrolled will be entered in the clinical database . The demographic 
information, informed consent /assent , Inclusion/Exclusion pages , anyadverse events leading 
to subject discontinuation (if applicable), and screening disposition must be completed for 
patients not enrolled. No other data will be entered into the clinical database for patients who 
are not enrolled .
 

Novartis Confidential Page 86
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
7.1.2 Pre-Treatment Phase
For details of assessments, refer to Table 7-1.
Enrollment/Pre -chemotherapy  evaluation visit ( W-8 to D-8)
Before the scheduled lymphodepleting chemotherap y regimen is to begin, the patient will 
undergo blood collection for safet y and  
 humoral & cellular immunogenicity  and RCL 
by VSV-GqPCR . These lab draws are preferably  drawn at enrollment, however if not 
obtained collection can be done any time prior to ly mphodepleting chemotherapy .In addition, 
adverse events and prior/concomitant medications will be reviewed. Samples from the 
apheresis material as well as the CTL019 product will be collected at the manufacturing site 
for correlative studies.
Lymphodepleting chemotherapy  visit (D-14to D-2)
It is anticipated that many  patients will have been receiving chemotherapy  for relapse or 
resistant disease. For inclusion they will have responding or stable disease to the most recent 
therap y.Prior to CTL0 19 cell infusion and after apheresis, an additional chemotherap y cycle 
is planned. Patients referred with stable disease on no recent therapy  will be eligible as well.
The use of additional chemotherap y prior to the recommended pre-infusion chemotherap y 
will be at the discretion of the investigator and dependent on the patient’s disease burden.
When given, lymphodepleting chemotherap y should be started before CTL 019 infusion so 
that these cells will be given 2 to 14 days after completion of the lymphodepleting 
chemotherap y.The timing of chemotherap y initiation therefore depends on the length of the 
regimen. The purpose of the chemotherap y is to induce lymphopenia in order to facilitate 
engraftment and homeostatic expansion of CTL 019cells. Fludarabine (30 mg/m2i.v. daily  for 
4 doses) andcyclophosphamide (500 mg/m2i.v. daily  for 2 doses starting with the first dose 
of fludarabine) is the regimen of choice, as there is the most experience with the use of this 
regimen in facilitat ing adoptive immunotherapy . Refer to Section 2.2.1 for additional 
information regarding l ymphodepleting chemotherap y.
If patients have a WBC count ≤ 1,000 cells/µL  within one week prior to CTL 019 infus ion, 
lymphodepleting chemotherapy  is NOT required. If the time between lymphodepleting 
chemotherap y and CTL019 infusion exceeds 4 we eks, lymphodepleting chemotherapy  will be 
repeated only if the patients WBC count is >1,000 cells/µL .
Patient s will also undergo blood tests including chemistry , lab tests of special interest (  
 fibrinogen, and LDH) ,and a CBC with differential. Adverse events and 
prior/concomitant medications will be reviewed.
Pre-infusion visit (D -1 +1d)
On the day prioror day ofthe scheduled CTL 019 infusion, patient s will undergo a physical 
exam (including weight and vital signs ),and a performance status assessment (Karnofsky  (age 
≥16 years) or Lansk y (age < 16 years). In addition, a urine or serum pregnancy  test will be 
performed on female patients of childbearing potential confirming a negative pregnancy 
result .In addition, adverse events and prior/concomitant medications will be reviewed.
 

Novartis Confidential Page 87
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Note: All patients must undergo a rapid influenza diagnostic test(only during the months of 
October through May)within 10 days prior to the planned CLT019 infusion. If the patient is 
positive for influenza, oseltamivir phosphate or zanamivir should administered for 10 days as 
preventative treatment (see Tamiflu® or Relenza® package insert for dosing). The patient 
must complete their 10 day preventative treatment course prior to receiving CTL019.  The 
test does not need to be repeated prior to CTL 019 infusion however if influenza sign and 
symptoms are present, CTL 019 infusion should be delay ed until patient is asy mptomatic.
7.1.3 Treatment and Primary  Follow -Up P hase
For details of assessments, refer to Table 7-1.
Infusion visit (D1 )
CTL 019 i nfusion will begin 2 to 14 day s after c ompletion of lymphodepleting chemotherap y .
The day  of (but prior to) the CTL 019 infusion, patients will undergo blood tests including 
chemistry ,labsof special interest (  LDH , and fibrinogen ),a CBC with 
differential and coagulation panel , and serum cy tokine . Final CTL019 infusion pre-requisites 
(including an ECG) will be checked prior to infusion (perSection 6.1.1.2).
CTL 019 transduced T cells will be given as a single dose of 2 to 5x 106CTL019 transduced
viable T cells per kg body with a maximum dose of 2 .5x 108CTL019 cells (non-weight 
adjusted) .Vital signs will be monitored before and following CTL019 infusion 
(per Section 6.1.1.2). A blood sample will be collected post -infusion for CTL 019 PK 
assessment. In addition, adverse events and prior/concomitant medications will be reviewed.
Details on the administration of the CTL 019 infusion are found in Section 6.1.1.2.
Post -infusion visits : D2, D4±1d, D7±1d, D11± 1
d,D14±3d,D17±3d, D21±3d
At the intervals following infusion listed above , patients will undergo one or more of the 
following: physical exam, blood tests including chemistry ,labsof special interest (
 
 LDH , and fibrinogen ),hematology , coagulation, serum immunoglobulin, humoral & 
cellular immunogenicity ,CTL 019 PK, , flow cy tometry  (Band T cells, 
tumor cells and CD19 assessment), a physical exam (with vital signs )and performance status 
assess
ment. In addition, adverse events and prior/concomitant medications will be reviewed.
On Day  2, onl y vital signs, phy sical examination, performance status, hematology , and 
chemistry  (inclusive of LFTs and creatinine) 
will be performed.
 
 
 
 
 
 
 
 
 
 

Novartis Confidential Page 88
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
 
 
Post -infusion visit (D28 ± 4d)
Patient s will undergo blood collection for hematology , chemistry ,labsof special interest 
(  LDH, and fibrinogen), coagulation, serum immunoglobulins, , flow 
cytometry  (B and T cells, tumor cells, and CD19 assessment) humoral and cellular 
immunogenicit y, . Patient s will 
have a lumbar puncture for CSF cy tologic assessments and CTL 019 PK. Patient s are required 
to have a 
bone marrow biopsy andaspirate for morphology , flow cy tometry , MRD, CTL 019 
PK, . In addition, patient s will undergo a ph ysical exam (inc luding 
vital signs , weight, and extramedullary  disease assessment), CNS sy mptom assessments and a
performance status assessment . Tumor response assessments will be conducted (see Appendix 
1 for response guidelines) .A lymph node or tissue aspirate or biops y ma y be done if clinicall y 
indicated. Adverse events and prior/concomitant medications will be reviewed.
For details of assessments, refer to Table 7-1.
Post -infusion visits (Monthly from M2 through M6 ±14d)
At the intervals following infusion listed above , patients will undergo one or more of the 
following: blood collection for hematology , chemistry , serum immunoglobulins, flow 
cytometry  (B and T 
cells, tumor cells, and CD19 assessment), cytokines, humoral & cellular 
immunogenicit yand ,andRCL by  
VSV -GqPCR . In addition, patient s will undergo a phy sical exam ( including vital signs , 
height, weight, Tanner staging (month 6 onl y),and extramedullary  disease assessment ), CNS 
symptom assessment, and a performance status assessment . Adverse events and 
prior/concomitant medications will be reviewed.
If patient s were not in CR or CRi at the D28 visit assessments, a bone marrow biopsy , aspirate 
and CSF assessm ent/lumbar puncture will be required for tumor response assessments at the 
first visit where clinical evidence remission is observed b y peripheral blood and 
extramedullary  disease assessment (physical exam and CNS sy mptom assessments).
Patient s may  also ha ve a bone marrow biops y, aspirate , LP/CSF assessment and ly mph node 
aspirate or biops y (if accessible) at month 3 and month 6 for tumor response assessments
(recommended but not required) .
For details of assessments at each visit , refer to Table 7 -1.
Post -infusion visit (M9 ±14d)
Patient s will undergo one or more of the following: blood collection for hematology , 
chemistry , serum immunoglobulins, flow cy tometry  (B and T 
cells, tumor cells, and CD19 
assessment), and CTL019 PK. I n addition, patient s will undergo a ph ysical exam ( including
vital signs and extramedullary  disease assessment ), CNS sy mptom assessment and a 
 

Novartis Confidential Page 89
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
performance status assessment . Adverse events and prior/concomitant medicati ons will be 
reviewed.
For details of assessments, refer to Table 7-1.
Post -infusion visit (M12 ±14d)
Patients will undergo the following: blood collection for hematology , chemistry , serum 
immunoglobulins, flow cytometry (B and T cells, tumor cells, and CD19 assessment), 
cytokines, humoral and cellular immunogenicit y,  
 and RCL by  VSV -G qPCR. I n addition, patients will undergo a phy sical exam 
(including heig ht, weight, GVHD assessment, Tanner staging, vital signs, and extramedullary  
disease assessment), CNS symptom assessment, and a performance status assessment. 
Adverse events and prior/concomitant medications will be reviewed.
For details of assessments, refer to Table 7-1.
Patients with CD19 CA R transgene levels equal to or greater than 1% of WBC
If ≥ 1% of the WBC in peripheral blood are positive for CD19 CAR vector sequenc es by 
qPCR at > 12 months from CD19 CART infusion, then the patient will be asked to return for 
a confirmatory  blood test prior to the next visit. If ≥1% of the WBC is positive upon the 
receipt of the confirmatory  qPCR result, then the genomic vector integ ration sites will be 
determined. Identified vector integration sites will be evaluated using bioinformatic 
approaches to determine the frequency  of integration events in regions with known 
relationships to human cancers (i.e. near oncogenes). If integratio n site analy sis reveals mono -
or oligo -clonality  pattern and/or integration at or near an oncogenic locus, a monitoring plan, 
including follow -up molecular analy ses, will be developed in collaboration between the 
Investigator, Novartis and Health Authoriti es that is specific for the health care risks that are 
anticipated given the nature of the integration site and vector target cell ty pe.
Post -infusion visit (M15 ±14d, M18 ±14d, M21 ±14d)
Patients will undergo the following: blood collection for hematology , chemistry  and CTL019 
PK. Blood will be collected for flow cytometry  (B and T cells, tumor cells) at M18 only. In 
addition, patients will undergo a physical exam (including height, weight and Tanner staging 
at M18 onl y), vital signs, extramedullary  diseas e assessment, CNS sy mptom assessment and a 
performance status assessment. Adverse events and prior/concomitant medications will be 
reviewed. An y pregnancies will be reported.
Post -infusion visit (M24 ±14d, M30 ±14d, M36 ±14d, M42 ±14d, M48 ±14d, M54 
±14d)
Patients will undergo the following: blood collection for hematology , chemistry  and CTL019 
PK. Blood will be collected for flow cy tometry  (B and T cells, tumor cells) and RCL  by VSV -
G qPCR annually  at M24, M36 and M48 only. Blood will be collected for  
 humoral & cellular immunogenicity  at M24 and M36 only. In addition, 
patients will undergo a physical exam (including height, weight and Tanner staging), vital 
signs, extramedullary  disease assessment, CNS symptom assessment and a performance status 
 

Novartis Confidential Page 90
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
assessment. Adverse events and prior/concomitant medications will be reviewed. Any 
pregnancies will be reported.
For all patients who receive a CTL 019 infusion, follow -up for survival every  3 m onths until 
end of study  or enrolling into the long term follow -up, whichever comes first, is required. If a 
patient misses a quarterly  scheduled visit where survival status is required, or if the quarterl y 
time-point where survival status is required does not align with a scheduled visit, survival 
status can be obtained via phone contact.
7.1.3.1 End of Treatment and Primary  Follow -Up visit (M60 ± 14d ) including 
premature discontinuation
The End of Treatment and Primary  Follow -Up(EOT ) visit for each patient will be 60 months
(5 years ) from the date of their infusion if they complete all scheduled visits . If a patient
discontinues early from the Treatment and Primary  follow -up, a visit should be scheduled as 
soon as possible, at which time all of the assessments listed for the Month 60 visit will be 
performed. A
nEnd of Treatment and Primary Follow -UpDisposition CRF (CRF )page 
should be completed, giving the date and, if applicable, reason for discontinuing from the 
treatment and primary  follow up 
the study .
During the EOT and Primary  Follow -Up visit, patient s will undergo the following: blood 
collection for hematology , chemistry , serum immunoglobulins, flow cy tometry  (B and T cells, 
tumor cells, and CD19 assessment), cytokines, humoral and cellular immunogenicity ,
 and RCL  by VSV -GqPCR . In 
addition, patient s will undergo a physical exam ( including height, weight, GVHD assessment, 
Tanner staging ,vital signs ,and extramedullary  disease assessment ), CNS symptom 
assessment, and a performance status assessment . Adverse events and prior/concomitant 
medications will be reviewed. Any pregnancies will be reported. 
Following completion of the Treatment and Primary  Follow -Up, patients will be followed for 
for survival until end of study  as defined in Section 4.2 (Section 7.1.5 ).Patients who 
discontinue or withdraw from the Treatment and Primary  Follow -Up early  will be asked to 
continue the study  in the Secondary  Follow -up Phase through Month 60.
For patients who are lost to follow -up, the investigator should show "due diligence" by 
documenting in the source documents steps taken to contact the patient, e.g., dates of 
telephone calls, registered let ters, etc.
7.1.3.2 Criteria for premature patient withdrawal from Treatment and Primary  
Follow -Up Phase
Patients must be followed according to the visit schedule for the Treatment and Primar y 
Follow -Up to ensure adequate data are collected for the proper assessmen t of study  primar y 
and secondary  objectives. Patients may voluntarily  withdraw from the Treatment and Primary 
Follow -Up Phase or be dropped 
from it at the discretion of the investigator at any time. It is 
anticipated that patients may leave the primary  follow-up and move to Secondary  Follow -Up 
due to reasons including:
Treatment failure
Relapse after remission
 

Novartis Confidential Page 91
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Pursuing HSCT while in remission
Patient voluntary  withdrawal from the primary  follow -up
For patients who are lost to follow -up, the investigator should show “due diligence” by 
documenting in the source documents steps taken to contact the patient, e.g., dates of 
telephone calls, registered letters, etc.
7.1.3.3 Relapse Evaluation
If at any time during the Treatment and Primary Follow -Up phase following infusion, a 
patient who was in remission relapses, a full disease evaluation will be completed. A s soon as 
possible after awareness of a relapse , the patient will be scheduled for a visit, and willhave a 
bone marrow biops y & aspirate, and peripheral blood colle ction. The following assessments 
will be performed:
a.Tumor characterization: Can be done on either blood or bone marrow with known tumor 
involvement of these components depending on availability  of specimens, but priority  is to 
do the majority  of testing onbone marrow:
1.Flow cy tometry  (B and T cells, tumor cells and CD19 assessment
)
2.Blood and bone marrow morphology
3.Cytogenetics/ FISH/ 
4.
b.CTL 019 cell characterization: Must be done on both peripheral blood and bone marrow ,
depending on availability of specimens :
1.PK by  q-PCR and flow cytometry
2.
c.Immunogenicit y (humoral & cellular)
d.  
 
In the event of relapse due to extramedullary  disease only, the patient may still be followed 
per the treatment and primary  follow -up phase visit schedule until the institution of systemic 
antineoplas
tic therap y.
7.1.4 Secondary  Follow -Up Phase
Patients who discontinue the Treatment and Primary  Follow -Up Phase before month 60 will 
continue to be followed in the secondary  follow -up phase in order to collect health authorit y 
requested data (e.g. delayed adverse events) up to 5 y ears after CTL019 infusion.
The first visit in the Secondary  Follow -Up Phase is determined according to the time since 
CTL 019 infusion when the patient discontinued from the Treatment and Primary  Follow -Up 
Phase. For example, if the patient discontinue from the Treatment and Primary  Follow -Up 
phase at Month 10, the first visit in the Secondary  Follow -Up Phase will be Month 12.
During the secondary  follow -up phase, patients will undergo one or more of the following at 
each visit according to Table 7 -2: B lood collection for hematology , humoral immunogenicity, 
 

Novartis Confidential Page 92
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
cytokines, CTL 019 transgene persistence, flow cytometry  (B and T cells, tumor cells) and 
RCL  by VSV -G qPCR. In addition, patients will undergo aphysical exam (including height, 
weight and Tanner staging), vital signs, and a performance status assessment. Adverse events 
and prior/concomitant medications will be reviewed. Any pregnancies will be reported. 
Efficacy  will be assessed in patients who a re still in remission until relapse. For these patients, 
relapse status will be assessed at each visit.
For all patients who receive a CTL 019 infusion, follow -up for survival every  3 m onths until 
end of study  or enrolling into the long term follow -up, whic hever comes first, is required. If a 
patient misses a quarterly  scheduled visit where survival status is required, or if the quarterl y 
time-point where survival status is required does not align with a scheduled visit, survival 
status can be obtained via p hone contact.
In addition, in the event a patient that is still in remission cannot attend any visit during the 
secondary  follow -up, the investigator should attempt to contact the patient by phone to 
determine relapse status.
For details of assessments, re fer to Table 7-2.
7.1.4.1 Criteria for premature patient withdrawal
Patients may voluntarily  withdraw from the study . Patients lost to follow up should be 
recorded as such on the CRF. 
Patients may  be withdrawn from the study  if an y of the following occur:
a.The patientis lost to follow -up.
b.Patient noncompliance with study  therapy  and/or clinic appointments
c.Voluntary  withdrawal; a patient may  remove himself/herself from the study at any  time 
without prejudice. 
d.Termination of the stud y by the Novartis or health authorities. 
Novartis will continue to retain and use all research results that have alread y been collected 
for the study  evaluation.  All biological samples that have alread y been collected may be 
retained and anal yzed at a later date (or as r equired by  local regulations).
7.1.5 Survival Follow -Up Phase
For all patients who complete or prematurel y discontinue from the primary  or secondary 
follow -up phase , attempts to follow -up will be made to determine survival every  3  m onths
post-CTL 019 infusion until end of study  as defined in Section 4.2or patient is enrolled inthe 
15 year long term follow-up ,whichever occurs first .
7.1.6 Long -Term Follow Up
As a single administration study , patient s are followe d on study  for 1 year post-infusion for 
safet y and efficacy  evaluations. A long term post-study  follow -up for lentiviral vector safet y 
will continue under a separate protocol for 15 years post infusion per health authorit y
guidelines (destination protocol) .
 

Novartis Confidential Page 93
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Under the 15 year long term follow -up protocol, semiannual and annual evaluations will be 
performed on all patient s who have received a CTL019 cell product infusion as recommended 
by the FDA and EMA in accordance with the relevant guidelines . All patient s who either 
complete the study  or prematurel y discontinue post-CTL 019 infusion will be enrolled in this 
destination protocol at the time of study  completion/discontinuation (a separate informed 
consent /assent form swill be provided for this protocol). One to two times a year patients will 
visit the clinical site for a physical exam and medical history  (including concomitant 
medications and adverse events) with careful attention to features possibly  related to lentiviral 
associated events such as new malign ancies, new incidence or exacerbation of a pre-existing 
neurologic disorder, new incidence or exacerbation of a prior rheumatologic or other 
autoimmune disorder, or new incidence of other hematologic disorders. In addition, labs will 
be drawn to evaluate r outine safet y endpoints, CTL019 vector persistence and RCL.
7.2 Assessment ty pes
7.2.1 Efficacy  assessments
Efficacy  assessments will be performed according to the Novartis guidelines for efficac y 
evaluation in Acute Lymphoblastic Leukemia studies (Appendix 1), whic h is based on the 
NCCN version 1.2013 guidelines, Cheson et al (2003) and Appelbaum et al (2007) .
An Independent Review Committee (IRC) appointed by Novartis will review data related to
disease response assessments in ALL patients according to the Novartis guideline (Appendix 
1). The IRC assessment will be used for the primary  efficacy  analysis. The local investigator
assessment s
will be used for sensitivity  analy sis for select efficacy endpoint s.
Patients with B-cell Lymphoblastic Lymphoma will be assessed for efficacy  per local 
investigator assessments only  in accordance with Novartis guideline ( Appendix 3 ).
 

Novartis Confidential Page 94
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Table 7-4 Imaging or disease a ssessment collection plan –Primary follow -up phase
Procedure Screening/Pre -infusion Post -infusion Assessments
Bone marrow aspirate and biopsy for 
morphologic blast cell countsMandated Mandated: Month 1 (D ay 28). If patient is not in CR/CRi at Month 1, then required at the 
first time clinical evidence ofremission is seen by peripheral blood and extramedullary 
disease assessment (physical exam and CNS symptoms)
Recommended (but not required) at month 3 and 6 and as clinically indicated
Peripheral blood for morphologic blast, 
neutrophil and platelet cell countsMandated Mandated: Months 1, 2, 3, 4, 5, 6, 9,12, 15, 18, 21, 24, 30, 36, 42, 48, 54 and 60 (EOT )
Lymph node or other involved tissue aspirate 
or biopsyAs clinically indicated As clinically indicated
CSF Assessment/Lumbar puncture for CNS 
diseaseMandated Mandated: Month 1 ( Day 28 ). If patient is no t in CR/CRi at Month 1, then required at the 
first time clinical evidence ofremission is seen by peripheral blood and extramedullary 
disease assessment (physical exam and CNS symptoms)
Additional CSF assessments as clinically indicated 
MRD assessments in bone marrow aspirate
by flow cytometry (includes normal B cell 
counts and CD19 status)Mandated Mandated: Month 1 (Day 28). If patient is not in CR/CRi at Month 1, then required at the 
first time clinical evidence of remission is seen by peripheral blo od and extramedullary 
disease assessment (physical exam and CNS symptoms)
Recommended (but not required) at month 3 and 6 and as clinically indicated . 
CNS Brain Imaging (CT/MRI) As clinically indicated As clinically indicated
Mediastinal disease assessment (chest CT 
scan or MRI scan) As clinically indicated, 
mandatory only for 
Lymphoblastic L ymphoma 
patientsMandated: Screening, M1. If at any time point, mediastinal disease is present by CT/MRI 
assessment, then follow -up CT/MR I is required to document the absence of mediastinal 
involvement whenever the patient meets all other criteria for complete remission.
Extramedullary disease assessment (physical 
exam and CNS symptom assessment )Mandated Mandated: Months 1, 2, 3, 4, 5, 6, 9 , 12 , 15, 18, 21, 24, 30, 36, 42, 48, 54 and 60  (EOT )
Flow Cytometry of peripheral blood (B and T
cell, tumor cell, CD19 assessment)Mandated Mandated: Days 7, 14, and 21, and Months 1, 3, 6, 9, 12 , 24, 36, 48 and 60 (EOT )
 

Novartis Confidential Page 95
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
7.2.1.1 Physical examination
A targeted physical examination focusing upon sites of extramedullary  disease involvement 
including assessments for hepatomegaly , splenomegaly , skin/gum infiltration, testicular 
masses and other disease manifestations are required. In addition, the physical examination 
will also include the assessments of general appearance, skin, neck, eyes, ears, nose, throat, 
lungs, heart, abdomen, back, lymph nodes, extremities, and the neurological system . If 
indicated based on medical history  and/or symptoms, rectal, external genitalia, breast, and 
pelvic exams will be performed.
Significant findings that were present prior to the signing of informed consent/assent must be 
included in the Medical History page on the patient’s CRF. Significant findings that begin or 
worsen after study  treatment (i.e. lymphodepleting chemotherap y) must be recorded on the 
Advert Even page of the patient’s CRF as defined in Section 8.1.1. For visits where disease 
response is assessed (mo
nth 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54 and 60), 
assessment results will be recorded on the ph ysical exam disease response CRF page.
7.2.1.2 CNS Sy mptom Assessments
Assessment of patient reported symptoms suggestive of leukemic involvement of the CNS 
will be performed and recorded with each phy sical examination. Examples of CNS sy mptoms 
suggestive of leukemic involvement may include, but are not limited to, severe headache or 
nausea, meningismus or cognitive impairment, without other apparent etiologies. If clinical 
signs of CNS leukemia exist, it must be confirmed by CNS imaging (CT or MRI  of brain) or 
other relevant methods (e.g. biops y, LP, etc.) to define CNS relapse. For visits where disease 
response is assessed (month 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54 and 60), 
assessment results will be recorded on the CNS disease response CRF page.
7.2.2 Safety  and tolerability assessments
Safety  will be monitored by physical exam, assessing immunogenicit y against CTL019, lab 
abnormalities as well as collecting adverse events at every visit. For details on AE collection 
and reporting, refer to Section 8.
7.2.2.1 Vital signs
Vital signs include 
temperature, blood pressure, pulse measu rements, and respiratory  rate.
Pulse oximetry  will be measured at select visits (see Table 7 -1).
7.2.2.2 Height and weight
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram [kg] in indoor 
clothing, but without shoes) will be measured.
 

Novartis Confidential Page 96
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
7.2.2.3 Performance status
Table 7-5 Karnofsky /Lansky  Performance Scales
Karnofsky  Scale (age ≥ 16 years) Lansky  Scale (age < 16 y ears)
Able to carry  on normal activity  and to work; no 
special care needed.Able to carry  on normal activity ; no special care is 
needed
100 Normal no complaints; no evidence of disease 100 Fully active
90 Able to carry on normal activity; minor signs or 
symptoms of disease90 Minor restriction in physically strenuous play
80 Normal activity with effort; some signs or 
symptoms of disease80 Restricted in strenuous play, tires more easily, 
otherwise active
Unable to work; able to live at home and care for
most personal needs; vary ing amount of 
assistance needed.Mild to moderate restriction
70 Cares for self; unable to carry on normal 
activity or to do active work70 Both greater restrictions of, and less time 
spent in active play
60 Requires occasional assistance, but is able to 
care for most of his personal needs60 Ambulatory up to 50% of the time, limited 
active play with assistance/supervision
50 Requires considerable assistance and frequent 
medical care50 Considerable assistance required for any 
active play, fully able to engage in quiet play
Unable to care for self; requires equivalent of 
institutional or hospital care; disease may  be 
progressing rapidly .Moderate to severe restriction
40 Disabled; requires special care and assistance 40 Able to initiate quiet activities
30 Severely disabled; hospital admission is 
indicated although death not imminent30 Needs considerable assistance for quiet 
activity
20 Very sick; hospital admission necessary; active 
supportive treatment necessary20 Limite d to very passive activity initiated by 
others ( e.g. television)
10 Moribund; fatal processes progressing rapidly 10 Completely disabled, not even passive play
0 Dead 0 Unresponsive
7.2.2.4 Tanner Staging
Tanner staging will be updated semiannually . If a patient is classified as Tanner Stage 5 at 
screening or at any point during the trial, no further Tanner staging will be required for the 
remainder of the trial. Female patient reproductive status (menstrual status and pregnancy  
information) will be update d monthly  from month 2 through 6, then quarterl y through two 
years, then semiannually  thereafter during either the primary  or secondary  follow -up.
7.2.2.4.1 Males
Genitalia stages:
Stage 1: Pre-adolescent. Testes, scrotum, and penis are of about the same size and proportion 
as in earl y childhood.
Stage 2: The scrotum and testes have enlarged and there is a change in the texture of the 
scrotal skin. There is also some reddening of the scrotal skin.
 

Novartis Confidential Page 97
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Stage 3: Growth of the penis has occurred, at first mainly  in length but with some increase in 
breadth. There has been further growth of testes and scrotum.
Stage 4: Penis further enlarged in length and breadth with development of glans. Testes and 
scrotum further enlarged. There is also further darkening of the scrotal skin .
Stage 5: Genitalia adult in size and shape. 
No further enlargement takes place after Stage 5 is 
reached.
Pubic Hair Stages:
Stage 1: Pre-adolescent. The velus over the pubesis no further developed than that over the 
abdominal wall, i.e. no pubic hair.
Stage 2: Sparse growth of long, slightl y pigmented, down y hair, straight or only slightl y 
curled, appearing chiefl y at the base of the penis. 
Stage 3: Considerably  darker, coarser, and more curled. The hair spreads sparsel y over the 
junction of the pubes.
Stage 4: Hair is now adult in type, but the area covered by it is still considerabl y smaller than 
inmost adults. There is no spread to the medial surface of the thighs.
Stage 5: Hair distribution is adult in quantity  and type and is described in the inverse triangle. 
Hair can be spread to the medial surface of the thighs.
7.2.2.4.2 Females
Breast stages:
Stage 1: Pre -adolescent; elevation of papilla onl y.  
Stage 2: Breast bud stage; elevation of breast andpapilla as a small mound, enlargement of 
areola diameter.
Stage 3: Further enlargement of breast and areola, with no separation of their contours.
Stage 4: Projection of areola and papilla to form asecondary  mound above the level of the 
breast.
Stage 5: Mature stage; projection of papilla only, due to recession of the areola to the general 
contour of the breast.
Pubic Hair Stages:
Stage 1: Pre-adolescent; the vellus over the pubes isnot further developed than that over the 
anterior abdominal wall, i.e. no pubic hair.
Stage 2. Sparse growth of long, slightly  pigmented, down y hair, straight or only slightl y 
curled, appearing chiefl y along the labia. 
Stage 3: Considerabl y darker, coarser, and more curled.   The hair spreads sparsel y over the 
junction of the pubes.
 

Novartis Confidential Page 98
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Stage 4: Hair is now adult in type, but the area covered by it is still considerabl y smaller than 
in most adults.   There is no spread to the medial surface of the thighs.
Stage 5: Adult in quantity  and type, distributed as aninverse triangle of the classically 
feminine pattern. Spread to the medial surfac e of the thighs, 
but notup the linea alba or 
elsewhere above the base of the inverse triangle.
7.2.2.5 Laboratory  evaluations
Screening and other laboratory  assessments will be performed accordingl y to Table 7 -1. Note: 
Additional assessments should be performed between visits as clinically  required to follow 
AEs or CTL 019 expected events and for detailed modified data capture for inpatient/in 
hospital events, refer to Section 
8.1.1. For all laboratory  assessments that occur on Day 1, 
these should be performed prior to CTL 019 infusion unless indicated otherwise.
The Investigator will evaluate the clinical significance of each applicable laboratory  value 
outsid e of the reference range. This decision shall be based upon the nature and degree of the 
observed abnormality . Values which are considered clinically  significant and/or study  related 
to 
CTL019 will be noted. The Investigator may choose to repeat any abnorm al result once, in 
order to rule out laboratory  error. "NCS" will be entered on the original laboratory  sheet of all 
laboratory  values which are outside the reference range, but are judged "not clinicall y 
significant." The ph ysician making these assessment s shall date and initial each form.
Table 7-6 Local clinical laboratory  parameters collection plan
Test Category Test Name
Hematology Hematocrit, Hemoglobin, Mean Corpuscular Hemoglobin Concentration ( MCHC ), 
MCV (Mean Corpuscular Volume) , Platelets, Red blood cells, W hite blood cells with 
complete differential (Basophils, Eosinophils, Lymphocytes, Atypical Lymphocytes,
Monocytes, Neutrophils , Lymphoblasts ,Plasma ce lls,Prolymphocytes, Myelocytes, 
Metamyelocytes, and Promyelocytes )
Chemistry Serum Glucose (fasting or non -fasting), Blood Urea Nitrogen (BUN), Creatinine, 
Sodium, Potassium, Calcium, Total Protein, Albumin, Total Bilirubin, Alkaline 
Phosphatase, Asparta te Aminotransferase (AST ), Alanine Aminotransferase (ALT ), 
Magnesium, Phosphorus, Lactate Dehydrogenase (LDH),  
and Uric Acid.
Urinalysis Macroscopic Panel (D ipstick) (Bilirubin, Blood, Glucose, Ketones,  pH, Protein, 
Specific Gravity , and either leukocyte esterase or nitrites )
If macroscopic panel is abnormal then perform microscopic p anel (Red Blood Cells, 
White Blood Cells, Casts, Crystals, Bacteria, Epithelial cells)
Coagulation Prothrombin time (PT) or Internation al normalized ratio (INR) , activated Partial 
thromboplastin time (aPTT) , fibrinogen, and D -dimer
Pregnancy screen Serum or urine tests
Viral Serology Hepatitis C Virus (HCV ) antibody, Hepatitis B surface antigen (HBsAg) ,Hepatitis B 
core antibody (anti-HBc), Hepatitis B surface antibody (anti- HBs), HIV (if an initial 
HIV screening test is positive then a confirmatory HIV test is required to be 
performed as per current local guidelines )
CSF White Blood Cells with differential (Monocytes, Lymphoctyes, Macrophages, 
Neutrophils, Lyymphoblasts ), Red Blood cells, Glucose, Protein 
 

Novartis Confidential Page 99
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Test Category Test Name
B cell and T cell levels Peripheral blood B cell, CD4 T cell, and CD8 T cell levels (flow cytometry) (all 
patients af ter 1 year)
Additional assessments Serum immunoglobulin levels (IgG, IgA, IgM )peripheral blood donor chimerism (prior 
allogeneic SCT patients only, or if unknown), bone marrow morphologic blast cell 
counts (flow cytometry), peripheral blood morphologic blast, neutrophil and platelet 
cell counts (flow cytometry)
Table 7-7 Central clinical laboratory  parameters collection plan
Test Category Test Name
MRD
Flow cytometryMRD flow panel (bone marrow aspirate)
Bcells, CD4 T cells, CD8 T cells, , CD19 as sessment 
(peripheral blood and bone marrow aspirate)
CTL019 assessments CTL019 PK by q -PCR and /orflow cytometry (peripheral blood and bone marrow 
aspirate and CSF if available ), 
RCL (VSV-G) VSV-g q-PCR ( peripheral blood)
Immunogenicity Prevalence and Incidence of immunogenicity against CTL019 (peripheral blood and 
serum)
  
 
Refer to the [Central Laboratory  Manual] for more detailed instructions for the collection, 
handling, and shipment of PK and 
7.2.3 Pharmacokinetics
Table 7-8 CTL019 pharmacokinetic sby q-PCR in peripheral blood collection log
Treatment Period or Cy cle Day/ Scheduled Time Point* Sample Volume** 
1 W-8 to D-8 Enrollment/Pre -Chemotherapy 3 mL
1 D1 10 min ± 5 min post -infusion 3 mL
1 D4±1d 3 mL
1 D7±1d 3 mL
1 D11 ±1d 3 mL
1 D14±3d 3 mL
1 D21±3d 3 mL
1 D28± 4d 3 mL
1 M3±14d 3 mL
1 M6±14d 3 mL
1 M9±14d 3 mL
1 M12±14d 3 mL
1 M18±14d 3 mL
1 M24±14d 3 mL
1 M30±14d 3 mL
1 M36±14d 3 mL
1 M42±14d 3 mL
 

Novartis Confidential Page 100
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Treatment Period or Cy cle Day/ Scheduled Time Point* Sample Volume** 
1 M48±14d 3 mL
1 M54±14d 3 mL
1 M60±14d (EOT) 3 mL
1 Unscheduled PK samples related to)*** 2 mL/collection
1 Unscheduled (PK samples related to safety events, 
relapse)3 mL/collection
*All measurement times are relative to date of CTL019 infusion unless otherwise specified.
**All patient sample volumes subject to adjustment for size and patient condition .
***Additional unscheduled samples may be collected as needed dependent upon individual patient differences in 
the clinical time -course of CRS, if clinically feasible. See Se ction 7.1.3 .
 
Table 7-9 CTL019 pharmacokinetics by flow cy tometry in peripheral blood 
collection log
Treatment Period or Cy cle Day/ Scheduled Time Point* Sample Volume 
1 W-8 to D-8 Enrollment/Pre -Chemotherapy 2 mL
1 D4±1d 2 mL
1 D7±1d 2 mL
1 D11±1d 2 mL
1 D14±3d 2 mL
1 D21±3d 2 mL
1 D28± 4d 2 mL
1 M3±14d 2 mL
1 M6±14d 2 mL
1 M9±14d 2 mL
1 M12±14d 2 mL
1 M18±14d 2 mL
1 M24±14d 2 mL
1 M30±14d 2 mL
1 M36±14d 2 mL
1 M42±14d 2 mL
1 M48±14d 2 mL
1 M54±14d 2 mL
1 M60±14d (EOT) 2 mL
1 Unscheduled PK samples related to CRS 2 mL/collection
1 Unscheduled (e.g. related to safety events, at
relapse)2 mL
*All measurement times are relative to date of CTL019 infusion unless otherwise specified.
** Additional unscheduled samples may be collected as needed dependent upon individual patient differences in 
the clinical time -course of CRS, if clinically feasible. See section 7.1.3.
Table 7-10 CTL019 pharmacokinetic s by q-PCR inbone marro w aspirate 
collection log
Treatment Period or Cy cle Day/ Scheduled Time Point* Sample Volume**
1 W-8 to W -4 Screening 2 mL
1 D28± 4d 2 mL
1 M3±14d (recommended but not required) 2 mL
 

Novartis Confidential Page 101
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Treatment Period or Cy cle Day/ Scheduled Time Point* Sample Volume**
1 M6±14d (recommended but not required) 2 mL
1 Unscheduled (e.g. related to safety events ,at relapse ) 2 mL/collection
*All measurement times are relative to date of CTL019 infusion unless otherwise specified.
**All patient sample volumes subject to adjustment for size and patient condition.
 
Table 7-11 CTL019 pharmacokinetics by  flow cy tometry  in bone marro w aspirate 
collection log
Treatment Period or Cy cle Day/ Scheduled Time Point* Sample Volume**
1 W-8 to W -4 Screeni ng 2 mL
1 D28±4 d 2 mL
1 M3±14d (recommended but not required) 2 mL
1 M6±14d (recommended but not required) 2 mL
1 Unscheduled (e.g. related to safety events, at relapse) 2 mL/collection
*All measurement times are relative to date of CTL019 infusion unless otherwise specified.
Table 7-12 CTL019 pharmacokinetic sby q-PCR inCSF collection log
Treatment Period or Cy cle Day/ Scheduled Time Point* Sample Volume
1 W-8 to W-4 Screening 4-6mL
1 D28± 4d 4-6mL
1 Unscheduled 4-6mL
*All measurement times are relative to date of CTL019 infusion unless otherwise specified.
Table 7-13 Immunogenicity  serum sample collection log
Treatment Period or Cy cle Day/ Scheduled Time Point* /** Sample Volume
1 W-8 to D-8 Enrollment/Pre -Chemotherapy 5 mL
1 D14±3d 5 mL
1 D28± 4d 5 mL
1 M3±14d 5 mL
1 M6±14d 5 mL
1 M12±14d 5 mL
1 M24±14d (Primary follow -up only) 5 mL
1 M36±14d (Primary follow -up only) 5 mL
1 Unscheduled  (e.g. related to safety events, at relapse) 5mL/collection
*All measurement times are relative to date of CTL019 infusion unless otherwise specified.
Table 7-14 Immunoge nicity  peripheral blood sample collection log
Treatment Period or Cy cle Day/ Scheduled Time Point* Sample Volume** 
1 W-8 to D-8 Enrollment/Pre -Chemotherapy 10 mL
1 D14±3d 10 mL
1 D28± 4d 10 mL
1 M3±14d (Primary follow -up only) 10 mL
1 M6±14d (Primary follow -up only) 10 mL
1 M12±14d (Primary follow -up only) 10 mL
 

Novartis Confidential Page 102
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Treatment Period or Cy cle Day/ Scheduled Time Point* Sample Volume** 
1 M24±14d (Primary follow -up only) 10 mL
1 M36±14d (Primary follow -up only) 10 mL
1 Unscheduled (e.g. related to safety events, at relapse) 10 mL/collection
*All measurement times are relative to date of CTL019 infu sion unless otherwise specified
**All patient sample volumes subject to adjustment for size and patient condition.
Table 7-15 Tocil izumab, CTL019 Pharmacokinetic s(PK), and sIL6R (PD) in 
tocilizumab treated patients during CRS
Day/ Scheduled 
Time Point*/**Dose 
Reference 
IDToci 
Sample 
NumberSample 
Volume 
(serum) 
(PK+PD)CTL019 PK 
by qPCR 
Sample 
NumberSample 
Volume
(whole 
blood)CTL019 PK 
by flow 
cytometry  
Sample 
NumberSample 
Volume
(whole 
blood)
D1 (5 -15 minutes 
post infusion)101 1 5 mL -- -- -- --
D1 1 hour ± 15 
min post infusion101 2 5 mL 201 2 mL 601 2 mL
D2 ± 2 hours 101 3 5 mL 202 2 mL 602 2 mL
D3 ± 4 hours 101 4 5 mL 203 2 mL 603 2 mL
D7 ± 1d 101 5 5 mL 204 2 mL 604 2 mL
D1 (pre -dose; 
second infusion)101 6 5 mL 205 2 mL 605 2 mL
D1(5 -15 minutes 
post second 
infusion)102 7 5 mL -- -- -- --
D2 ± 2 hours from 
second infusion102 8 5 mL 206 2 mL 606 2 mL
*All measurement times are relative to tocilizumab infusion unless otherwise specified. A serum sample collected 
at D1 for cytokine analysis (see Table 7 -17) would serve as the baseline sample.
**Samples may be collected as needed dependent upon administration of tocilizumab, if clinically feasible. 
Unscheduled CTL019 PK sample collections related to CRS as specified in Table 7-8and Table 7 -9will cease 
once PK/PD sample collections related to tocilizumab infusion commence, if applicable.
Table 7-16 Anti-cytokine therapy  (other than tocilizumab) PK, CTL019 PKand 
sIL6R (PD) in anti-cytokine therapy  treated patients during CRS
Day/ Scheduled 
Time Point*/**Dose 
Reference 
IDAnti-
cytokine 
Rx 
Sample 
NumberSample 
Volume 
(serum) 
(PK+PD)CTL019 
PK b y 
qPCR 
Sample 
NumberSample 
Volume
(whole 
blood)CTL019 PK 
by flow 
cytometry  
Sample 
NumberSample 
Volume
(whole 
blood)
D1 (5 -15 minutes 
post infusion)301 401 5 mL -- -- -- --
D1 1 hour ± 15 min 
post infusion301 402 5 mL 501 2 mL 701 2 mL
D2 ± 2 hours 301 403 5 mL 502 2 mL 702 2 mL
D3 ± 4 hours 301 404 5 mL 503 2 mL 703 2 mL
D7 ± 1d 301 405 5 mL 504 2 mL 704 2 mL
D1 (pre -dose; second 
infusion)301 406 5 mL 505 2 mL 705 2 mL
 

Novartis Confidential Page 103
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Day/ Scheduled 
Time Point*/**Dose 
Reference 
IDAnti-
cytokine 
Rx 
Sample 
NumberSample 
Volume 
(serum) 
(PK+PD)CTL019 
PK b y 
qPCR 
Sample 
NumberSample 
Volume
(whole 
blood)CTL019 PK 
by flow 
cytometry  
Sample 
NumberSample 
Volume
(whole 
blood)
D1(5 -15 minutes post 
second infusion)302 407 5 mL -- -- -- --
D2 ± 2 hours from 
second infusion302 408 5 mL 506 2 mL 706 2 mL
*All measurement times are relative to anti -cytokine therapy administration unless otherwise specified. A serum 
sample collected at D1 for cytokine analysis (see Table 7 -17) would serve as the baseline sample.
**Samples may be collected as needed dependent upon administration of anti -cytokine therapy, if clinically 
feasible. 
Unscheduled CTL019 PK sample collections related to CRS as specified in Table 7 -8and Table 7 -9will cease 
once PK/PD sample collections related to anti -cytokine therapy administration commence, if applicable.
7.2.3.1 Analytical method
The assay s to be utilized for various PK/ include q-PCR assay  to detect 
CTL 019/4 -1BB+ cells (transgene copies/microgram DNA) in peripheral blood and other 
tissues and flow cytometric analysis to detect CTL 019 positive cells. Details of sample 
collections for these assays will be provided in the 
[Central L aboratory  Manual] .
 

Novartis Confidential Page 104
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
 

Novartis Confidential Page 105
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
7.2.5 Resource utilization
Not applicable .
7.2.6 Patient reported outcomes
Not applicable .
 

Novartis Confidential Page 106
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions 
An adverse event is defined as the appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s), or medical condition(s) that occur after patient ’s signed 
informed consent /assent has been obtained.
Abnormal laboratory  values or test results occurring after informed consent /assent constitute 
adverse events only if they induce clinical signs or symptoms, are considered clinicall y 
significant, require therapy  (e.g., hematologic abnormality  that requires transfusion or 
hematological stem cell support), or require changes in study  medication(s).
8.1.2 Reporting
Adverse events that begin or worsen after informed consent will be recorded in the patient’s 
source documents. New or worsening adverse events prior to starting study treatment (i.e. 
lymphode pleting chemotherap y or the pre -infusion visit if the ly mphodepleting chemotherap y 
is not given per Section 6.1.1.1) are required to be recorded in the CRF if they  meet one of the 
following criteria:
All infections
All clinical AEs Grade ≥ 3
All laboratory  abnormalities deemed clinically  significant by  the investigator 
All AEs related to a study procedure
All AEs leading to stud y discontinuation
If apatient is simultaneousl y enrolled in the active phase (start of apheresis until 24 hours 
thereafter ) of the Nova rtis [CTL 019B2206] leukapheresis protocol and this treatment 
protocol, collection and reporting of adverse events during this overlapping period should 
follow the CTL 019B2206 safet y reporting criteria . Therefore during this overlap period, AEs 
should only be reported to the CTL019B2206 protocol, and not on the CTL 019B2205J 
protocol . After completion of the active phase on CCTL 019B2206, reporting of SAEs should 
follow the criteria of the respect ive treatment protocol the patient is participating in.
Once the patient begins lymphodepleting chemotherapy or the pre-infusion visit, all new 
or worsening adverse events, including laboratory  abnormalities deemed clinically  significant 
by the investigato r,will be recorded in the Adverse Events CRF.
Adverse event monitoring should be continued through the Month 60 visit. Following the 
Month 12 visit, and through the Month 60 visit, adverse events should only be reported to 
Novartis and recorded in the Ad verse Events CRF if it meets one of the following criteria:
Events leading to death
Events related to a stud y procedure
Infections:
 

Novartis Confidential Page 107
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Serious or opportunistic infections. Defined as bacterial, viral, fungal or parasitic 
infections that fulfill one of the fol lowing criteria:
Require anti -infective treatment OR
Lead to significant disability  or hospitalization OR
Need for surgical or other intervention
New incidence or exacerbation of a pre -existing neurologic disorder
New incidence or exacerbation of a prior rheumatologic or other autoimmune disorder
New incidence of other hematologic disorder
Any severe adverse event or condition the investigator believes may  have a reasonable 
relationship to CD19 CART therap y
Positive RCL  test result
Vector insertion site se quencing result with a mono -or oligoclonality  pattern or in a 
location near a known human oncogene
New malignancy  (T-cell & non T -cell), other than the primary  malignancy
Progressive multifocal leucoencephalopath y (PML)
Hepatitis B reactivation
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underl ying signs and symptoms. When a 
clear diagnosis cannot be identified, each sign or symptom should be reported as a separate 
Adverse Event.
Adverse events will be assessed according to the Medical Dictionary  for Regulator y 
Authorities ( MedDRA )version 16.1 and the Common Terminology  Criteria for Adverse 
Events (CTCAE version 4.03, with the exception of CRS, which will follow 
Table 6-1. If CTCAE grading does not exist for an adverse event, the severity  of mild, 
moderate, severe, and life-threatening, corresponding toGrades 1 
- 4, will be used. CTCAE 
Grade 5 (death) will not be used in this study ; rather, information about deaths will be 
collected though a Death form .
The occurrence of adverse events should be sought by  non-directive questioning of the patient 
during the screenin g process after signing informed consent /assent and at each visit during the 
study . Adverse events also may be detected when they are volunteered by the patient during 
the screening process or between visits, or through physical examination, laboratory  test, or 
other assessments. As far as possible, each adverse event should be evaluated to determine:
1.The severit y grade (CTCAE v. 4.03 Grade 1 -4)
2.Its duration (Start and end dates)
3.Its relationship to the study  treatment (Reasonable possibility  that AE is re lated: No;
Yes, investigational treatment; Yes, the study  treatment (non -investigational); Yes, both 
and/or indistinguishable)
4.Action taken with respect to study  or investigational treatment (none, temporaril y 
interrupted, permanentl y discontinued, not app licable)
5.Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
 

Novartis Confidential Page 108
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
6. Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequalae, fatal, u nknown)
7.Whether it is serious, where a serious adverse event is defined as in Section 8.2.1
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y is given, this a ction should be recorded on the Adverse Event CRF.
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequently , if 
necessary ) of any changes in severit y, the suspected relationship to the study  treatment, the 
interventions required to treat it, and the outcome.
Progression of malignan cy (including fatal outcomes), if documented by use of appropriate 
method should not be reported as a serious adverse event.
Modified data capture for inpatient/in hospital events
A significant number of CTL 019 treated patients will require multiple days o f inpatient and/or
ICU care. These side effects are mostly  due to CRS and MAS, although there may besome 
contribution from the preceding lymphodepleting chemotherap y (neutropenia fever, 
cytopenias). CRS/MAS toxicity  is an ‘on-target’ effect resulting from the expected CTL 019 
cell expansion, activation and tumor cell killing.
A typical inpatient or ICU day can generate hundreds of data points and many  therapeutic 
dose changes throughout a given day. These inpatient events and days are not scheduled 
protocol defined visits although they are anticipated to occur in some patients. A revised 
inpatient data capture sy stem will be utilized for this study  to sy stematically  collect subsets of 
patient data to describe the management of safet y events associated with CTL019 therapy  for 
the purpose of:
1. A dequatel y informing physicians and patients of the expected risks of CTL019 and the 
recommended interv entions to manage these risks
2. H ealth authorit y submission
This is done through atargeted collection of concomitant med ications and laboratory  data and 
CRS CRF sspecificall y designed to capture CTL019 -related toxicity , severity , interventions 
and response/resolution following intervention. Details can be found in the CRF Completion 
Guidelines (CCGs) and the Modified Data R eporting (Appendix 4 ).
8.1.3 Laboratory  test abnormalities
8.1.3.1 Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therapy  or 
require changes in study  treatment), should be recorded on the Adverse Events CRF. 
Whenever possible, a diagnosis, rather than a symptom should be provided (e.g. anemia 
instead of low hemoglobin). Laboratory  abnormalities that meet the criteria for Adverse 
Events should be followed until they have returned to normal or an adequate explanation of 
the abnormality  is found. When an abnormal laboratory  or test result corresponds to a 
 

Novartis Confidential Page 109
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
sign/sy mptom of an already  reported adverse event, it is not necessary  to separately  record the 
lab/test result as an additional event.
Laboratory  abnormalities that do not meet the definition of an adverse event (as defined 
above) should not be reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE 
does not automatically  indicate a SAE unless it meets the definition of serious as defined 
below and/or as per investigator’s discretion. A medication for the lab abnormality  may be 
required by the protocol in whic h case the lab abnormality  would still, by definition, be an 
adverse event and must be reported as such.
8.1.4 Adverse events of special interest
Adverse events of special interest (AESI) are described in Table 10-4 below. The current 
search criteria of AESI  are based on limited experience from ongoing clinical studies without 
an accurate assessment of causality . The search criteria of the AESI may be updated prior to 
database lock for primary  analysis reporting. Based on current clinical experience, AESI 
typicall y occur and resolve within 8 weeks of CTL019 infusion in ALL patients.
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the
outcomes listed above
Requires inpatient hospitalization or prolongation of existing hospitalization,
Note that hospitalizations for the following reasons should not be reported as serious 
adverse events:
Routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed 
consent /assent
Social reasons and respite care in the absence of any deterioration in the patient’s 
general condition
Note that treatment on an emergency outpatient basis that does not result in hospital 
admission and involves an event not fulfilling an y of the definitions of a SAE given above 
is not a serious a dverse event
8.2.2 Reporting
Any SAEs experienced during the screening/pre -treatment phase (from the time of patient 
providing informed consent /assent until the patient begins study -related treatment )should 
 

Novartis Confidential Page 110
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
only be reported Novartis and be captured if the CRF/safety  database if the event meets at 
least one of the following criteria:
All events leading to d eath. 
All p ulmonary  or cardiac abnormalities 
Allinfections
All events r elated to a study  procedure
Any AE reportable for this study  period that also meets criteria for serious
S
ubstantial change in the status of the patient that the investigator deems may  have a potential 
impact during lymphodepletion and CTL 019 infusion or precludes the patient from 
proceeding to study  treatment (e.g. GVHD, rapid progression of malignancy , marked decline 
in clinical status)
Under the circumstance when a patient is simultaneously  enrolled in the active phase (up to 
Day 2) of the Novartis [CTL 019B2206] leukapheresis (apheresis collection) protocol and this 
treatment protocol, collection and reporting of serious adverse events during this overlapping 
period should follow the CTL 019B2206 safety  reporting criteria.
To ensure patient safet y, every  SAE, regardless of suspected causality , occurring after the 
patient has begun study -related treatment (i.e. ly mphodepleting chemotherapy , or pre -CTL019 
infusion visit if no ly mphodepleting chemotherapy  was given) and through the Month 12 visit 
must be reported to Novartis within 24 hours of learning of its occurrence . 
Any SAEs experienced after the Month 12 visit, and through the Month 60 (EOT) visit should 
only be reported 
to Novartis and recorded in the Adverse Events CRF if it meets one of the 
following criteria:
Events leading to death
Events related to a stud y procedure
Infections:
Serious or opportunistic infections. Defined as bacterial, viral, fungal or parasitic 
infections that fulfill one of the following criteria:
Require anti -infective treatment OR
Lead to significant disability  or hospitalization OR
Need for surgical or other intervention
New incidence or exacerbation of a pre -existing neurologic disorder
New incidence or exacerbation of a prior rheumatologic or other autoimmune disorder
New incidence of other hematologic disorder
Any severe adverse event or condition the investigator believes may  have a reasonable 
relationship to CD19 CART therap y
Positive RCL  test result
Vector insertion site sequencing result with a mono
-or oligoclonality  pattern or in a 
location near a known human oncogene
New malignanc y (T-cell & non T -cell), other than the primary  malignancy
Progressive multifocal leucoencephalopath y (PML)
 

Novartis Confidential Page 111
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Hepatitis B reactivation
In addition, at the specific r equest of theFDA, the following SAEs will be reported in an
expedited manner to the FDA :
All occurrences of CRS G rade ≥ 3
All deaths regardless of attribution following ly mphodepleting chemotherapy  and/or 
CTL 019 infusion and within 30 day s of receiving CTL 019 infusion
Death attributed to CTL019 occurring 30 day s post CTL 019 infusion
Any SAEs e xperienced after the Month 60(EOT) visit should only  be reported to the Novartis
if the investigator suspects a causal relationship to the study  treatment. Recurrent episodes, 
complications, or progression of the initial SAE must be reported as follow -up to the original 
episode within 24 hours of the investigator receiving the follow -up information. An SAE 
occurring at a different time interval or otherwise considered completely  unrelated to a 
previously  reported one should be reported separately  as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form ; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relati onship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form, and send the completed, signed form b y fax or email within 24 hours to Novartis .
The telephone and telefax number of the contact persons in the local department of DS&E, 
specific to the site, are listed in the investigator folder provided to each site. The original copy 
of the SAE Report Form and the fax confirmation sheet must be kept with the source
documentation at the study  site.
Follow -up information is sent to the same contact(s) to whom the original SAE Report Form 
was sent, using a new SAE Report Form stating that this is a follow -up to the previously  
reported SAE and giving the date of the original report. Each re-occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs. The follow -up information should describe whether the event has resolved or 
continues, if and how it was treated , and whether the patient continued or withdrew from 
study  participation.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the study  treatment, Novartis may urgentl y 
require further information from the investigator for Health Authorit y reporting. Novartis may 
need to issue an Investigator Notification (IN), to inform all investigators involved in any 
study  with the same drug that this SAE has been reported. Suspected Unexpected Serious 
Adverse Reactions (SUSARs) will be collected and reported to the competent authorities and 
relevant ethics committees in accordance with Directive 2001/20/EC or as per national 
regulatory  requirements in participating countries.
8.3 Emergency  unblinding of treatment assignment
Not applicable .
 

Novartis Confidential Page 112
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
8.4 Pregnancies
No data are currentl y available to determine the duration of contraception after receiving 
CTL 019. CTL019 is within Pregnancy  Category  C. Animal reproduction studies have not 
been conducted with CTL019. It is also not known whether CTL019 can cause fetal harm 
when administered to a pregnant woman or can affect reproduction capacity.
Women regardless of age that may have child- bearing potential (defined as all women 
physiologicall y capable of becoming pregnant) are recommended to continue contraception 
until CAR cells are no longer present in blood as measured by PCR and for a minimum of 12 
months from CTL019 infusion . Women who are not yet of reproductive potential are also to 
agree touse acceptable forms of contraception when they reach reproductive potential. Male 
participants must use highl y effective methods of contraception for a period of 1 year after 
CLT019 infusion. Highl y effective contraception methods include:
a.Total abstinen ce (when this is in line with the preferred and usual lifest yle of the patient ). 
Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation methods) 
and withdrawal are NOT acceptable methods of contraception
b.Female sterilization (have ha d surgical bilateral oophorectom y with or without 
hysterectom y) or tubal ligation at least six weeks before taking stud y treatment. I ncase of 
oophorectom y alone, only when the reproductive status of the woman has been confirmed 
by follow up hormone level assessment
c.Male sterilization (at least 6 months prior to screening). For female patient s on the study  
the vasectomized male partner should be the sole partner for that patient .
d. Use of oral, injected or implanted hormonal methods of contraception or other forms of 
hormonal contraception that have comparable efficacy  (failure rate <1%), for example 
hormone vaginal ring or transdermal hormone contraception
e.Use of intrauterine devices are excluded due to increased risks of infection and bleeding.
f.In case of use of oral contraception, women must be stable on the same pill for a minimum 
of 3 months before taking stud y treatment.
Women who are not of reproductive potential (defined as either <11 years of age, Tanner 
Stage 1, post -menopausal for at lea st 24 consecutive months (i.e. have had no menses) or have 
undergone hysterectom y, bilateral salpingectom y, and/or bilateral oophorectomy )are eligible 
without requiring the use of contraception. Women who are not yet of reproductive potential 
are to agree to use acceptable forms of contraception when they reach reproductive potential if 
within 1 year of CTL019 or if CAR cells are present in the blood by PCR. Acceptable 
documentation includes written or oral documentation communicated by clinician or 
clinic ian’s staff of one of the following:
a.Demographics show age <11
b.Physical examination indicates Tanner Stage 1
c.Physician report/letter
d. Operative report or other source documentation in the patient record
e.Discharge summary
f.Follicle stimulating hormone measurement elevated into the menopausal range
 

Novartis Confidential Page 113
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
To ensure patient safet y, each pregnancy  occurring while the patient is on study  treatment 
must be reported to Novartiswithin 24 hours of learning of its occurrence. The pregnancy  
should be followed up to determine o utcome, including spontaneous or voluntary  termination, 
details of the birth, and the presence or absence of any  birth defects, congenital abnormalities, 
or maternal and/or newborn complications. Pregnanc ieswill be followed for pregnancy 
outcome. In the case of live birth the newborn will be followed up until 6months of age to 
detect any developmental issue or abnormalit y that would not be seen at birth.  Pregnancy 
outcomes must also be collected for the female partners of any males who received CTL 019 
inthis study . Consent to report information regarding these pregnancy  outcomes should be 
obtained from the mother . Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form 
and reported by the investigator to Novartis . Pregnancy  follow -up should be recorded on the 
same form and should include an assessment of the possible relationship to the CTL019 
transduced cells toany pregnancy  outcome. Any SAE experienced during pregnancy  must be 
reported on the SAE Report Form.
8.5 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided [Investigator 
Brochure ]. Additional safet y information collected between Investigator Brochure (IB)
updates will be communicated in the form of Investigator Notifications. This information will 
be included in the patient informed consent /assent and should be discussed with the patient 
during the stud y as neede d.
8.6 Data Monitoring Committee
Prior to the transfer of the study  from UPenn IND to Novartis IND, an independent Data 
Safety  Monitoring Board (DSMB) had reviewed safety  and efficacy  data up until August 
2015. After the transfer of the IND is complete, an independent Novartis Data Monitoring 
Committee with oversee the safet y data for the study.
The DMC will be responsible for reviewing the safety  data of the patients treated in the study . 
The DMC will consist of members who are not involved in patient recruitment or trial 
conduct, with at least two oncologists (at least one pediatric hematologist /oncologist) and one 
biostatistician. Safety  reviews will occur every  sixmonths, unless otherwise reque sted by the 
Chairman of the DMC . Additional meetings will be held at the request of theDMC or
Novartis’ request, or in the event that significant safet y issues arise. Detailed recruitment 
status and interim safet y reports will be provided to the DMC on a regular basis.
Further details regarding the constitution of the DMC and its specific roles will be outlined in 
the DMC charter.
8.7 Steering Committee
The steering committee (SC) will be established comprising investigators participating in the 
trial, Novart is representatives from the Clinical Trial team . . The SC will ensure transparent 
management of the study  according to the protocol through recommending and approving 
modifications as circumstances require. The SC will review protocol amendments as 
 

Novartis Confidential Page 114
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
appropr iate. Together with the clinical trial team, the SC will also develop recommendations 
for publications of study  results including authorship rules. 
The SC will meet regularly , approximately every  3 months.  Documentation of these meetings 
will be maintain ed in the Master Study  File. Actionable outcomes and recommendations will 
be sent to all participating sites for local reporting.
The details of the role of the Steering Committee will be defined in a Steering Committee 
charter.
8.8 Independent Review Committee ( IRC)
AnIRC will be established to review data related to disease response assessment and
determine remission and relapse for the primary analy sisin acute lymphoblastic leukemia 
patients. An IRC charter will detail the IRC data flow and review process in alignment with 
the response definitions inAppendix 1. Patient management will be based upon local 
investigator assessment s. The designation of remission and relapse for the primary  analysis 
and other related secondary  efficacy  endpoints will be based only on the evaluations made by 
the IRC. Details regarding the constitution of the IRC and its specific roles will be 
documented in the IRC charter agreed upon between Novartis and the IRCbefore initiation of 
any IRC reviews.
9 Data collection and management
9.1 Data confidentiality
Information about study  patient s will be kept confidential and managed under the applicable 
laws and regulations. Those regulations require a signed patient authorization informing the 
patient of the following:
What protected health information (PHI) will be collected from patient s in this study
Who will have access to that information and wh y
Who will use or disclose that information
The rights of a research patient to revoke their authorization for use of their PHI
In the event that a patient revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability  to use all information collected prior to the revocation of patient
authorization. For patient s that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g.has the 
patient experienced an y new or worsened AEs ) at the end of their scheduled s tudy period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made available only to authorized personnel who 
have completed prerequisite training.
Prior to entering key sensitive personally  identifiable information (patient initials and exact 
date of birth), the system will prompt site to verify that this data is allowed to be collected. If 
 

Novartis Confidential Page 115
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
the site indicates that country  rules or ethics committee standards do not permit collection of 
these items, the system will not solicit patient initials. Year of birth will be solicited (in the 
place of exact date of birth) to establish that the patient satisfies protocol age requirements 
and to enable appropriate age-related normal ranges to be used in assessing laboratory  test 
results.
9.2 Site monitoring
Before study  initiation at a site initiation visit, Novartis personnel or designee will review the 
protocol and CRFs with the investigators and their staff. During the study, the field monitor 
will visit the site regularly  to check the completeness of patient records, the accuracy  of 
entries on the CRFs, the adherence to the protocol to Good Clinical Practice, the progress of 
enrollment, and to ensure that study  treatment is being stored, dispensed, and accounted for 
according to specifications. Key study personnel must be available to assist the field monitor 
during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on CRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
copy  is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. Monitoring standards require full verification for the 
presence of informed consent /assent , adherence to the inclusion/exclusion criteria and 
documentation of SAEs. Additional checks of the consistency  of the source data with the 
CRFs are performed according to the stud y-specific monitoring plan.
9.3 Data collection
This study  will use a Novartis Electronic Data Capture (EDC) system for data collection.  The 
designated investigator staff will enter the data required by the protocol into the Electronic 
Case Report Forms (eCRF). T he eCRFs have been built using fully validated secure web-
enabled software that conforms to 21 CFR Part 11 requirements, Investigator site staff will 
not be given access to the EDC system until they have been trained. Automatic validation 
programs check for data discrepancies in the eCRFs and, allow modifica tion or verification of 
the entered data b y the investigator staff.
The Principal Investigator is responsible for assuring that the data entered into eCRF sare
complete, accurate, and that entry  and updates are performed in a timely  manner.
9.4 Database management and quality  control
Novartis or designee will review the data entered by  investigational staff for completeness and 
accuracy .Electronic data queries stating the nature of the problem and requesting clarification 
will be created for discrepancies and missing values and sent to the investigational site via the 
EDC system. Designated investigator site staff are required to respond promptly  to queries 
and to make an y necessary changes to the data.
 

Novartis Confidential Page 116
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Concomitant treatments and prior medications entered into the database will be coded using 
the WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical 
classification system. Medical history /current medical conditions and adverse events will be 
coded using the MedDRA terminology .
For EDC studies, after database lock, the investigator will receive a CD -ROM or paper copies 
of the patient data for archiving at the investigati onal site.
10 Statistical methods and data analy sis
Data from all participating centers will be combined .
The primary  analysis will be performed when at least 50 acute lymphoblastic leukemia or 
lymphoblastic lymphoma patients (including 40 patients less than 18 years of age)have 
received CTL 019 infusion and completed 6 months from study  day 1 infusion or discontinued 
earlier . The additional data for any patients continuing past this time will be further 
summarized in the final Clinical Study  Report ( CSR) once allpatients complete the study .
10.1 Analysis sets
The analy sis sets for acute lymphoblastic leukemia patients will be separate from the analysis 
sets for lymphoblastic lymphoma patients. The analy sis sets to be used are defined as below. 
The FAS will be used as the primary  efficacy  analysis set. The Safety  Set will be used for all 
the safet y analysis. The Pharmacokinetic Analy sis Set (PAS)will be used for the 
pharmacokinetics anal ysis.
Tables and listings will be presented by acute lymphoblastic leukemia and lymphoblastic 
lymphoma separatel y, within the single treatment arm of CTL 019. If there are no more than 5 
lymphoblastic lymphoma patients treated, data for these patients will be summarized 
primarily  via listings. 
10.1.1 Screened Set
The Screened Set comprises all patients who have signed informed consent /assent and 
screened in the study .
10.1.2 Enrolled Set
The Enrolled Set comprises all patients who are enrolled in the study .Enrollment is defined as 
the point at which the patient meets all inclusion/exclusion criter ia, and the patients’ apheres is
product is received and accepted b y the manufacturing facility .
10.1.3 Full A nalysis Set
The Full Anal ysis Set (FAS) comprises all patients to whom study  treatment has been 
assigned, and has received infusion of CTL 019.
10.1.4 Safety Set
The Safet y Set comprises all pa tients who received infusion of CTL 019.
 

Novartis Confidential Page 117
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
10.1.5 Per-Protocol Set
The Per-Protocol Set (PPS) consists of a subset of the patients in the FAS who are compliant 
with major requirements of the clinical study  protocol ( CSP) .
Major protocol deviations leading to exclusion from the PPS include:
No d iagnosis of ALL atbaseline;
Prior therap y does not match with CSP requirements in terms of number and ty pes of 
previous therap y regimens;
Missing or incomplete documentation of disease;
In addition, patients who receive a dose less than the minimum target dose (2 × 106CTL019 
transduced cells/ kg bod y weight) will also be excluded.
The detailed exclusion criteria of PPS will be determined prior to primary  analy sis.
10.1.6 Pharmacokinetic analy sisset
The pharmacokinetic analy sis set (PAS) consists of FAS who have at least one sample 
providing evaluable pharmacokinetic (PK) data. The PAS will be used for summaries (tables 
and figures) . FAS will be used for listings of PK data.
Note that patients will be removed from the estimation of certain PK parameters on an 
individual basis depending on the number of available samples. These patients will be 
identified at the time of the anal yses.
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline data will be listed by patient and/or summarized 
descriptivel y for the FAS. Categorical data will be presented as frequencies and percentages. 
For continuous data, summary  statistics will be presented (i.e., mean, median, standard 
deviati on, minimum, maximum).
Number and percentage of patients failing prior anti-neoplastic medications/therapies will be 
summarized.
Patients will be classified by the allogeneic SCT andresidual donor engraftment status into 
one of the following categories:
Relapsed after prior allogeneic SCT with an y degree of residual donor engraftment
Relapsed after prior allogeneic SCT with no residual donor engraftment
No prior allogeneic SCT
Patients will also be classified by  their prior response status into:
Primary  refractory : If patient never had a morphologic complete remission (CR) prior to 
the study
Relapse without SCT: I f patient has not had SCT, had a CR from other therapy  and 
relapsed prior to the study
Relapse 
after SCT: If patient has had and relapsed after SCT prior to the study
 

Novartis Confidential Page 118
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
10.3 Treatments (study  treatment, concomitant therapies, 
compliance)
The total cells infused (cells /kg) and total CTL 019 transduced cells infused (cells /kg) will be
listed and summarized using descriptive statistics. Patients will be categorized as below, 
within or above the prescribed dose range.
Prior and concomitant medications and significant non-drug therapies prior to and after the 
start of infusion will belisted by patient and summarized by the Anatomical Ther apeutic 
Chemical (ATC )term.Transfusion during the study  will be listed. In addition, whether 
patients have received anti-cytokine medications for the management of CRS will be 
summarized.
10.4 Primary  objective
The primary  objective of the study  is to evaluat e the efficacy  of CTL 019 therap y in acute 
lymphoblastic leukemia patients and separately  in lymphoblastic leukemia patients as 
measured by overall remission rate (ORR) during the6 months after CTL019 administration, 
which includes CR and CR with incomplet e blood count recovery (CRi) in the FAS 
population .The primary  analysis will be based on the I RC assessment for acute ly mphoblastic 
leukemia patients, and based on local investigator’s assessment for lymphoblastic lymphoma 
patients. In addition, sensitivity  analysis will be performed using the local investigator 
response assessment sinstead of the IRCassessment for acute lymphoblastic leukemia 
patients.
10.4.1 Variable
The primary  endpoint is the ORR during the 6 months after CTL 019 administration, as 
determined by IRC assessment for acute lymphoblastic leukemia patients and as determined 
by local investigator’s assessment for l ymphoblastic ly mphoma patients.
The ORR is defined as the proportion of patients with a best overall disease response of CR or 
CRi, wher e the best overall disease response is defined as the best disease response recorded 
from CTL 019 infusion until the start of new anticancer therapy . Best response will be assigned 
according to the following order:
CR
CRi
CR or CRi with residual mediastinal disease (for ly mphoblastic l ymphoma patients only )
No response (NR)
Unknown
The disease response criteria for ALL patients are outline below in Table 10-1. See also
Appendix 1 for details. (Please note: For lymphoblastic lymphoma patients, all criteria below 
plus those listed in Table 10-2, Appendix 2, Table 14- 5 must be met.)
 

Novartis Confidential Page 119
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Table 10-1 Definition of CR, CRi and relapse at a given evaluation time in Acute 
Lymphoblastic Leuke miapatients (excluding Ly mphoblastic 
Lymphoma patients )
Response category Definition
Completeremi ssion (CR) All the following criteria are met:
Bone marrow
● Trilineage Hematopoiesis (TLH) and < 5% blasts
Peripheral blood
●Neutrophils > 1.0 x 109/L, and
●Platelets > 100 x 109/L, and
●Circulating blasts < 1%
Extramedullary  disease
●No clinical evidence of extramedullary disease (by physical exam and CNS 
symptom assessment ), and 
●If additional assessments (e.g. CSF assessment by LP, CNS imaging, biopsy, 
etc.) are performed, results must show remission status
Trans fusionindepen dency
●No platelet and/or neutrophil transfusions ≤ 7 days before peripheral blood 
sample for disease assessment
Complete remission with 
incomplete blood count 
recovery  (CRi)All criteria for CR as defined above are met, except that the following exist:
●Neutrophils ≤ 1.0 x 109/L, or
●Platelets ≤ 100 x 109/L, or
●Platelet and/or neutrophil transfusions ≤ 7 days before peripheral blood sample 
for disease assessment
Relapsed Disease Only in patients who obtained a CR or CRi:
●Reappearance of blasts in the blood ( ≥ 1%), or
● Reappearance of blasts in bone marrow ( ≥ 5%), or
●(Re-)appearance of any extramedullary disease after CR or Cri
A full response evaluation, including assessments of peripheral blood, bone marrow, CNS 
symptoms, physical exam, and CSF assessment by LP, is required at the first time a CR or 
CRi is demonstrated. Bone marrow biops y/aspirate and CSF assessment by LP arerequired 1 
month (Day  28) after infusion . If the patient is not in CR/CRi at Month 1 , then a bone marrow 
biopsy /aspirate and CSF assessment by LP arealso required at the first time clinical 
evidence 
of remission is seen by peripheral blood and extramedulla ry disease assessment (physical 
exam and CNS symptom assessment )to establish that a patient has achieved CR/CRi for the 
first time. Additional bone marrow biopsies/aspirates and CSF assessments by LP are not 
required after initial establishment of CR or CRi unless clinically  indicated (recommended but 
not required at months 3 and 6).
Complete remissions in patients with ALL have been observed to take place within 1 month 
after infusion with CTL019. The onset of complete remissions israpid and dramatic, and 
patients quickly  regain a normal performance status. ALL relapse in the bone marrow is 
rapidly  followed by signs or symptoms of disease recurrence as well as abnormalities in the 
peripheral blood.
Therefore, following initial achievement of CR/CRi, patie nts will be considered to have 
maintained aclinical CR/CRi if the patient has no evidence of extramedullary  disease (by 
physical exam and CNS symptom assessment) and circulating blasts in peripheral blood are 
<1%. In order for the best ORR to be categorized asCR or CRi,there must be no clinical 
evidence of relapse as assessed by peripheral blood and extramedullary  disease assessment 
(physical exam and CNS symptom assessment )at a minimum of 4 weeks (28 days)after the 
 

Novartis Confidential Page 120
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
initial achievement of CR or CRi.Please note, if additional assessments (e.g. bone marrow, 
CSF assessment by LP, CNS imaging , biopsy ,etc.) are performed in the same evaluation for 
disease response evaluation purpose ,they will also need to show remission status.
The additional disease response criteria for lymphoblastic lymphoma patients are outline 
below in Table 10-3. See alsoAppendix 2 for more details.
Table 10-2 Additional definition of remission and relapse at a given evaluation 
time for Lymphoblastic Lymphoma patients
Response category Definition
Completeremission (CR) All the criteria for ALL are met, and in addition CR for mediastinal 
disease.
Complete remission with incomplete blood 
count recovery (CRi)All the criteria for ALL are met, and in addition CR for mediastinal 
disease. 
CR or CRi with residual mediastinal 
diseaseAll criteria for CR or CRi as defined above are met, except that 
mediastinal disease as defined by CRu or PR is observed.
Relapsed Disease Same criteria for ALL, and in addition mediastinal relapse will also 
indicate relapse for LBL.
10.4.2 Statistical hy pothesis, model, and method of analy sis
The primary  efficacy  analysis will be based on statistical testing in acute lymphoblastic 
leukemia patients and descriptive analy sis in ly mphoblastic ly mphoma patients. In addition, it 
will be summarized descriptively  in all patients combined.
In acute lymphoblastic leukemia patients, theprimary  efficacy  analysis will be performed by 
testing the null hypothesis of ORR being less than or equal to 20% against the alternative 
hypothesis of ORR being great er than 20% at overall one-sided 2.5% level of significance, 
i.e.,
H0: p ≤ 0.2 vs. H a: p > 0.2.
The primary  efficacy  endpoint, ORR will be analy zed at the interim look and final look of a 
group sequential design based on the data observed in the FAS. The ORR will be summarized 
along with the 2
-sided 95% exact Clopper -Pearson confidence intervals with coverage level 
determined by the O’Brien -Fleming type α-spending approach according to Lan-DeMets as 
implemented in East 5.4 (Lan and DeMets, 1983). The study  will be considered successful if 
the lower bound of the 2 -sided 95% exact confidence interval for ORR is greater than 20%, so 
that the null hy pothesis that the ORR is less than or equal to 20% can be rejected.
In lymphoblastic lymphoma patients and in all patients combined, the ORR will be 
summarized descriptively together with 95% CIs if appropriate.
Tables and listings will be presented by acute lymphoblastic leukemia and lymphoblastic 
lymphoma separatel y, as well as one treatment arm of CTL 019.
In addit ion, the percentage of patients who achieve CR or CRi at Day 28 +/- 4 days will also 
be summarized. Response will also be summarized by baseline tumor burden (MRD, 
extramedullary  disease, etc.).
 

Novartis Confidential Page 121
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
10.4.3 Handling of missing values/censoring/discontinuations
Patient s in the study  who are of unknown clinical response will be treated as non-responders. 
See also the Novartis guideline for efficacy  evaluation in ALL (Appendix 1 ) for more details.
Other missing data are simply  noted as missing on appropriate tables/listings.
10.4.4 Supportive analy ses
The primary  analysis will also be performed on the Enrolled Set and PPS using the same 
methodology .In addition, analysis will also be performed using all patients who satisfy  all 
clinical eligibility  criteria.
10.4.4.1 Subgroup analy sis
Subgroup analyses will be performed on the following based on the patient’s baseline status:
Age: <10 years, ≥ 10 years to <15 y ears, ≥15 y earsto <18 y ears, ≥ 18 years
Gender: Male, Female
Race: Asian, Bl ack, Caucasian, Native American, Other, Pacific Islander, Unknown
Ethnicity : Hispanic or Latino, Chinese, I ndian, Japanese, Mixed ethnicity , Other
Prior response status: Primary  refractory , relapse without SCT, relapse from SCT
Eligibility  for SCT: Eligibl e for SCT, ineligible for SCT
Baseline bone marrow tumor burden: Low (defined as either morphologic or MRD result 
is <50% and neither 
≥50%), High (defined as either morphologic or MRD result is ≥50%) 
Baseline extramedullary  disease presence: Yes, No 
Philadelphia chromosome/BCR -ABL : Positive, Negative
Mixed -Lineage Leukemia ( MLL ) rearrangement: Yes, No
Hypoploidy : Yes, No
BCR -ABL1 -like: Yes, No
Complex Kary otypes ( ≥5 unrelated abnormalities): Yes, No
The rationale for performing subgroup anal yses are a s follows:
Age, gender, race and ethnicity  are demographic factors that are t ypicall y requested b y 
health authorities to assess internal consistency  of the study  results.
Prior response status is a key  prognosis factor due to potentially  higher rates of tr eatment 
related morbidit y in patients who have relapsed following allogeneic SCT .
Baseline bone marrow tumor burden and extramedullary  disease presence can be  
important indicators of overall disease burden, which is a potential predictive factor
BCR -ABL, MLL rearrangement , hypoploidy  and BCR -ABL1 -like gene signatures and 
complex kary otype (
≥5 unrelated abnormalities) are high risk factors for ALL. Patients 
with these high risk factors have poorer diagnosis ( Harrison et al 2010 ; van der Veer et al 
2013; NCCN v1 2013 ).In case there are very few patients with these high risk mutations 
individually , anal ysis may  be performed for patients with any  of these high risk mutations 
versus those who do not.
 

Novartis Confidential Page 122
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Subgroup analyses will only be performed if at least 5 patients are present in each subgroup. 
Some grouping of classes will be considered if there are too few patients in some subgroups. 
10.5 Secon dary  objectives
IRC assessment will be used in the main analy sis of secondary  endpoints that involve disease 
response.
10.5.1 Key secondary  objective(s)
Not applicable because no formal hypothesis testing is planned other than for the primary 
objective.
10.5.2 Other sec ondary  efficacy  objectives
The secondary  efficacy  objectives are outlined as follows in the order of importance.
Additional analy ses will be performed to further assess the efficacy  of CTL 019 treatment by 
combining data collected in this protocol together with the 15 year long term follow -up 
protocol, if appropriate.
10.5.2.1 Percentage of patients who achieve CR or CRi at Month 6 without SCT 
between CTL019 infusion and Month 6 response assessment
The percentage of patients who achieve CR or CRi at Month 6 without SCT(post CTL 019 
infusion) between CTL019 infusion and Month 6 response assessment , among all patients in 
the FAS, will be summarized along with exact 95% Confidence Interval (CI).In addition, the 
percentage among patients who achieved CR or CRi will also be summarized. The time of 
proceeding to SCT is defined as the time of commencing the conditioning regimen as required 
for hematopoietic SCT. This definition applies to all anal yses.
10.5.2.2 Percentage of patients who achieve CR or CRi and then proceed to
SCT w hile inremission before Month 6 response assessment
The percentage of patients who achieve CR or CRi and then proceed to SCT while in
remission by the time of Month 6, among all patients in the FAS, will be summarized along 
with exact 95% CI.In addition, the percentage will also be summarized among all patients 
who achieved CR or CRi .
All patients that proceed to SCT post CTL 019 infusion will be listed.
10.5.2.3 Duration of remission (DOR)
Duration of remission (DOR) is defined as the duration from the date when the response 
criteria of CR or CRi is first met to the date of relapse or death due to underly ing cancer.
I
n casea patient does not haverelapseor death due tothe underl ying disease prior to data 
cutoff ,DOR will be ce
nsored at the dat e of the la stadeq uate assessment on or prior to the 
earliest censoring event . The censoring reason could be:
Ongoing without event
Lost to follow -
up
 

Novartis Confidential Page 123
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Withdrew consent
New anticancer therap y (also see below for handling SCT)
Event after at least two missing scheduled disease assessment s
In addition, death due to reason other than the underl ying disease will be considered as a 
competing risk event to other events of interest (relapse or death due to the underl ying 
disease ).
As SCT is an important treatment option in responding patients, it is appro priate to consider 
the date of SCT as censoring date, instead of censoring at the last tumor assessment date.
However, censoring due to SCT will overestimate the rate of relapse and therefore may be 
considered inappropriate for the main analy sis when a substantial number of patients choose 
to receive SCT ( CHMP 2010). If a patient received SCT after a CR or CRi, relapse or survival 
status after SCT will be recorded on the corresponding follow -up e CRFs, although data on 
individual disease response components (e.g. bone marrow) will not be collected. In such 
cases, the date of relapse or death (if due to the underly ing cancer) after SCT will be used for 
the calculation of DOR as a sensitivity  anal ysis.
Additional sensitivity  analysis will be performed by censoring death due to reason other than 
the underly ing disease instead of considering it as the competing risk event to other events of 
interest (relapse or death due to the underl ying disease ).
The proposed analyses for DOR are summarized in Table 10-3 below. Method 1 will be 
considered as the main analy sis for DOR. Additional anal yses may  be considered.
Table 10
-3 Analyses of duration of response (DOR)
Death due to reason other than the underly ing disease SCT after remission
Method 1 Censor at last adequate tumor assessment Censor at time of SCT
Method 2 Censor at last adequate tumor assessment Censor at time of SCT
Method 3 Competing risk analysis Ignore SCT
Method 4 Competing risk analysis Ignore SCT
DOR will be assessed only in patients with the best overall response of CR or CRi. The 
estimated percentage of relapsed patients (at 6 months, 12 months, etc.) will be presented with 
95% confidence intervals using the cumulative incidence function (CIF) or the Kaplan -Meier 
(KM) method.
For Method 1 and Method 2, the distribution function of DOR will b e estimated using the KM 
method. The median DOR along with 95% confidence intervals will be presented if 
appropriate.
For Method 3 and Method 4, the CIF is used to estimate the probability  of the event of interest 
in the presence of the competing risk s
(Kim 2007 ).
If a considerable number of patients receive SCT while in remission after CTL 019 infusion, 
then exploratory  analyses may be performed on patients who achieve CR/CRi after CTL 019 
infusion to assess the effect of SCT on DOR. Baseline disease characteristics and post-
baseline factors (e.g. time to CR/CRi, minimal residual disease) that may be correlated with 
the decision to receive SCT and with DOR will be identified. A Cox model with SCT as a 
time depende nt covariate and potential confounding factors as additional covariates may then 
 

Novartis Confidential Page 124
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
be explored in patients who achieve CR/CRi after CTL019 infusion. The hazard ratio (SCT 
v/s No SCT after CR/CRi) estimate along with its 95% confidence interval will be provid ed. 
Additional exploratory  analy ses may  be considered to account for the confounding factors.
10.5.2.4 CR or CRi w ith MRD negative bone marrow
The percentage of patients who achieved BOR of CR or CRi with MRD negative bone 
marrow (performed by central laboratory  with sensitivity  of detection of 0.01%) during the 6 
months after CTL 019 administration among all patients in the FAS population will be 
summarized along with the 2-sided 95% exact Clopper -Pearson confidence intervals . 
Additional analy sis will be done to summarize this percentage among all patients with BOR 
of CR or CRi. See Appendix 1 for details of determination of MRD negativity .
The percentage above will be also summarized among all patients who achiev ed BOR of CR 
or CRi.
In addition, qualit y of response using MRD disease assessme nts before treatment, at day 28 
+/-4 day s after treatment will be described.
10.5.2.5 Relapse free survival (RFS)
R
elapse freesurvival(RFS) is m easured by the time from achievement of CRorCRi
whatever occurs firsttorelapse or death duetoanycause during CR or CRi.
Incase a pa tient does not have rel aps e or death dueto an y cause prior to data cutoff , RFS will
be ce nsored at th e dateofthel a stadequa teass essment on or prior to the earliest censoring 
event. The censoring reason could be
Ongoing without event
Lost to follow -up
Withdrew consent
New anticancer therap y (also see below for handling SCT)
Event after at least two missing scheduled disease assessment
In the main analy sis of RFS, patients who proceed to SCT after CTL019 infusion will be 
censored at the time of SCT. In addition, a sensitivity  analysis of RFS will be performed without 
censoring SCT.
RFS will be assessed only in patients with the best overall response of CR or CRi. The 
distribution function of RFS will be estimated using the KM method. The median RFS along 
with 95% confidence intervals will be presented if appropriate.
10.5.2.6 Event free survival (EFS)
Even t freesurvival(EFS) is the timefrom date of first CTL019 infusion tothe earliest of 
the following:
Deathfrom anycause
Relapse
Treatment failure: Defined as no response in the study  and discontinuation from the study  
due to an y of the following reasons:
 

Novartis Confidential Page 125
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Adverse event (including abnormal laboratory  value s or abnormal test procedure 
results)
Lack of efficacy  or progressive disease
New anticancer therapy
In case of treatment failure, the event date wi ll be set to study  Day 1 (CHMP 2010 ).
Incas
e apatient does not have rel apse, d eath due to an y cause or treatment failure (e.g. 
discontinuation as a result ofwithdrawal of consent, lost to follow -up, protocol violation or
administrative problems )prior to data cutoff, EFS iscenso redatthelastadequa te response 
assessment date on or prior to the earliest censoring event (except for SCT) .The censoring 
reason could be
Ongoing without event
Lost to follow -up
Withdrew consent
New anticancer therap y (also see below for handling SCT)
Event after at least two missing scheduled disease assessment
In the main analy sis of EFS, patients who proceed to SCT after CTL019 infusion will be 
censored at the time of SCT. In addition, a sensitivity  analysis of EFS will be performed without 
censoring SCT.
EFS will be assessed in all patients (FAS) . The distribution function of EFS will be estimated 
using the KM method. The median EFS along with 95% confidence intervals will be 
presented if appropriate.
10.5.2.7 Overall survival (OS)
Overallsurviva l ( OS) is thetimefrom date o f first CTL 019 infusion tothe dateof death due
toany r eason.
In ca seapatient is alive at the date of last contact on or before data cutoff, OSiscensored at
thedateof la stcontact. No censori ngwill bedone incase ofSCT. Thus, patients should be 
follow ed-up for sur viv al alsoincase of SCT.
OS will be assessed in all patients (FAS) . The distribution function of OS will be estimated 
using the Kaplan Meier (KM)method. The median OS along with 95% confidence intervals 
will be presented if appropriate.
10.5.2.8 Response at Day  28 +/- 4 day s
Proportion of patients attaining CR or CRi at Day  28 +/ -4 day s post CTL 019 infusion, among 
all patients in the FAS, will be summariz ed along with exact 95 % Confidence Interval (CI).
10.5.2.9 Impact of baseline tumor burden on response
Best overall response will be summarized by baseline tumor burden (MRD, extramedullary 
disease, etc).
 

Novartis Confidential Page 126
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
10.5.3 Safety  objectives
10.5.3.1 Analysis set and grouping for the analy ses
For all safet y analyses, the safet y set will be used. All listings and tables will be presented by 
one treatment arm of CTL019.
The overall observation period will be divided into two mutually  exclusive segments:
Pre-infusion period: from day  of patient’ s informed consent /assent to the day  before
infusion of CTL 019
Post-infusion period: starting at day  ofCTL019 infusion
10.5.3.2 Adverse events (A Es)
Reporting of adverse events will be based on MedDRA and CTCAE version 4.03.
Summary  tables for adverse events have to include only AEs that started or worsened during 
the post-infusion period , i.e. the CTL019 treatment -emergent AEs. However, all safet y data 
(including those from the pre-infusion period) will be listed and those collected during the 
pre-infusion period are to be flagged.
The incidence of CTL019 -treatment -emergent adverse events (new or worsening from 
baseline) will be summarized by system organ class, preferred term, severit y (based on 
CTCAE grades), and relation to study  treatment. A patient with multiple CTC grades for an 
AE will be summarized under the maximum CTC grade recorded for the event. The frequency 
of Common Toxicity  Criteria ( CTC ) Grade 3 and 4 AEs will be summarized separately .
Deaths reportable as SAEs and non-fatal serious adverse events will be listed by patient and 
tabulated b y type of adverse event.
Adverse events of special interest (AESI) are 
described in Table 10-4 below. The current 
search criteria of AESI  are based on limited experience from ongoing clinical studies witho ut 
an accurate assessment of causality . The search criteria of the AESI may be updated prior to 
reporting. 
AESI that occur within 8 weeks of the CTL 019 infusion will be summarized by 
group term and preferred term.
Table 10-4 Adverse events of special interest (A ESI) search criteria 
AESI group term MedDRA term Type
Syndromes Cytokine Release Syndrome PT
Histiocytosis haematophagic PT
Tumor Lysis Syndrome PT
Cytokine Release Syndrome Symptoms Pyrexia PT
Myalgia PT
Hypotension PT
Dyspnea PT
Tachypnea PT
Capillary Leak Syndrome PT
Hypoxia PT
Organ Failure PT
Acute Respiratory Distress Syndrome PT
 

Novartis Confidential Page 127
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
AESI group term MedDRA term Type
Tumor Lysis Syndrome Symptoms Hyperkalemia PT
Hyperphosphatemia PT
Hyperuricemia PT
Hypocalcemia PT
Histiocytosis Haematophagic Symptoms Splenomegaly PT
Marrow depression and hypoplastic anemias HLT
Hemolysis PT
Disseminated intravascular coagulation PT
Blood triglycerides increased PT
Organ Dysfunction Hepatic enzymes and function abnormalities HLT
Renal Failure and Impairment HLT
Confusion and disorientation HLT
Allergic Reaction Infusion related reaction PT
10.5.3.3 Laboratory  abnormalities
For laboratory  tests covered by the CTCAE, the study ’s biostatistics and reporting team will 
grade laboratory  data accordingl y. For laboratory  tests covered by CTCAE, aGrade 0 will be 
assigned for all non- missing values not graded as 1 or higher. Grade 5 will not be used.
For laboratory  tests where grades are not defined by CTCAE, results will be graded by the 
low/normal/high classifications based on laboratory  normal r anges .
The following summaries will be generated separatel y for hematology, biochemistry  and 
urinary laboratory  tests:
shift tables using CTCAE grades to compare baseline to the worst post-infusion value
for laboratory  tests where CTCAE grades are not defined, shift tables using the 
low/normal/high/(low and high)
In addition to the above mentioned tables and listings, other exploratory  analy ses, for example 
figures plotting time-course of raw or change in laboratory  tests over time or box plots might 
be spe cified in the Master Anal ysis Plan (MAP) and/or the Report and Analy sis Plan (RAP).
10.5.3.4 Immunogenicity
Humoral immunogenicity  assessment will include prevalence of immunogenicity  (subjects 
with pre-existing antibodies that bind to CTL 019), incidence of immunog enicity  (subjects 
with treatment -induced or treatment -boosted antibodies that bind to CTL019), together with 
antibody tite rs. Data will be further fractionated to determine proportion of subjects who make 
transient versus sustained antibody  responses. The assay  for humoral immunogenicity  will be 
a cell-based assay , detecting antibodies that bind to a Jurkat cell line transfected with the 
CTL 019 construct. This cell line stably  expresses the complete CTL 019 sequence and can be 
used to detect antibodies that bind to any epitope on the extracellular domain of the protein.   
Cellular immunogenicity  assessment will include percentage of CD4+ and CD8+ T cells 
specific for CTL 019. 
 

Novartis Confidential Page 128
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
10.5.3.5 Derivation of a score to predict cy tokine release sy ndrome 
Clinical  data will be analyzed to potentially  identify  an early  predictive score 
which reflects the risk of developing severe cytokine release syndrome. Only  parameters that 
can be potentially  utilized in clinical setting by treating physicians will be considered for the 
score development.
10.5.3.6 Soluble Immune factors
Soluble immune and  
 will be listed and summarized by patient and time point. Baseline 
and absolute and relative change (percent and or fold change) from baseline will be calculated 
for each treatment group and time point and summarized using sample size, mean, standard 
deviation, median, minimum and maximum. If both the baseline and post baseline values are 
below LLOQ, absolute, percent and fold change from baseline will not be imputed and 
reported as missing. Baseline levels may also be summarized by clinical response status and 
severit y of CRS and potentially  graphed using strip plots. In addition, the maximum chan ge 
from baseline measure for each cytokine may also be graphed against clinical response status 
and severity  of CRS response using strip plots. Patient level and averaged cytokine measures 
and percent change from baseline may  be display ed using longitudina l plots.
 
10.5.3.7 B-cell and T -cell level s
The levels of B and T cells (peripheral blood and bone marrow) prior to and following 
CTL 019 infusion will be described. Malignant and normal B cell populations will be listed 
and summarized by  patient and time point. 
It is anticipated that all patients who achieve complete remission will exhibit B-cell aplasia. 
Timing of B-cell recovery  (i.e. when normal B-cell becomes detectable again after patients 
achieving complete response) will be summarized.
CD8 and CD4 positive T cells will be listed and summarized by time point. Data may also be 
summarized by response status and potentially  graphed using strip plots. Patient level and 
average longitudinal plots of the cell counts and percent changes from baseline may be 
generated.
 
For abnormal T cell or B cell results, associated safet y events such as infections and use of 
associated therapies (i.e. antibiotics, immunoglobulin replacement) will be investigated using 
patient listings.
10.5.3.8 Other safety  data
Vital signs will be collected as clinicall y needed. Findings supportive of GVHD will be listed 
for patients who have received prior allogeneic SCT. All safet y data will be listed.
 

Novartis Confidential Page 129
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
10.5.3.9 Safety  subgroup analysis
Key safety summaries for adverse events regardless of relationship to study drug bySystem, 
Organ, Class (SOC )and PT, and adverse events of special interest will be repeated on the 
Safety  Set in the following subgroups:
Age: <10 years, ≥ 10 years to <15 y ears, ≥15 y earsto <18 y ears,  ≥ 18 years
Gender: Male, Female
Race: Asian, Black, Caucasian, Native American, O ther, Pacific Islander, Unknown
Ethnicity : Hispanic or Latino, Chinese, I ndian, Japanese, Mixed ethnicity , Other
Prior response status: Primary  refractory , relapse without SCT, relapse from SCT
Prior SCT therapy  and residual donor engraftment status: Prior SCT with any  degree of 
residual donor engraftment
, SCT without residual donor engraftment, or no prior SCT.
The objective of carry ing out these subgroup analy ses is to identify  safety  problems that are 
limited to a subgroup of patients or that are more commonly  observed in a subgroup of 
patients.
Summary  tables will only be performed if at least 5 patients are present in each subgroup. 
Some grouping of classes will be considered.
10.5.4 Pharmacokinetics
CTL 019 concentrations in peripheral blood (and bone marrow and CSF if available) will be 
listed, graphed, and summarized by time point as assessed by the following (see Section 
10.6.1):
CTL 019 transgene levels as measured by  q-PCR 
  
The PK parameters listed in Table 10-5along with other relevant PK parameters will be 
estimated from the individual concentration versus time profiles using a non-compartmental 
approach within the modeling program Phoenix®(Pharsight, Mountain View, CA). All 
concentrations below the limit of quantitation or missing data will be labeled as such in the 
concentration data listings. Concentrations below the limit of quantitation will be treated as 
zero in summary  statistics. For the calculation of the PK parameters, a zero value will be 
imputed for the values below the limit of quantification after the administration and during the 
expansion phase. The values below the limit of quantification during the elimination phase 
will no t be imputed and will be considered as missing.
Table 10
-5 Noncompartmental pharmacokinetic parameters
AUC 0 - Tmax The AUC from time zero to T maxin peripheral blood ( % or c opies/µg x days x volume-1)
AUC Tmax -28d or 
M3 The AUC from time Tmax to day 28 and M3 or other disease assessment days, in 
peripheral blood ( (% or copies/µg x days x volume -1)
AUC 0 -28d or M3 The AUC from time zero to day 28 andM3 or other diseas e assessment days, in peripheral 
blood (% or copies/µg x volume -1)
Cmax The maximum (peak) observed in peripheral blood or other body fluid drug concentration 
after single dose administration (% or copies/µg x volume-1)
 

Novartis Confidential Page 130
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Tmax The time to reach maximum (peak) peripheral blood or other body fluid drug concentration 
after single dose administration ( days )
T1/2 The half -life associated with the elimination phase slope  of a semi logarithmic 
concentration -time curve ( days ) in peripheral blood
Ci Initial co ncentration in peripheral blood following infusion (µg x volume-1) (only applicable 
for qPCR)
(Cmax / Ci) In vivo CTL019 T -cell expansion in peripheral blood (using ratio of Cmax to Ci (only 
applicable for qPCR)
TLOG Duration of time patient concentration levels are at or above the limit of quantitation (LOQ) 
for a given assay (days)
MRTlast Mean residence time from the time of dosing to the time of the last measurable 
concentration in peripheral blood (days) . 
Descriptive statistics of PK parameters will be summarized by mean, standard deviation, 
coefficient of variation, min and max. When a geometric mean will be presented, it will be 
stated as such. A range of values will be presented for selected variables. Since Tmaxis 
generall y evaluat ed by a nonparametric method, median values and ranges will be given for 
this parameter.
The relationship between anti-cytokine treatment, use of steroids, occurrence of 
immunogenicit y or other relevant covariates and PK might be expored. Population or 
mechanistic PK/PD may also be generated for ALL patients. For patients whose tocilizumab 
PK data were collected during CRS, the tocilizumab concentrations will be summarized by 
time points, relative to time of tocilizumab dose.
 

Novartis Confidential Page 131
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
10.7 Interim anal ysis
The trial will be transferred under Novartis IND from UPenn IND. After the IND transfer, all 
CTL 019 products will be man ufactured according to the Novartis CMC process. The trial was 
initially  conducted under the UPenn IND  with CTL 019 product manufactured according to 
the UPenn CMC process. From protocol amendment 2 going forward, the trial is transferred 
under Novartis IND. After the IND transfer, all CTL019 products will be manufactured 
according to the Novartis CMC process. 
 

Novartis Confidential Page 132
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
An interim analysis is planned when all patients who were treated with UPenn manufactured 
CTL 019 product and have completed 6 months from study  day1 infusion or discontinue d
earlier. Only acute lymphoblastic leukemia patients will be treated with UPenn manufactured 
CTL 019 products. The interim analy sis will be performed in the acute lymphoblastic 
leukemia patients by testing the null hypothesis of ORR being less than or equal to 20% 
against the alternative hypothesis of ORR being greater than 20% at overall one-sided 2.5% 
level of significance. 
Approximately  30 patients will be included in the interim analysisand approximately  45 
patients will be included in the final analysis in acute lymphoblastic leukemia patients. The 
study  will not be stopped for outstanding efficacy  at the interim analysis regardless of the 
interim result.
An α -spending function according to Lan -DeMets (O’Brien -Fleming), as i mplemented in East 
5.4, will be used to construct the efficacy  stopping boundaries (Lan and DeMets 1983). 
Based on the choice of α-spending functions described above, if the interim analy sis is 
performed exactly  with 30 patients, the lower bound of the 2-sided 98.79% exact CI of the 
ORR will need to be greater than 20% to declare statistical significance. As a result, an ORR 
of 13/30 = 43% is needed to claim success at interim. At the final analysis, 2-sided 95.37% 
exact CI will be used correspond
ingly. Asa result, an ORR of 16/45 = 35% will be needed to 
claim success at final analy sis.
In case the actual number of patients at the interim analy sis cut -off date is not exactly  equal to 
30 patients, the efficacy  boundaries will need to be re-calculated based on the actual number 
of patients using the pre-specified α-spending functions. The efficacy  boundary  at the final 
analysis will be based on the actual number of patients and the alpha alread y spent at the 
interim analy sis. If the number of patients in the final analysis deviates from the expected n, 
the final analysis criteria will be determined so that the overall significance level across all 
analyses is maintained at one -sided 0.025.
Statistical properties of the group sequential design are summarized in Table 10 -6below.
Table 10-6 Simulated probabilities to claim success at the interim or final 
analy sis
Scenario Look# of 
patientsSimulated cumulative 
probabilities (% ) to claim 
successSimulated incremental 
probabilities (% ) to claim 
success
p=0.4 Interim 30 42%
Final 45 78% 36%
p=0.45 (H 1) Interim 30 64%
Final 45 93% 29%
p=0.5 Interim 30 83%
Final 45 99% 16%
Note: Simulation is performed in R 3.0.0 with number of simulations = 10,000.
In addition, t he DMC will review safet y data periodically.
 

Novartis Confidential Page 133
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
10.8 Sample size calculation
The final primary  analysis will be performed when at least 50 acute lymphoblastic leukemia 
or lymphoblastic ly mphoma patients (with at least 40 patients <18 years of age) have received 
CTL 019 infusion and completed 6 months from study  day 1 infusion or discontinued earlier. 
The sample size calculation is primarily  based on the hypothesis testing for acute 
lymphoblastic leukemia patients.
The number of acute lymphoblastic leukemia and lymphoblastic lymphoma patients to be 
treated respectivel y will be based on the actual recruitment of the two populations. It is 
anticipated that the lymphoblastic lymphoma population is small and will represent less than 
10% of the entire population. Therefore with 50 patients treated in the study, it is assumed that 
45 acute l ymphoblastic leukemia patients will be treated.
In a previous study  of clofarabine in patients with r/r B-cell ALL who have had 2 or more 
prior regimens, the reported ORR was 20% (95% CI  [10%, 34%] (Jeha et al. 2006 ). Hence, an 
ORR of 45% that excludes a 20% ORR at the 0.025 significance level would indicate 
meaningful efficacy  in this highly  refractory  population.
Based on the null hypothesis of ORR ≤ 20% and alternative hypothesis of ORR > 20%, 45
acute lymphoblastic leukemia patients in the FAS will provide 93% power to demonstrate 
statistical significance using a 2-look Lan-Demets group sequential design with O’Brien -
Fleming type boundary  at one
-sided 0.025 level of significance , if the underly ing ORR is 
45%. The actual number of patients to be enrolled will depend on the pre-infusion dropout 
rate. Limited data are available sofar to provide robust estimate on the pre-infusion dropout 
rate. Assuming 20% to 25% enrolled patients will not be infused due to reasons such as 
product manufacturing issues , worsening of patient’s condition, etc., at least 63to 67patients 
need to be enrolled respectivel y to ensure at least 50infused patients (including 
40 patients
less than age of 18 )are treated and hence will be used for the primary  anal ysis.
10.9 Power for analy sis of key secondary  variables
Not applicable because no formal hypothesis testing is planned other than for the primary 
objective.
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the
International Conference on Harmonization ( ICH
)Harmonized Tripartite Guidelines for Good 
Clinical Practice (GCP) , with applicable local regulations (including European Directive 
2001/20/EC and US Code of Federal Regulations Title 21), and with the ethical principles laid 
down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/ SRC
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board /Institutional Biosafet y Committee/Scientific 
 

Novartis Confidential Page 134
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Review Committee (IRB/IEC/REB ) before study  start. Prior to study  start, the investigator is 
required to sign a protocol signature page confirming his/her agreement to conduct the study 
in accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to the Novartis monitors ,auditors, 
Novartis Clinical Quality  Assurance representatives, designated agents of Novartis, 
IRBs/IBCs/ REBs ,and regulatory  authorities as required.
11.3 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by law or regulation), IRB/ IEC/REB -approved informed consent or, if incapable of 
doing so, after such consent has been provided by a legally  accept able representative of the 
patient. In cases where the patient’s representative gives consent, the patient should be 
informed about the study  to the extent possible given his/her understanding. If the patient is 
capable of doing so, he/she should indicate assent by  personally  signing and dating the written 
informed consent document or a separate assent form.
Informed consent /assent must be obtained before conducting any study -specific procedures 
(i.e. all of the procedures described in the protocol). The process of obtaining informed 
consent /assent should be documented in the patient source documents. The date when a 
patient ’s informed consent /assent was actuall y obtained will be captured in their CRFs.
Novartis will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) and assent form that is considered appropriate for this study  and complies with the 
ICH GCP guideline and regulatory  requirements. Any changes to this ICF/assent form
suggested by the investigator must be 
agreed to by Novartis before submission to the IRB/ 
IEC/ REB and a copy of the approved version must be provided to the Novartis monitor after 
IRB/IEC/ REB approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
11.4 Discontinuation of the study
Novartis
reserves the right to discontinue this study  under the conditions specified in the 
clinical study  agreement. Specific conditions for terminating the study  are outlined in Section 
4.3.
11.5 Publication of study  protocol and results
Novartis assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the study  report
,the results of this study  will be either submitted for publication 
and/or posted in a publicly  accessible database of clinical study  results.
 

Novartis Confidential Page 135
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
11.6 Study  documentation, record keeping and retention of 
documents
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional 
requirements for the protection of confidentiality of patient s. As part of participating in a 
Novartis sponsored study , each site will permit authorized representatives of Novartis and 
regulatory  agencies to examine (and when required by applicable law, to copy) clinical 
records for the purposes of qualit y assurance reviews, audits and evaluation of the study 
safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. 
Examples of these original documents and data records include, but a re not limited to, hospital 
records, clinical and office charts, laboratory notes, memoranda, patients’ diaries or 
evaluation checklists, pharmacy  dispensing records, recorded data from automated 
instruments, copies or transcriptions certified after verifi cation as being accurate and 
complete, microfiches, photographic negatives, microfilm or magnetic media, x-rays, and 
patient files and records kept at the pharmacy , at the laboratories, and medico- technical 
departments involved in the clinical trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Principal Investigator. The study  electronic case report form (eCRF) is the primary 
data collection instrument for the study . The investigator should ensure the accuracy , 
completeness, legibility , and timeliness of the data reported in the eCRFs and all other 
required reports. Data reported on the eCRF, that are derived from source documents, should 
be consistent with the source documents or the discre pancies should be explained. All data 
requested on the eCRF must be recorded. Any missing data must be explained. For eCRFs an 
audit trail will be maintained by  the sy stem.
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by 
applicable regulations and/or guidelines. The investigator/institution should take measures to 
prevent accidental or premature destruction of these documents.
Essen tial documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Novartis provides written 
permission to dispose of them or, requires their retention for an addition al period of time 
because of applicable laws, regulations and/or guidelines
11.7 Confidentiality  of study  documents and patient records
The investigator must ensure anon ymity of the patients; patients must not be identified by 
names in any documents submitted to Novartis . Signed informed consent /assent forms and 
patient enrollment log must be kept strictly  confidential to enable patient identification at the 
site.
 

Novartis Confidential Page 136
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
11.8 Audits and inspections
Source data/documents must be available to inspections by Novartis or designee or Health 
Authorities.
11.9 Financial disclosures
Financial disclosures should be provided by study personnel who are directly  involved in the 
treatment or evaluation of patients at the site -prior to study  start.
12 Protocol adherence
Investigators ascertain they will apply  due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact the Novartis or its agents, if any , monitoring the 
study to request approval of a protocol deviation, as no authorized deviations are p ermitted. If 
the investigator feels a protocol deviation would improve the conduct of the study  this must 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
Novartis and approved by the IRB/IEC/REB it cannot be implemented. All significant 
protocol deviations will be recorded and reported in the Clinical Study  Report (CSR) 
developed b y Novartis .
12.1 Amendments to the protocol
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis , Health Authorit ies where required, and the IRB/IEC/REB . 
Only  amendments that are required for patient safety  may be implemented prior to 
IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol 
amendments, the invest igator is expected to take any immediate action required for the safet y 
of any patient included in this study , even if this action represents a deviation from the 
protocol. In such cases, Novartis should be notified of this action and the IRB /IEC/REB at the 
study  site should be informed according to local regulations but not later than 10 working 
days.
 

Novartis Confidential Page 137
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
13 References
Aiuti A , Biasco L, Scaramuzza S, et al. (2013) L entiviral hematopoietic stem cell gene 
therap y in patients with Wiskott -Aldrich syndrome. Science 341(6148): 1233151.
Anon (2010) CHMP (2010) Appendix 2 to the Guidance on the evaluation of anticancer 
medicinal products in man (CPMP/EWP/205/95 Rev. 3) on confirmatory  studies in 
hematological malignancies. Available from < 
ema.europa.eu/docs/en_GB/docume nt_library /Scientific_guideline/2010/03/WC500074949.p
df>
Anon (2013) National cancer institute. Surveillance epidemiology  and end results. Available 
from < seer.cancer.gov/>
Anon (2013) National Comprehensive Cancer Network (NCCN) Guidelines (NCCN, 2013 
vl), Acute Lymphoblastic Leukemia. Available from 
<nccn.org/professionals/phy sician_gls/f_guidelines.asp#site>
Appelbaum FR (2001) Hematopoietic cell transplantation as immunotherapy . Nature; 
411(6835):385 -389
Appelbaum FR, Rosenblum D, Arceci RJ, et al. (2007) End points to establish the efficacy  of 
new agents in the treatment of acute leukemia. Blood 109 (5):1810 -1816
Biffi A, Montini E, Lorioli L , et al. (2013) Lentiviral hematopoietic stem c ell gene therap y 
benefits m etachromatic leukody strophy .Science 34 1(6148):1233158
Brentjens RJ, L atouche J, Santos E, et al. 
(2003) Eradication of s ystemic B -cell tumors by  
geneticall y targeted human T lymphocytes co -stimulated by  CD80 and interleukin-15. Nat. 
Med 9 :279-286
Brentjens R, Yeh R, Bernal Y, et al. (2010) Treatment of chronic l ymphocy tic leukemia with 
geneticall y targeted autologous T cells: case report of an unforeseen adverse event in a phase I 
clinical trial. Mol Ther; 18(4):666
-668
Cairo MS, Bishop M. (2004) Tumor ly sis sy ndrome: new therapeutic strateg ies and 
classifications. Br J Haematol ;127 (1):3
-11
Cavazzana -Calvo M, Payen E, Negre O et al. (2010)] Transfusion independence and HMGA2 
activation after gene therapy of human beta -thalassaemia. Nature;467(7313):318 -322
Calogero A, DeLeij LFMH, Mulder N, et al. (2000) Recombinant T -cell receptors: an 
immunologic link to cancer therap y. J I mmunol; 23(4):393-400
Cella D, Jensen SE, Webster K et al. (2012)] Measuring health- related quality  of life in 
leukemia: the Functional Assessment of Cancer Therap y--Leu kemia (FACT -Leu) 
questionnaire. Value Health; 15(8):1051 -1058
Cheson B, Bennet JM, Kopecky  K, et al (2003) Revised Recommendations of the 
International Working Group for Diagnosis, Standardization of Response Criteria, Treatment 
Outcomes, and Reporting Sta ndards for Therapeutic Trials in Acute M yeloid L eukemia. J 
Clin Oncol; 21(24):4642-9
Clay  T, Morse M, Ly erly HK. (2002) Redirecting cytotoxic T ly mphocy te responses with T -
cell receptor transgenes. Expert Opin Biol Ther; 2(4):353 -360
 

Novartis Confidential Page 138
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Cooper L, Topp M, Serr ano L M, et al. (2003) T-cell clones can be rendered specific for 
CD19: toward the selective augmentation of the graft -versus
-B-lineage leukemia effect. Blood 
101(4) :1637 - 1644
Dudley  ME, Wunderlich JR, Robbins P, et al. (2002) Cancer regression and autoimmu nity in 
patients after clonal repopulation with antitumor lymphocy tes. Science; 298:850 -854
Dudley  ME, Wunderlich JR, Yang JC, et al. (2005) Adoptive cell transfer therap y following 
non-myeloablative but lymphodepleting chemotherapy  for the treatment of pa tients with 
refractory  metastatic melanoma. J Clin Oncol
; 23(10): 2346-2357
Duval M, Klein JP, He W et al (2010) Hematopoietic Stem -Cell Transplantation for Acute 
Leukemia in Relapse or Primary  Induction Failure. J Clin Oncol; 28:3730 -
8
Dummer W, Niethammer AG, Baccala R, et al. (2002) T cell homeostatic proliferation elicits 
effective antitumor autoimmunity . J. Clin I nvest ; 110(2): 185-192
Eshhar Z, Waks T, Bendavid A, et al. (2001) Functional expression of chimeric receptor 
genes in huma n T cells. J I mmunol Methods; 248:67 -76
European Medicines Agency  (2008) Guideline on Safety  and Efficacy  Follow -up – Risk 
Management of Advanced Therap y Medic inal Products. Available from 
<ema.europa.eu/docs/en_GB/document_library /Regulatory _and_procedura l_guideline/2009/1
0/WC500006326.pdf>
European Medicines Agency  (2009) Guideline on Follow -up of Patients Administered with 
Gene Therap y Medic inal Products. Available from 
<ema.europa.eu/docs/en_GB/document_library /Scientific_guideline/2009/11/WC500013424.
pdf>
Fearon D, Carroll M. (2000) Regulation of B l ymphocy te responses to foreign and self -
antigens b y the CD19/CD21 complex. Annu Rev I mmunol; 18:393 -
422
Finney  H, Lawson A, Bebbington C, et al. (1998) Chimeric receptors providing both primary  
and costimula tory signaling in T cells from a single gene product. J I mmunol; 161 (6):2791 -
2797
Finney  H, Akbar A, Lawson A. (2004) Activation of resting human primary  T cells with 
chimeric receptors: costimulation from CD28, inducible, costimulator, CD134 and CD137 in 
series with signals from the TCR zeta chain. J I mmunol; 172 (1):104-113
Food and Drug Administration (2006a) Guidance for Industry : Gene therapy  clinical trials -–
Observing subjects for delay ed adverse events. Available from 
<.fda.gov/biologicsbloodvaccines/ guidancecomplianceregulatory information/guidances/cellul
arandgenetherap y/ucm072957.htm>
Food and Drug Administration (2006b) Guidance for Industry : Supplemental Guidance on 
Testing for Replication Competent Retrovirus in Retroviral Vector Based Gene Therap y 
Products and During Follow-up of Patients in Clinical Trials Using Retro viral Vectors. 
Available from 
<fda.gov/biologicsbloodvaccines/guidancecomplianceregulatory information/guidances/cellula
randgenetherap y/ucm072961.htm>
 

Novartis Confidential Page 139
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Friedmann -Morvinski D, Bendavid A, Waks T, et al. (2005) Redirected primary  T cells 
harboring a chimeric receptor require costimulation for their antigen -specific activation. 
Blood; 105(8) :3087 -3093
Goldrath AW, Bevan MJ. (1999) Selecting and maintaining a diverse T -cell repertoire. Natu re 
402(6759): 255-262
Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin
-T-cell receptor chimeric 
molecules as functional receptors with antibod y-type specificit y. Proc Natl Acad Sci USA ;
86(24): 10024-10028
Gross G, Eshhar Z (1992) Endowing T cel ls with antibody  specificit y using chimeric T cell 
receptors. FASEB J; 6:3370
-3378
Grupp SA, Kalos M, Barrett D, et al. (2013) Chimeric antigen receptor -modified T cells for 
acute l ymphoid leukemia. N Engl J Med; 368(16):1509-1518
Hacein -Bey-Abina S, Garri gue A, Wang GP et al. (2008)] Insertional oncogenesis in 4 
patients after retrovirus -mediated gene therap y of SCI D-X1. J Clin I nvest;118(9):3132-3142.
Harrison CJ, Haas O, Harbott J, et al. (2010) Detection of prognostically  relevant genetic 
abnormalities in childhood B- cell precursor acute ly mphoblastic leukaemia: recommendations 
from the Biology  and Diagnosis Committee of the International Berlin -Frankfürt -Münster 
study  group. Brit J Hematol; 151 (2):132-142.
Hombach A, Heuser C, Abken H. (2002) The recombinant T cell receptor strategy : insights 
into structure and function of recombinant immunoreceptors on the way  towards an optimal 
receptor design for cellular immunotherap y. Curr Gene Ther; 2:211 -226
Hoofnagle JH. (2009) Reactivation of hepatitis B. Hepatology ; 49(5 Suppl):S156-65
Jeha S, Gandhi V, Chan KW, et al. (2004) Clofarabine, a novel nucleoside analog, is active in 
pediatric patients with advanced leukemia. Blood, 103 (3):784-
789
Jeha S, Gay non PS, Razzouk BI, et al. 
(2006 ) Phase II study  of clofarabine in pediatric 
patients with refractory  or relapsed acute l ymphoblastic leukemia. J Clin Oncol, 24 (12):1917 –
1923
June CH. (2007) Adoptive T cell therap
y for cancer in the clinic. J Cl in Invest 117 ;1466 -1476
June CH, Blazar BR, Riley  JL. (2009) Ly mphocy te Subset Engineering: tools, trials and 
tribulations. Nat Rev I mmunol 9 (10): 704-716
Kaech SM andAhmed R (2001) Memory  CD8+ T cell differentiation: initial antigen 
encounter triggers a d evelopmental program in naive cells. Nat Immunol 2 (5):415-422
Kim H (2007) Cumulative incidence in competing r isks data and competing risks regression 
analysis. Clin Cancer Re s;13(2 Pt 1):559 -565
King C, Ilic A, Koelsch K , et al. (2004) Homeostatic expansion of T cells during immune 
insufficiency  generates autoimmunity . Cell ;
117:265-277
Klebanoff CA, Khong HT, Antony  PA, et al. (2005) Sinks, suppressors and antigen 
presenters: how l ymphodepletion enhances T cell
-mediated tumor immunotherap y. Trends 
Immunol ; 26(2): 111-117
 

Novartis Confidential Page 140
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Ko RH, Ji L , Barnette P, et al. (2010) Outcome of patients treated for relapsed or refractory  
acute l ymphoblastic leukemia: therapeutic advances in childhood leukemia consortium study . 
J Clin Oncol; 28:648-654
Kohn DB, Dotti G, Brentjens R, et al. (2011) CARS on t rack in the c linic. Mol Ther; 
19(3):432-438
Kolb HJ, Schattenberg A, Goldman JM, et al (1995) Graft -versus -leukemia effect of donor 
lymphocy te transfusions in marrow grafted patients. European group for bl ood and marrow 
transplantation working party chronic leukemia. Blood; 86(5):2041 -2050
Krause A, Guo HF, LaTouche JB, et al (1998) Antigen -dependent CD28 signaling selectivel y 
enhances survival and proliferation in geneticall y modified activated human prima ry T 
lymphocy tes. J Exp Med; 188(4):619-626
Lamers CH, Sleijfer S, Vulto A, et al (2006) Treatment of metastatic renal cell carcinoma 
with autologous T -lymphocy tes genetically  retargeted against carbonic anhydrase ix: first 
clinical experience. J Clin Onco l; 24(13):20e- 22e
Laport GG, Levine BL, Stadtmauer EA, et al. (2003) Adoptive transfer of costimulated T cells 
induces ly mphocy tosis in patients with relapsed/refractory  non-Hodgkin l ymphoma following 
CD34+ -selected hematopoietic cell transplantation. Blood; 102(6): 2004 -2013
Ledbetter J, Rabinovitch P, June C, et al. (1988) Antigen -independent regulation of 
cytoplasmic calcium in b cells with a 12 -kDa b -cell growth factor and anti -CD19. Proc Natl 
Acad Sci USA; 85 (6):1897 -1901
Maher J, Brentjens R, Gunset G, et al. (2002) Human T -lymphocy te cy totoxicity  and 
proliferation directed b y a single chimeric TCR zeta/ CD28 receptor. Nat Biotechn; 20:70-75
Martin A, Morgan E, Hijiy a N (2012) Relapsed or Refractory  Pediatric Acute Ly mphoblastic 
Leukemia: Current and Em erging Treatments. Pediatric Drugs; 14(6):377 -87
Maude S, Frey  N, Shaw P, et al. (2014)] Chimeric Antigen Receptor T Cells for Sustained 
Remissions in L eukemia. N Engl J Med; 371:1507 -17
Mellman I , Coukos G, Dranoff G. (2011) Cancer immunotherapy  comes of age. Nature; 
480(7378) :22- 29
Milone M, Fi sh J, Carpenito C, et al (2009) Chimeric receptors containing CD137 signal 
transduction domains mediate enhanced survival of T cells and increased antileukemic 
efficacy  in vivo. Mol Ther Nucleic Acids; 17(8):1453-1464
Mitchell ME, L owe K, Fry zek J. (2012) A multisource approach to improving epidemiologic 
estimates: application to global B- cell malignancies. ISRN Oncol; 2012: 129713-129722
Montini E, Cesana D, Schmidt M et al. (2009)] The genotoxic potential of retrov iral vectors is 
strongl y modulated b y vector design and integration site selection in a mouse model of HSC 
gene therap y. Journa l of Clinical I nvestigation;119(4):964-975.
Mullaney  BP, Pallavicini MG (2001) Protein- protein interactions in hematology  and pha ge 
display . Exp Hematol; 29(10):1136 - 1146
O’Brien S, Schiller G, L ister J, et al. (2013) High- dose vincristine sulfate liposome injection 
for advanced, relapsed, and refractory adult Philadelphia chromosome -negative acute 
lymphoblastic leukemia. J Clin Onc ol; 31(6):676 -83
 

Novartis Confidential Page 141
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Oudot C, Auclerc MF, Levy  V et al (2008) Prognostic factors for leukemic induction failure 
in children with acute l ymphoblastic leukemia and outcome after salvage therap y: the 
FRALLE 93 stud y. J Clin Oncol; 26:1496 -503
Palmer DC, Balasubra maniam S, Hanada K, et al. (2004) Vaccine -stimulated, adoptively  
transferred CD8+ T cells traffic indiscriminatel y and ubiquitously  while mediating specific 
tumor destruction. J. I mmunol ; 173(12): 7209 -7216
Pinthus JH, Waks T, Kaufman -Francis K, et al (2003) Immuno -gene therapy of established 
prostate tumors using chimeric receptor -redirected human ly mphocy tes. Cancer Res; 
63(10):2470-2476
Porter D, Levine B, Bunin N, et al (2006 A phase 1 trial of donor ly mphocy te infusions 
expanded and activated ex vivo via CD3/CD28 combination. Blood; 107(4):1325 -1331
Porter D, Levine B, Kalos M, et al. (2011) Chimeric antigen receptor -modified T cells in 
chronic l ymphoid leukemia. N Engl J Med; 365(8):725 -733
Pule M, Finney  H, Lawson A (2003) Artificial T- cell receptors. Cytotherapy ; 5(3):211 -226
Rapoport AP, Stadtmauer EA, Aqui NA, et al (2005 )Restoration of immunity  in ly mphopenic 
individuals with cancer by vaccination and adoptive T -cell transfer. Nat Med ; 11(11): 1230-
1237
Roessig C, Scherer SP, Baer A, et al. (2002) Targeting CD19 with genetically  modified 
EBV -specific human T ly mphocy tes. Ann Hematol; 81(2 Suppl):42S -
43S
Russell JA, Walley  KR, Singer J, et al. (2008) Vasopressin versus Norepinephrine Infusion in 
Patients with Septic Shock. N Engl J Med; 358:877-887
Sadelain M, Riviere I, Brentjens R (2003) Targeting tumours with genetically  enhanced T 
lymphocy tes. Nat Rev Cancer; 3 (1):35-45
Sant M, Allemani C, Tereanu C, et al. (2010) Incidence of hematologic malignancies in 
Europe b y morphologic subty pe: results of the HAEMACARE project. Blood; 116(19): 3724-
3734
Serrano L, Pfeiffer T, Olivares S, et al. (2006) Differentiation of naïve cord -blood T cells into 
CD19- specific cy tolytic effectors for post transplantation adoptive immunotherapy . Blood; 
107(7):2643-2652
Sinn PL , Sauter SL , McCray  PB (2005) Gene therapy  progress and prospects: development of 
improved lentiviral and retroviral vectors -design, biosafet y, and production. Gene Ther 
12(14): 1089-1098
Smith MA, Seibel NL , Altekruse SF et al (2010) Outcomes for chil dren and adolescents with 
cancer: challenges for the twent y
-first century . J Clin Oncol; 28: 2625-34
Stamenkovic I , Seed B. (1988) CD19, the earliest differentiation antigen of the B cell lineage, 
bears three extracellular immunoglobulin- like domains and a n epstein -barr virus-related 
cytoplasmic tail. J Exp Med; 168:1205 -1210
Sullivan KM, Storb R, Buckner CD, e t al (1989) Graft -versus- host as adoptive 
immunotherapy  in patients with advanced hematologic neoplasms. N Engl J Med; 
320(13):828-834
 

Novartis Confidential Page 142
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Surh CD, Sprent J (2000) Homeostatic T cell proliferation: how far can T cells be activated to 
self-ligands? J Exp Med; 192(4): F9-F14 
Tallen G, Ratei R, Kaspers G, et al. (2010) Long -term outcome in children with relapsed 
acute l ymphoblastic leukemia after time -point and site -of-relapse stratification and intensified 
short -course multidrug chemotherap y: results of trial all -rez bfm 90. J Clin Oncol; 
28(14):2339-2347
Tedder T, Isaacs C. (1989) Isolation of cDNAs encoding the CD19 antigen of human and 
mouse B l ymphocy tes. A new member of the immunoglobulin superfamily . J Immunol; 
143(2):717-717
van der Veer A, Waan ders E, Pieters R, et al (2013) Independent prognostic value of BCR-
ABL1 -like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B -
cell precursor ALL. Blood ; 122(15):2622-2629.
van Stipdonk MJ, L emmens EE, Schoenberger SP (2001) Naive CTLs require a single brief 
period of antigenic stimulation for clonal expansion and differentiation. Nat I mmunol 2 (5):
423-429
Weissert R. (2010) Progres
sive multifocal leukoencephalopath y.  J Neuroimmunology  231:  
73-77.
Willemsen RA, Weijtens MEM, Ronteltap C, et al (2000) Grafting primary  human T 
lymphocy tes with cancer -
specific chimeric single chain and two chain TCR. Gene Ther; 
7:1369 -1377
 

Novartis Confidential Page 143
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
14 Appendi ces
14.1 Appendix 1 : 
Guidelines for efficacy  evaluation in Acute Ly mphoblastic 
Leukemia (A LL) studies
Author(s)
Document type: CTL019 Project Specific Guideline
Document status: Version 1 .2: 26-Aug-l--2015
Document History
Version Date Changes
Final 1.0 5-Mar-2014 First version
Final 1.1 23-Dec-2014 Change the calculation of overall response date so that if the overall 
response classified as “No response”, the date of overall response will 
be calculated as the earliest of any component that reveals lack of 
response.
Final 1.2 26-Aug-2015 ● Clarify that the qualitative assessment of tumor involvement will be used to 
determine response status when no blast count result is available from either 
bone marrow biopsy or aspirate.
● Clarify that peripheral blood can be considered to be in remission status when 
bone marrow is in remission status at the same time.
● Change the baseline disease assessment definition to indicate that the most 
current assessments within the protocol specified window will be used
 

Novartis Confidential Page 144
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
List of abbreviations
ALL Acute lymphoblastic leukemia
(e)CRF (electronic) case report form
AML Acute myeloid leukemia
ASH American Society of Hematology
CHMP Committee for Medicinal Products for Human Use
CR Complete remission
CRi CR with incomplete blood count recovery
CSF Cerebral spinal fluid
CT scan Computed Tomography scan
DOR Duration of response
EFS Event -free survival
FDA United States Food and Drug Administration
IWG International Working Group
LP Lumbar puncture
mcL Micro liter
MNC Mononuclear cells
MRD Minimal residual disease
NCCN National Comprehensive Cancer Network
NCI-WG National Cancer Institute -Working Group
ORR Overall remission rate
OS Overall survival
PQ-PCR Real-time quantitative polymerase chain reaction
PR Partial remission
RAP Report and Analysis Plan
RBC Red blood cell
RFS Relapse -free survival
SCT Stem cell transplant
SPD Sum of the product of the diameters
TOC Table of Contents
TTR Time to remission
WBC White blood cell
 

Novartis Confidential Page 145
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
14.1.1 Introduction
This document provides the working definitions and specifications for a consistent and 
efficient analysis of efficacy  for CTL019 clinical studies assessing antineoplastic activity  in 
adult and pediatric acute lymphoblastic leukemia (ALL). The current document is written 
primarily  for the relapse and refractory  disease setting. Modifications may be indicated for 
earlier disease settings.
This document is based on the standardized response criteria defined by National 
Comprehensive Cancer Network (NCCN) Guidelines (NCCN 2013 v1) and further supported 
by the workshop report on acute leukemia from American Societ y of Hematology  (ASH) 
(Appelbaum et 
al 2007) and the International Working Group (IWG) guideline for acute 
myeloid leukemia (AML) ( Cheson et al 2003 ).
The Cheson IWG guideline and Appelbaum ASH report were used in recent drug appro vals 
(e.g. Marqibo) in ALL, prior to the NCCN guideline availability . The NCCN guidance is a 
more recentl y published United States based guideline for ALL.
The objectives of this document are to :
Ensure that the definitions of responses in a clinical study protocol correctly  reflect the 
above mentioned guidelines.
Provide guidance for the response assessment and clinical monitoring to ensure 
consistency  in appl ying the guidelines.
Moreover, this document describes data handling and derivation rules. Respect ive sections 
may be used in the report and anal ysis plan (RAP) to provide further details. Relevant sections 
of this document will be copied into individual clinical trial protocols as appendix to the 
protocol.
14.1.2 Efficacy  evaluation
Efficacy  assessments arebased on bone marrow and blood morphologic criteria, physical 
examination findings, along with laboratory  assessments of cerebral spinal fluid (CSF) and 
bone marrow minimal residual disease (MRD) assessment. Radiologic assessments are used 
only in specifi c settings as defined below. It needs to be clearl y specified in the protocol 
which response categories are considered as primary . Selection criteria for choosing efficacy 
endpoints should reflect the study  setting accordingl y.
14.1.2.1 Types of efficacy  assessment s
Disease characterization at baseline and evaluation of response rel y on the following: 
Bone marrow assessment
Peripheral blood assessment
Extramedullary  disease assessment, including
CNS disease
Other extramedullary  sites
Minimal residual disease (MRD) assessment of bone marrow
 

Novartis Confidential Page 146
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
For timing of the disease assessments for response classification, see Section 14.1.2.3.1 for 
details. The timing of each assessment for disease response should coincide with the other 
response assessment timing.
14.1.2.1.1 Assessment of bone marrow blast counts
Bone marrow will be assessed for blast cells. Percentage of blast cells will be determined by 
morphologic or cytologic examination. This assessment can be performed on bone marrow 
biopsy  and/or aspirate. If the blast counts are assessed, results from these assessments are 
considered to be interchangeable. Some laboratories do not perform differential counts on 
bone marrow biopsies, but rather provide a qualitative assessment whethe r there is tumor 
involvement or not: i.e. Yes or No tumor (blast) cells are seen in the bone marrow biops y 
section or the touch print from the bone marrow biopsy . In this case, it may  not be possible to 
definitively  determine whether the blast count is <5% or not.
Both bone marrow biopsy  and aspirate tests will be considered for response assessment as 
follows :
In the case of onl y one assessment with non -missing blast count values: Result of the non-
missing assessment will be used.
In the case of both assessments with differing, non- missing blast count values : The highest 
blasts value will be considered. The corresponding assessment date will be used as 
reference for other assessments for the determination of evaluation windows.
In the case of no blast count values available from either aspirate or biops y, but a 
qualitative assessment of tumor involvement from biopsy  is available: The bone marrow 
result will be considered to be in remission if there is no tumor involvement, and will be 
consi dered to indicate no response or relapsed disease if there is tumor involvement.
In the case of no blast count values available from either aspirate or biops y, and no 
qualitative assessment of tumor involvement from biopsy  is available: The bone marrow 
result will be considered as “unknown”.
14.1.2.1.2 Assessment of peripheral blood
All values must be taken from the same blood sample. Relevant variables are platelet and 
neutrophil counts and percentage of leukemic blasts. Recent transfusion status also has to be 
taken into account (See Section 14.1.2.3.3 for details).
In some rare cases the blood results are not available (e.g. typicall y when WBC < 500
preventing an accurate assessment of differential count), but the bone marrow result is 
showing complete remission status (per definition in Table 14-1). In this case, the patient will 
also be considered to be in remission status in peripheral blood. 
14.1.2.1.3 Assessment of extramedullary disease
Extramedullary  involvement is t
o be assessed at baseline and at each visit for response 
assessment. Presence or absence and physical location of extramedullary  disease is to be 
captured in the (e)CRF.
 

Novartis Confidential Page 147
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Extramedullary  disease is to be assessed via physical examination, CSF assessment, andif 
clinically  appropriate relevant imaging techniques. In case of extramedullary  disease at 
baseline or (re-)appearance during the study, the lesions should be considered for 
confirmation b y imaging or biopsy if technically and/or clinically feasible.
14.1.2.1.3.1 Assessment of CNS disease
Baseline CSF assessment by  lumbar puncture (L P) is mandatory. The frequency  and timing of 
post-baseline CSF assessment may depend upon the study  setting and standard of care for 
each setting (e.g. front line or relapse/r efractory , pediatric vs adult, etc.) and should be clearly 
specified in the protocol. At a minimum, lumbar puncture should be performed as clinicall y 
indicated b y the presence of neurologic s ymptoms.
The classification of CNS status includes the following:
CNS -1 refers to no ly mphoblasts in the CSF regardless of WBC count; 
CNS -2 is defined as WBC less than 5/mcL  in CSF with presence of ly mphoblasts; 
CNS -3 is defined as WBC of 5/mcL  or greater with presence of l ymphoblasts. 
If the patient has leukemic cells in the peripheral blood and the LP is traumatic and WBC ≥ 
5/mcL  in CSF with blasts, then compare the CSF WBC/RBC ratio to the blood WBC/RBC 
ratio. If the CSF ratio is at least two-fold greater than the blood ratio, then the classification is 
CNS -3; if not, then it is CNS
-2.
CNS remission is defined as achievement of CNS -1 status in a patient with CNS -2 or CNS -3 
at initial assessment.
CNS relapse is defined as development of CNS -3 status or development of clinical signs of 
CNS leukemia (e.g., facial nerve palsy , brain/ey e involvement, hypothalamic syndrome, etc.). 
If clinical signs of CNS leukemia exist, it must be confirmed by  CNS imaging (CT or MRI of 
brain) or other relevant methods (e.g. biopsy, LP, etc.) to define CNS relapse.
14.1.2.1.3.2 Assessment of mediastinal disease
Radiographic assessments are not standard components for routine disease assessments of 
acute l ymphoblastic leukemia ( NCCN 2013 v1 , Cheson et al 2003 ). 
The classification of mediastinal response in NCCN 2013 v1 based on radiographic 
assessments ishence not applicable for studies where only acute lymphoblastic leukemia are 
studied.
14.1. 2.1.3.3 Assessment of other extramedullary disease
The assessment of other extramedullary  disease (hepatomegaly , splenomegaly , skin/gum 
infiltration, testicular mass or other masses) will be performed via ph ysical exam.
Hepatomegal y and splenomegaly  due toleukemic involvement, disease involvement by 
lymph nodes, infiltration of the skin or gums, unilateral or bilateral testicular mass, or other 
masses will be assessed by physical exam. Results will be coded as “Normal”, “Abnormal 
with no or low suspicion for leukemic involvement”, or “Abnormal with high suspicion for 
leukemic involvement”. The rationale for these three categories is as follows. Other 
 

Novartis Confidential Page 148
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
abnormalities that are not related to leukemic infiltration can often be observed in these organ 
sites on ph ysical examination in patients with ALL, especially  during the first 28 days after 
lymphodepleting chemotherap y followed by CTL019 cell infusion. Definitive proof of 
leukemic infiltration (e.g. liver biopsy ) is often not definitive, indicated or ethicall y justified. 
Some abnormalities may occur (e.g. ecchymosis in skin or gums, acute/transient 
hepatosplenomegal y associated with acute infections or Macrophage Activation Syndrome 
(MAS)) but are clearl y not leukemic involvement. Therefore three categories will more 
accuratel y capture these different clinical scenarios. In the analysis, “Normal” or “Abnormal 
with no or low suspicion for leukemic involvement” will be considered eligible for overall CR 
or CRi assessment; “Abnormal with high suspicion for leukemic involvement” will not be 
considered eligible for overall CR or CRi assessment, and will be considered to trigger 
relapsed disease assessment. Serial physical examinations for these assessments will be 
performed (at protocol specified frequency ) to validate the persistence or resolution of such 
findings.
Lym ph nodes on physical exam are considered to be abnormal if greater than 1.5 cm. Note 
that although the cutoff of 1.5 cm is not defined in the NCCN ( NCCN 201 3 v1) or the Cheson 
guidelines (Cheson et al 2003), it is used in the international harmonization project revised 
response criteria for lymphoma 
(Cheson et al 2007a and Cheson et al 2007b) and the 
international working group guideline for chronic lymphocy tic leukemia ( Hallek et al 2008).
14.1.2.1.4 Assessment of minimum residual disease (MRD) in bone marrow
MRD in ALL refers to the presence of leukemic cells below the threshold of detection using 
conventional morphologic methods. Patients who experienced a CR according to morphologic 
assessment alone can potentially  harbor a large number of leukemic cells in the bone marrow: 
up to 1010malignant cells which can confer a poor outcome. The most frequentl y used 
methods for MRD assessment include multicolor flow cytometry  to detect abnormal 
immunophenoty pes and PCR assay s to detect clo
nal rearrangements in immunoglobulin 
heav y chain genes and/or T -cell receptor genes or fusion transcripts (e.g. BCR- ABL). Current 
flow cytometry  or PCR methods can detect leukemic cells at a sensitivity  threshold of fewer 
than 1 × 10-4(<0.01%) bone marrow mononuclear cells (MNCs). The concordance rate for 
detecting MRD between these methods is high. Numerous studies in childhood and adult ALL 
have shown the prognostic importance of post-induction (and/or post-consolidation) MRD 
measurements in predicting the likelihood of disease relapse. The timing of MRD assessment 
varies depending on the ALL treatment protocol and the disease setting (e.g. initial/up front 
treatment vs relapse/refractory ). For MRD evaluation on multicolor flow cy tometry , sampling 
of bone marrow MNCs is preferred over peripheral blood samples. At least 1 × 106MNCs are 
required for analysis (≈ 2 mL of bone marrow or 5–10 mL of peripheral blood provides 
sufficient number of cells for multiple analysis). For MRD evaluation with real-time 
quantitative PCR (RQ
-PCR), sampling of bone marrow MNC is preferred. At least 1 × 107
MNCs are required for initial marker characterization and generation of individual dilution 
series; 1 × 106MNCs are sufficient for follow -up analysis. The minimal limit of assay 
sensitivity  (to declare MRD negativity ) should be less than 1 × 10-4(< 0.01%).
For Ph+ ALL, BCR -ABL quantitative PCR may  also be used to assess MRD status.
 

Novartis Confidential Page 149
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
The timing of MRD assessment is dependent upon the disease setting and should be specified 
inthe protocol.
MRD assessment by flow cytometry  or RQ-PCR should be performed via a central certified 
lab with 0.01% sensitivity .  
14.1.2.2 Baseline evaluation
The following baseline assessments a re mandatory :
Bone marrow biops y and/or aspirate for blast cell counts (Section 14.1.2.1.1)
Peripheral blood for blast, neutrophil and platelet cell counts (Section 14.1.2.1.2)
CSF cy tology  via lumbar puncture for WBC, RBC cell and l ymphoblast numbers (Section 
14.1.2.1.3.1)
CNS imaging (CT or MRI of brain) if clinical signs of CNS leukemia exist (Section 
14.1.2.1.3.1)
Physical exam for extramedullary  disease (Section 14.1.2.1.3.3
)
MRD assessment by  flow cy tometry  (Section 14.1.2.1.4 )
Cytogenetics and/or FI SH from bone marrow aspirate 
For disease characterization at baseline, the most current bone marrow assessment within the 
protocol specified window should be used as the baseline bone marr ow assessment. The blood 
count and extramedullary  disease (physical exam, CSF, etc) assessments that are most 
proximal to the above defined baseline bone marrow assessment should then be used as the 
baseline blood count and baseline extramedullary  disease assessments, respectivel y.
14.1.2.3 Post -baseline overall disease response evaluation
14.1.2.3.1 Components and timing of overall disease response evaluation
The initial achievement of CR or CRi will require evaluation of remission in bone marrow, 
peripheral blood, and the absence of extramedullary  disease. Following initial achievement of 
CR or CRi, if the patients have normal peripheral blood, physical exam and no CNS 
symptoms, they will be considered to remain in clinical CR or CRi, i.e. there is no clinical 
evidence of rel apse ( Section 14.1.2.3.4 ).
An overall disease response evaluation must consist all of the following components:
Peripheral blood for morphologic blast, neutrophil and platelet cell counts (Section 
14.1.2.1.2)
CNS sy mptom assessment ( Section 14.1.2.1.3.1)
Physical examination for extramedullary  disease 
(Section 14.1.2.1.3.3)
In addition,
Post-baseline bone marrow biopsies and/or aspirates (Section 14.1.2.1.1) for morphologic 
blast cell counts are required to demonstrate that a patient has achieved CR or CRi for the 
first time. Following initial achievement of CR or CRi, a bone marrow biopsy  or aspirate 
will not be required unless it is clinically  indicated (e.g. worsening of platelet or 
 

Novartis Confidential Page 150
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
neutrophils; reappearance of blast in peripheral blood, etc.) or as specified per individual 
protocol.
Post-baseline CSF cy tology  via lumbar puncture ( Section 14.1.2.1.3.1) is required to 
demonstrate that a p atient has achieved CR or CRi for the first time. Following ini
tial 
achievement of CR or CRi, a lumbar puncture will not be required unless it is clinically  
indicated b y the presence of neurologic s ymptoms and as specified per individual 
protocol . 
MRD assessment ( Section 14.1.2.1.4 ) should be performed per protocol specification .
In order for all components of disease assessments to be qualified as the same response 
evaluation, peripheral blood sample collection, CNS symptom assessment, physical exam, 
bone marrow biops y/aspirate (if needed) and lumbar puncture (if needed) need to be 
performed, in general, within 14 day s of each other, unless specified otherwise in the protocol.
In case of missing data for the full evaluation required to qualify  for a certain response 
category , the overall evaluation “unknown” will be assigned unless at least one observation 
was made which qualifies for relapse. Relapse can be determined by the relapsed component 
alone.
Also see Section 14.1.2.3.2 and Section 14.1.2.3.4 for the definition and confirmation of 
disease response.
The frequency  of response evaluation for each component needs to be clearly  specified in the 
protocol. The timing should be coordinated so that a full r esponse evaluation can be made.
14.1.2.3.2 Response criteria
The overall disease response is determined at a given evaluation using the criteria described in
Table 14
-1. Note that:
The NCCN guidance ( NCCN 2013 v1) has defined a progressive disease (PD) category . 
In this document, PD is considered the same as “ No response”, which is consistent with 
Cheson et al (2003) guideline. The difference between PD and “No response” in ALL is 
not believed to be clinically  meaningful.
See Section 14.1.2.1.1 for details regarding assess ing bone marrow response status.
Table 14-1 Overall disease response classi fication at a given evaluation time
Response category Definition
Completeremi ssion (CR) All the following criteria are met:
Bone marrow
● Trilineage Hematopeisis (TLH) and < 5% blasts
Peripheral blood
● Neutrophils > 1.0 x 109 /L, and
● Platelets > 100 x 109/L, and
● Circulating blasts  < 1% 
Extramedullary  disease
● No clinical evidence of extramedullary disease (by physical exam and CNS 
symptom assessment )  and
● If additional assessments (e.g. CSF assessment by LP, CNS imaging, biopsy, 
etc.) are performed, results must show remission status
Trans fusionindepen dency (seeSection 14.1.2.3.3 ).
● No platelet and/or neutrophil transfusions less than or equal to 7 days before the 
 

Novartis Confidential Page 151
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Response category Definition
date of the peripheral blood sample for disease assessment
Complete remission with 
incomplete blood count 
recovery  (CRi)All criteria for CR as defined above are met, except that the following exist: 
● Neut rophils≤ 1.0 x 109/L, or 
● Platelets≤ 100 x 109/L, or
● Platelet and/or neutrophil transfusions less than or equal to 7 days before the 
date of the peripheral blood sample for disease assessment
No response Failure to attain the criteria needed for any response categories or relapse
Relapsed Disease Only in patients who achieved a CR or CRi and who have:
● Reappearance of blasts in the blood ( ≥ 1%), or 
● Reappearance of blasts in bone marrow ( ≥ 5%), or
● (Re-)appearance of any extramedullary disease after CR or CRi
Unknown “Unknown” is assigned in case the bas elineassessm ent or the response 
assessment is notdone,in
complete, indeterminate, ornotperformed withinthe
respecti vetime frame (Section 14.1.2.2 and Section 14.1.2.3.1).
If there is evidence of relapse, the overall response will assessed as “relapsed 
disease” with the relapsed component alone.
14.1.2.3.3 Evaluation of transfusion dependency
Information on transfusion dependency  will be assessed at baseline as well as during the 
course of the trial for all patients. Transfusion of blood products will be recorded in a separate 
module of the (e)CRF. The type of transfusion, start and end date as well as the volume of 
blood product will be captured at each visit with hematologic assessment.
A period of at least one week (7 day s) without any  transfusion has been taken as a convention 
to define the status of transfusion independence to assess a CR vs CRi response (Cheson et al 
2006). Any sample of peripheral blood sample for disease assessment which was taken less 
than or equal to seven day s after a transfusion will be considered as transfusion dependent.
14.1.2.3.4 Establishing CR/C
Ri and subsequent maintenance of CR/CRi with no 
clinical evidence of relapse
A full response evaluation, including assessments of peripheral blood, bone marrow, CNS 
symptoms, phy sical exam and CSF assessment by  LP, is required at the first time a CR or CRi
is demonstrated ( Section 14.1.2.3.1 ). Bone marrow biopsy /aspirate and CSF assessment by  LP 
are required 1 month (Day 28) after infusion. If the patient is not in CR/CRi at Month 1, then 
a bone marrow biops y/aspirate and CSF assessment by LP are also required at the first time 
clinical evidence of remission is seen by peripheral blood and extramedullary  disease 
assessment (physical exam and CNS symptom assessment) to establish that a patient has 
achieved CR/CRi for the first time. Additional bone marrow biopsies/aspirates and CSF 
assessments by  LP may  be recommended in the protocol.
Complete remissions in patients with ALL have been observed to take place within 1 month 
after infusion with CTL019. The onset of complete remissions are rapid and dramatic, and 
patients quickly  regain a normal performance status. ALL relapse in the bone marrow is 
rapidly  followed by signs or symptoms of disease recurrence as well as abnormalities in the 
peripheral blood.
There fore, following initial achievement of CR/CRi, patients will be considered to have 
maintained a clinical CR/CRi if the patient has no evidence of extramedullary  disease (by 
 

Novartis Confidential Page 152
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
physical exam and CNS symptom assessment) and circulating blas ts in peripheral bloo d are 
<1%.
In order for the best overall disease response to be categorized as CR or CRi, there must be no 
clinical evidence of relapse as assessed by peripheral blood and extramedullary  disease 
assessment (physical exam and CNS symptom assessment) at a minimum of 4 weeks (28 
days) after the initial achievement of CR or CRi. Please note, if additional assessments (e.g. 
bone marrow, CSF assessment by LP, CNS imaging, biops y, etc.) are performed (Section 
14.1.2.3.1) in the same evaluation for disease response evaluation purpose , they  will also need 
to show remission status.
The onset date of CR or CRi will then be derived as the 
evaluation date of the initial CR or 
CRi assessment. If a patient satisfied CRi at one evaluation and later confirmed as a CR in the 
next evaluation, the patient will be considered as having confirmed CR. However, the date of 
CR will be derived as the latter (confirmed) evaluation date.
14.1.2.3.5 Date of overall disease response evaluation
A complete evaluation of response includes at the minimum the assessments of peripheral 
blood, CNS sy mptoms and phy sical exam. In addition, bone marrow andCSF assessment may 
be required. All components of disease assessments must be performed within the specified 
time frame ( Section 14.1.2.3.1 ) to be qualified as the same response evaluation.
If the overall disease response is CR, CRi, or Unknown, the evaluation date (i.e. for one 
evaluation number) is defined as the latest of all dates of required measurements at that 
evaluation number. This rule applies also in case of multiple measurements of the same 
variable.
Relapse or no response can be assessed based on a partial evaluation (e.g. a relapse is assessed 
from blood alone). The assessment date for relapse or no response is calculated as the earliest 
date of all assessments that reveal a relapse or lack of a response .
14.1.3 Data collection
14.1.3.1 Data sources
The summary  of data sources refers to 
disease -specific (e)CRF standard modules. It is not 
appropriate to deviate from these specifications in Table 14-2.
Table 14-2 Data sources
(e)CRF module Specification
Overall disease response Overall disease response and assessment s of individual components from
● bone marrow;
●blood;
●CNS disease;
●other extramedullary disease.
Bone marrow biopsy / aspirate Aspirate or biopsy; morphologic blast counts and MRD assessment. 
Blood response Response status for platelets, neutrophils, morphologic blast counts; status 
of platelet and/or neutrophils transfusion.
CSF assessment 1CSF lymphoblast, W BC, RBC 
 

Novartis Confidential Page 153
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
(e)CRF module Specification
Other CNS disease CNS symptoms, confirmation of CNS disease via imaging or other methods 
(if applicable)
Extramedullary disease by 
physical examPresence/absence, location, method of assessment, confirmation by biopsy 
or imaging or not if feasible
Blood component trans fusions Type and number of units of transfusions, timing with respect to disease 
assessment
Hematopoietic Stem Cell 
Transplant (SCT) – post infusionDate, type of post -treatment SCT
1When there is clinical signs of CNS disease and/or at protocol specified time points
14.1.3.2 Recording response evaluation on the (e)CRFs
The components and timing needed to adequatel y assess overall disease response is outlined 
in Section 14.1.2.3.1. In practice, disease response evaluation (either a complete assessment or 
only some components) may be performed on both scheduled and unscheduled time points. 
Also it is not uncommon in oncology trials that disease responses are sometimes assessed at 
time points not matching the scheduled time points. For example, when a patient’s condition 
prevents certain assessments, the scheduled evaluation will have to bedelay ed to a later time 
point.
As a result, the recording of response evaluation is aligned using the “Evaluation number” on 
the (e)CRFs. A new evaluation number should be assigned whenever a scheduled or 
unscheduled disease response assessment is performed, and hence is not 
necessarily  aligned 
with the study visits.
When relapse can be judge based on any component. E.g. if a relapse is observed from blood 
sample alone without bone marrow assessment etc. at any time, it will be recorded on the 
(s)CRFs, with all other assessments as “not done” or “unknown”.
See also Section 14.1.2.3.5 regarding assigning date of the overall response.
14.1.3.3 Capturing overall response evaluation
Data monitoring reports will be prepared to identify  investigator’s assessm ents which differ 
from calculated response based on the rules of this document. This discrepancy  may be 
queried for clarification. However, the investigator’s response will not be overruled in any 
case.
14.1.4 Efficacy  analy sis definitions
14.1.4.1 Local vs central evalua tion of efficacy
The overall disease response at a given assessment may  be provided from different sources: 
Investigator overall disease response based on local radiological assessments, local 
clinical, pathological (e.g. bone marrow) and laboratory  respo nse.
Central review based on review of the totality  of the source data by  an independent review 
committee (I RC).
The Study  Protocol should state which evaluation source will be used for the primary 
analysis.
 

Novartis Confidential Page 154
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
14.1.4.2 Best overall disease response
The best overall disease response is the best disease response recorded from 
randomization/first CTL019 infusion until start of new anticancer therapy.
Best response will be assigned ac cording to the following order:
1.CR
2.CRi
3.No response
4.Unknown
The best overall disease respo nse for a patient is alway s calculated, based on the sequence of 
overall disease responses. For the best overall disease response to be categorized as CR or 
CRi, there must be no clinical evidence of relapse as assessed by peripheral blood and 
extramedulla ry disease assessment (physical exam and CNS symptom assessment) at a 
minimum of 4 weeks (28 days) after the initial achievement of CR or CRi, as explained in
Section 14.1.2.3.4.
The overall remission rate (ORR) is defined as the proportion of patients with a best overall 
disease response of CR or CRi.
14.1.4.3 T
ime-to-eventdefinitions
General rule for the calcula tion ofthetime to ev entintervalis: 
Time toe
vent = event date -start date+ 1 (in days)
Whennopost-baseline r
esponse assessme ntsareavailable, thedate ofrandomization/first 
CTL019 infusion willbeused asevent date when time is to becensored atlastpost- baseline
respon se ass
essment,i.e.time to event var i ables willnever be nega tive .
Often censoring time is determined based on da teofadeq uaterespon seassessment. Any 
response assessment isconsidered tobeadequate iftheassessment w asperformed andthe 
outcome of theassessm entwasotherthan “unkn own”or“not done”.
14.1.4.3.1 O
verall survival (OS)
Overallsurviva l (OS) is thetimefrom date of randomization/ first CTL019 infusion tothe
date of death duetoa ny reason.
In ca seapatient is alive at the date of last contact on or before data cutoff, OSiscensored at
thedateof la stcontact. The handling of SCT for the calculation of OS must be clearly 
specified in the protocol. See also Section 14.1.4.4 for more discussion.
OS will be assessed in all patients (FAS).
14.1.4.3.2 Duration ofremis sion (DOR)
Duration of remission (DOR) is defined as theduration from the first documented onset of 
C
Rior CR to thedate of relapse or deathduetoALL.
 

Novartis Confidential Page 155
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
In ca sea patient does not haverelapseor death due toALL prior to data cutoff ,DOR willbe 
censore d at the dat e ofthel a stadeq uate assessment on or prior to the earliest censoring event .
The censoring reason could be
Ongoing without event
Lost to follow -
up
Withdrew consent
New anticancer therap y
Event after at least two missing scheduled disease assessment
In addition, death due to reason other than ALL can be considered as either a competing risk 
event to other events of interest (relapse or death due to ALL), or a censoring event. The 
protocol should clearl y specify  which anal ysis is used as the primary  anal ysis for DOR.
Since patients in remission might choose to receive SCT, censoring due to SCT will 
overestimate the risk of relapse and therefore may be considered inappropriate for the main 
analysis, when there is a substantial number of patien ts choose to receive SCT ( CHMP 2010 ). 
The handling of SCT for the calculation of DOR must be clearl y specified in the protocol. 
See also Section 14.1.4.4 for more discussion.
DOR will be assessed only  in patients with the best overall response of CR or CRi.
14.1.4.3.3 Relapse -free survival (RFS)
Relapse-freesurvival(RFS) is m easured by the time from achievement of CR orCRi
whatever occurs firsttorelapse or death duetoanycause during CR or CRi.
Incase a pa tient does not have rel aps e or death dueto an y cause prior to data cutoff , RFS will
be ce nsored at th e dateofthel a stadequa teass essment on or prior to the earliest censoring 
event. The censoring reason could be 
Ongoing without event
Lost to follow -up
Withdrew consent
New anticancer therap y
Event after at least two missing scheduled disease assessment
The handling of SCT for the calculation of RFS must be clearl y specified in the pr otocol.
See also Section 14.1.4.4 for more discussion.
RFS will be assessed only  in patients with the best overall response of CR or CRi.
14.1.4.3.4 Event-freesurvival (EFS)
Even t-freesurvival(EFS) is the timefrom date of randomization/first CTL019 infusion
tothe earliest of the following:
Deathfrom anycause
Relapse
 

Novartis Confidential Page 156
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Treatment failure: Defined as no response in the study  and discontinuation from the study  
due to an y of the following reasons:
Adverse event (in cluding abnormal laboratory  values or abnormal test procedure 
results)
Lack of efficacy
New anticancer therap y
In case of treatment failure, the event date will be set to study  Day 1 (CHMP 2010 ).
Incase
apatient does not ex perience ane vent (e.g. discontinuation as a result of withdrawal 
of consent, lost to follow -up, protocol violation or administrative problems) prior to data 
cutoff, EFS iscenso redatthelast adequa te response assessment date on or prior to the 
earliest censoring event. The censoring reason could be 
Ongoing without event
Lost to follow -up
Withdrew consent
New anticancer therap y
Event after at least two missing scheduled disease assessment
The handling of SCT for the calcu lation of EFS must be cle arly specified in the protocol.
See also Section 14.1.4.4 for more discussion.
EFS will be assessed in all patients (FAS).
14.1.4.4 Event and censoring date,sensitivityanalyses
This section outlines thepossible event and censor ingd ates for relapse ( Table 14-3),
addresses theissues
ofmissing response asses sments during thestudy, and the options for 
handling new anticancer therap y.Itisimportant thatthe protocol a nd RAP specify the pr imary
analy sis in detailwith respecttothedefinition of eve nt a nd censoring dates and al soinclude a
description of sensitivi ty analyses tobe performed.
SCT isasta
ndardtreatment option forA LL pa tients. For time-to-event endpoints itneeds
tobe specified in theprotocol how patients who choose to undergo SCT following study 
protocol treatment willbehandled for analysi s.
Usin gthe draft FDA guideline (2007 ) onendpoi nts(Clinical Trial Endpoi ntsfor the Approval 
of Ca ncer Drugsand Biologic s) and the EMA guideline on the evaluation of Anticancer 
Medicinal Products in Man on Confirmatory  studies in Haematological Malignancies (CHMP 
2010) as r efe rences,thefollowi nganalys es can beconsidered:
 

Novartis Confidential Page 157
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Table 14-3 Options foreventdates usedinDOR, EFS andRFS
SituationOptionsfor event da te
(1)= def aultunless s pecified differently inthe
protocoloranalysisplan Outcome
A Nobaseli neassessm ent (1)Date of rando mizat ion/startof treatment Censor
B Relapse at sched u led a ssessm ent 
date or
before next sched u l ed 
assessm ent(
1)Date of relapse
(2)Date of ne xtsched uledasse ssmentEvent
Event
C1 Relapse af terexactlyonemissing 
assessm ent(1)Date of relapse
(2)Date of ne xtsched uledasse ssmentEvent
Event
C2 Relapse af tertwo or moremissing 
assessm ents(
1)Date of last ad equateassessm ent
(2)Date of ne xtsched uledasse ssment
(3)Date of relapseCensor 
Event
Event
D New a nticanc ertherapy giv en
(excluding SCT)(1)Date of last ad equateassessm ent
(
2)Date of seconda ryanti-cancer the rapy
(3)Date of seconda ryanti-cancer the rapy
(4)N/ACensor
Censor
Event
Ignored
E SCT (1) Date of SCT
(2) N/A
(3) Date of SCT
(4) Date of last adequate assessment prior to SCTCensor
Ignored
Competing 
Risk Event
Censor
F Death due to reasons other than 
ALL (for DOR only)(1) Date of death
(2) Date of last adequate assessmentCompeting 
Risk Event
Censor
The primary analysisandthesensitivity  analysesmust bespecified inthestudy protocol. 
Clearly define ifandwhyoptions (1)arenot us edforsituations, D and(ifapplicable) E.
Situations
C (C1and C2):Relapse or death a fterone or more mi ssing asses sments:The 
prima ryanalysisisusually usingoptions (1)forsituations C1andC2,i.e.
(C1) taking theactual relapseor de athd ate in the case ofonemissi ngassessment
(
C2)censor ingatthe date of the la stadequa teassessmentin the case of two or m ore 
consecutive missing assessments
In the case of t woor m oremissingassessments (situation C2), option (3)may be conside red 
jointlywith option (1) in situation C1as se nsitivi ty analy sis.A variant of this sensitivi ty 
analysisconsists ofbackdating theeventtothenext scheduled assessme ntasproposed with 
option (2)insituations C1andC2.
Situation D: New anticancer therapy  (excluding SCT) given: the handling of this situation 
must be specified in detail in the protocol. However, option (1), i.e. censoring at last adequate 
assessment prior to new anticancer therap y ma y be used as a default in this case.
Situation E: As SCT is an important treatment opt ion in responding patients, it is appropriate 
to consider the date of SCT as censoring date, instead of censoring at the last tumor 
assessment date. However, censoring due to SCT will overestimate the rate of relapse and 
therefore may be considered inappropriate for the default analysis when a substantial number 
of patients choose to receive SCT. Anal ysis ignoring SCT should be considered (CHMP 
2010).
 

Novartis Confidential Page 158
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Since SCT during remission after the experimental treatment may affect the risk of relapse, a 
sensitivity  analysis may be considered in which SCT is regarded as a competing risk to the 
event of interest (e.g., relapse after the experimental treatment). In this analy sis, the 
cumulative incidence function (CIF), instead of the usual KM, is used to estimate the 
probability  of remaining free of the event of interest in the presence of the competing risk 
(Kim 2007).
Situation F: Note that the KM method used to analy ze DOR in the presence of censoring can 
be biased if the censoring event is not independent to the event of interest (i.e. relapse and 
death due to ALL). Therefore, analysis can also be performed considering death due to reason 
other than ALL as a competing risk event. In this case, the cumulative incidence function 
(CIF) instead of KM is used to estimate the probability  of relapse in the presence of the 
competing risk ( Kim 2007).
Additional sugges tions forsensitivit y anal yses
Other suggestions foradditional sensitiv ity analy sesm ay include an alysestocheck for 
potential bias infollow- upschedules forresponse assessments, e.g. by assigning thedates for 
censori ngandevents only atscheduled visit dates.Thelatter could be handled byreplacing in 
Table 14-3 the“Dat eoflastadeq uate assessm ent” by the“Date of previous schedu led 
assessment (from baseline)”, with thefollowi ng de finition:
Date of previous sch e duledassessme nt (from b aseline)isthe date when a response 
assessment would have taken place, if the protocol assessment scheme was strictly  followed 
from baseline, immediately  before or on the date of the last adequate assessment.
Theneed for theset ypes of sensitivi ty analyses wi lldepend on theindividu a lrequirementsfor 
thespecific study andh ave to be specifiedinthestudyprotocol orRAP documentation.
14.1.5 References
Appelbaum, FR, et al (2007) End points to establish the efficacy  of new agents 
in the 
treatment of acute leukemia. Blood 109: 1810 -1816.
Cheson B, Bennet JM, Kopeck y K, et al (2003) Revised Recommendations of the 
International Working Group for Diagnosis, Standardization of Response Criteria, Treatment 
Outcomes, and Reporting Standar ds for Therapeutic Trials in Acute Myeloid L eukemia. 
Journal of Clinical Oncology ; 21(24):4642 -9.
Cheson BD (2007a) The international harmonization project for response criteria in 
lymphoma clinical trials. Hematol Oncol Clin N Am 21:841-854.
Cheson BD, Pf istner B, Juweid ME, et al (2007b) Revised response criteria for malignant 
lymphoma. J Clin Oncol 25:579 -586.
CHMP (2010) Appendix 2 to the Guidance on the evaluation of anticancer medicinal products 
in man (CPMP/EWP/205/95 Rev. 3) on confirmatory  studies in haematological malignancies.
FDA Guideline (2007) Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, May  2007.
Hallek M, et al (2008) Guidelines for the diagnosis and treatment of chronic ly mphocy tic 
leukemia: a report from the International Workshop on Chronic Ly mphocy tic Leukemia 
 

Novartis Confidential Page 159
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
updating the National Cancer Institute–Working Group 1996 guidelines. Blood 111.12: 5446 -
5456.
National Comprehensive Cancer Network (NCCN) Guidelines (NCCN, 2013 v1), Acute 
Lym phoblastic Leukemia
Cheson BD, Greenberg P, Bennett J, et al (2006) Clinical application and proposal for 
modification of the International Working Group (I WG) response criteria in my elodysplasia. 
Blood; 108: 419
-425.
Kim H (2007) Cumulative Incidence in Competing Risks Data and Com peting Risks 
Regression Anal ysis. Clinical Cancer Research 2007;13:559-565.
 

Novartis Confidential Page 160
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
14.2 Appendix 2: Guidelines for efficacy  evaluation in Ly mphoblastic 
Lymphoma patients
14.2.1 Introduction
The efficacy  evaluation inlymphoblastic lymphoma patients follows the same guidelines for 
acute lymphoblastic leukemia (ALL) patients as outlined in Appendix 1. In addition, based on 
the standardized response criteria defined by National 
Comprehensive Cancer Network 
(NCCN) Guidelines (NCCN 2013 v1) and further supported by other literatures, 
considerations outlined below should be followed.
14.2.2 Types of efficacy  assessments
In addition to allthe efficacy  assessments for ALL patients, mediastinal disease must be 
assessed for extramedullary  disease.
14.2.2.1 Assessment of mediastinal disease
A baseline CT or MRI (CT/MRI ) scan of the mediastinum is only  required to confirm whether 
mediastinal disease is present for patients with a history  of lymphoblastic lymphoma. If a 
patient does not have a history  of lymphoblastic lymphoma, no CT/MRI  scan is required 
throughout the stud y.
For patients with history  of lymphoblastic lymphoma , the frequency  and timing of post-
baseline chest CT/MRI assessment may depend upon the study  setting (e.g. front line or 
relapse/refractory , pediatric vs adult, etc.) and should be clearl y specified in the protocol. 
Post-baseline chest CT/MRI  assessment is required at Month 1 
only for patients with proven 
mediastinal disease at baseline. Additional chest CT/MRI  assessments may be performed per 
protocol specification. 
If at any time point, mediastinal disease is present by CT/MRI  assessment, then follow -up 
CT/MRI  is required to docum ent the absence of mediastinal involvement whenever the patient 
meets all other criteria for complete remission. The timing of the CT/MRI  must be within the 
required time window of the other disease response components.
For optimal evaluation of patients, the same imaging method of assessment (i.e. CT or MRI ) 
and technique (i.e. with or without contrast) should be used to characterize each identified and 
reported lesion at baseline and during follow -up. A change in methodology  can be defined as 
either a change in contrast use (e.g. keeping the same technique, like CT, but switching from 
with to without intravenous contrast use or vice-versa, regardless of the justification for the 
change) or a change in technique (e.g. from CT to MRI , or vice -versa). 
The investigator or the central blinded reviewer should decide if a definitive overall 
radiological response can be provided and justified to be based on the available information. 
Otherwise, overall lesion response should be “Unknown”, unless there is evidence of relapse.
Although the NCCN guideline has provided some guidance on the classification of 
mediastinal response, the exact definition of lymph node normalization requires further 
clarification. Following the NCCN guideline (NCCN 2013 v1 ) and also referencing the 
 

Novartis Confidential Page 161
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
international harmonization project revised response criteria for lymphoma (Cheson et al 
2007a and Cheson et al 2007b), the f ollowing guidelines are adopted:
Radiological classification of mediastinal lymph nodes 
Lym ph nodes in the mediastinum are classified according to their size and/or relationship to 
the disease:
A lymph node that can be measured accurately  in 2 perpendicular dimensions and if the 
long axis is > 15 mm, regardless of the length of the short axis above will constitute a 
measurable nodal lesion .
A lymph node not meeting the measurabilit y requirement (above) but with long axis > 15 
mm (e.g. short axis cannot be measured accurately) will constitute a non-measurable 
nodal lesion
A lymph node not meeting the measurabilit y criteria but with a size of 11 mm to 15 mm in 
the long axis and > 10 mm in the short axis will be checked for relationship to disease:
If it is t hought to be disease related, it will constitute a non-measurable nodal lesion
If it is not thought to be disease related, it will constitute an abnormal lymph node but 
not a lesion.
All other ly mph nodes will be considered normal and will not constitute n odal lesions.
Normalization of mediastinal lymph nodes after baseline
Mediastinal ly mph nodes will be considered to have normalized if:
A measurable nodal lesion hast become ≤ 15 mm in long axis.
A non
-measurable nodal lesion has decreased to ≤ 10 mm in th e short axis and be ≤ 15 
mm in long axis.
New mediastinal lymph nodes
A new mediastinal l ymph node is defined as:
Either a previousl y normal mediastinal lymph node becoming > 15 mm in any  axis, or,
A previously  identified abnormal mediastinal ly mph node showing an increase of at least 
50% in the long axis.
Response criteria for mediastinal disease
The response for measurable mediastinal lymph nodes is evaluated by calculating the Sum of 
the Products of the greatest perpendicular Diameters (SPD) of all measurable lesions (see 
Table 14-4), except when there is complete normalization of all measurable mediastinal 
lymph nodes.
 

Novartis Confidential Page 162
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Table 14-4 Response criteria for mediastinal disease
Response Status 1Criteria
Comp lete R esponse (CR) Complete normalization of all mediastinal lymph nodes 
CR Unconfirmed (CRu) Residual mediastinal lymph nodes that have regressed by >75% in the 
SPD from baseline & without unequivocal worsening of non -measurable 
lymph nodes
Partial R esponse (P R) At least 50% decre ase frombasel ine in the SPD of all measurable 
mediastinal lymph nodes & without unequivocal worsening of non -
measurable lymph nodes
No Response ( NR) Failure to attain the crit erianeeded for CR, CRu or PR
Relapse Recurrence of mediastinal lymph nodes after achieving mediastinal CR 
or CRu
1At each assessment (if t he measurable mediastinal lymph nodes are not in CR stat us), the r espon se stat us 
based on SPD ca lculation will be first assess ed for meeting NRstatus criteria, then PR status.
Note that NCCN guidance has defined a mediastinal progressive disease (PD) category . In 
this document, mediastinal PD is considered the same as “No response”. The difference 
between mediastinal progressive disease and no response in lymphoblastic lymphoma within 
the mediastinum is not believed to be clinical meaningful.
14.2.2.2 Baseline Evaluation
CT or MRI  scan is required for patients with a history  of ly mphoblastic l ymphoma. 
For disease characterization at baseline, the most current bone marrow assessment withi n the 
protocol specified window should be used as the baseline bone marrow assessment. The blood 
count and extramedullary  disease (phy sical exam, CSF, imaging if indicated) assessments that 
are most proximal to the above defined baseline bone marrow assess ment should then be used 
as the baseline mediastinal disease assessments.
14.2.2.3 Post -baseline overall disease response evaluation
Post-baseline CT/MRI  for mediastinal disease assessment is required to demonstrate that a 
patient has achieved CR or CRi for the first time.I N order for all components of disease 
assessments to be qualified as the same response evaluation, peripheral blood sample 
collection, CNS symptom assessment, physical exam, bone marrow biopsy / aspirate (if 
needed), CT/MRI  scan (if needed) and lumbar puncture (if needed) need to be performed, in 
general, within 14 day s of each other, unless specified otherwise in the protocol.
The overall disease response is determined at a given evaluation using the criteria described in 
Table 14-5 below. 
 

Novartis Confidential Page 163
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Table 14-5 Overall disease response classification at a given evaluation time for 
lymphoblastic ly mphoma patients
Response cate gory Definition
Completeremission (CR) All the criteria for ALL are met, and in addition CR for mediastinal 
disease.
Complete remission with incomplete blood 
count recovery (CRi)All the criteria for ALL are met, and in addition CR for mediastinal 
disease. 
CR or CRi with residual mediastinal disease All criteria for CR or CRi as defined above are met, except that 
mediastinal disease as defined by CRu or PR is observed.
No response Failure to attain the criteria needed for any response categories or 
relapse
Relapsed Disease Same criteria for ALL, and in addition mediastinal relapse wi ll also 
indicate relapse for lymphoblastic lymphoma.
Unknown Same criteria for ALL.
Note that the NCCN guideline (NCCN 2013 v1 ) has defined mediastinal response criteria 
including CRu and PR, however has not incorporated these categories into the overall disease 
response. Residual nodal disease in the presence of clearance of all other sites of disease may 
represent a unique biologic setting. Therefore, in the case a patient achieves CR or CRi at all 
other non-mediastinal disease sites, and has residual mediastinal disease (mediastinal CRu or 
PR), a 
category  for overall disease response of “CR or CRi with residual mediastinal disease” 
has been included in this document, which is not part of the NCCN guideline. The clinical 
significance of such a category , however, has not been demonstrated.
14.2.2.3.1 Establishing and subsequent maintenance of response with no clinical 
evidence of relapse
Following initial achievement of CR/CRi, patients will be considered to have maintained a 
clinical CR/CRi if the patient has no evidence of extramedullary  disease (by physical exam
and CNS sy mptom assessment) and circulating blas ts in peripheral blood are <1%.
In order for the best overall disease response to be categorized as CR or CRi, there must be no 
clinical evidence of relapse as assessed by peripheral blood and extramedullary disease 
assessment (physical exam and CNS symptom assessment) at a minimum of 4 weeks (28 
days) after the initial achievement of CR or CRi. Please note, if additional assessments (e.g. 
bone marrow, CSF assessment by LP, CNS imaging, CT/MRI  scans, etc.) are performed in 
the same evaluation for disease response evaluation purpose , they will also need to show 
remission status.
14.2.2.3.2 Date of overall disease response evaluation
Dates of CT/MRI scans are also considered in the same fashion as other components to 
deter mine the date of overall response for lymphoblastic ly mphoma patients.
 

Novartis Confidential Page 164
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
14.3 Appendix 3: Eligibility  based on serologic markers for hepatitis B 
infection
Test Results
HBsAg + - - - -
Anti-HBc Any + - + -
Anti-HBs Any - + + -
Eligibility Not Eligible Not Eligible Eligible Eligible Eligible
If indeterminate results are obtained, viral DNA levels should be measured to confirm 
negative viral status.
HBsAg positive: Indicates active infection and/or chronic active and potential for reactivation 
with fulminant hepatitis. These patients are not eligible for this trial.
Anti -HBs positive: Protective –Indicates vaccination or previous infection that has been 
successfull y resolved. These patients are eligible for this trial.
HBsAg negative, Anti -HBc positive, Anti -HBs negative : Indicates latent infection. These 
patients are also at risk for viral reactivation. These patients are not eligible for this trial.
 

Novartis Confidential Page 165
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
14.4 Appendix 4: CTL019 Modified Safety  Reporting
14.4.1 Adverse Event (A E) and Serious A dverse Event (S AE) Reporting
Pre-treatment period
(ICF to LD chemo/pre -infusion visit)Post -treatment Period
(Starting from LD chemo/pre -infusion visit )
Through Month 
12 Visit After Month 12 Visit, through Month 60
Non-serious 
Adverse Events 
(AE)Modified:
● All infections
● All laboratory abnormalities deem ed 
clinically significant by the investigator 
● All clinical AEs grade ≥ 3
● All AEs related to a study procedure
● All AEs leading to study discontinuationAll, including all 
laboratory 
abnormalities 
deemed clinically 
significant by the 
investigatorModi fied –Whether serious or non -serious, report following:
● Events leading to death
● Related to a study procedure
● Infections
● Serious or opportunistic infections. Defined as bacterial, viral, fungal or 
parasitic infections that fulfill one of the follow ing criteria: Require anti -infective 
treatment OR  Lead to significant disability or hospitalization OR Need surgical or 
other intervention
● New incidence or exacerbation of a pre -existing neurologic disorder
● New incidence or exacerbation of a prior rhe umatologic or other autoimmune 
disorder
● New incidence of other hematologic disorder
● Any severe adverse event or condition the investigator believes may have a 
reasonable relationship to CD19 CART therapy
● Positive RCL test result
● Vector insertion si te sequencing result with a mono-or oligoclonality pattern or 
in a location near a known human oncogene
● New malignancy (T -cell & non T -cell), other than the primary malignancy
● Progressive multifocal leucoencephalopathy ( PML)
● Hepatitis B reactivationSerious 
Adverse Events 
(SAE)Modified:
● All events leading to death
● All events related to a study procedure
● Any AE reportable for this study period 
that also meets criteria for serious
● All pulmonary or cardiac abnormalities
● All infections
● Any s ubstantial change in the status of the 
patient that precludes the patient from 
proceeding to study treatment (e.g. GVHD, 
rapid progression of malignancy, marked 
decline in performance status)
● Any other substantial change in the status 
of the patient that the investigator deems 
may have a potential impact on the patients 
during lymphodepletion and CTL019 
treatmentAll
 

Novartis Confidential Page 166
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
14.4.2 Concomitant Medication
Pre-treatment period
(ICF to LD chemo/pre -infusion visit)Post -treatment Period 
(Starting from LD chemo/pre -infusion visit, through Month 
12 )Post -treatment Period 
(After Month 12, through Month 60 )
Inpatient/ICU OR Outpatient Inpatient/ICU Outpatient Inpatient/ICU OR Outpatient
Concomitant 
medicationsModified:
Drugs:
Record allof the following medications: 
● Anticytokine therapies (e.g. tocilizumab, or other)
● Corticosteroids (including prophylactically for blood product administrations, physiologic 
replacement doses, high or stress doses, etc.)
● Anti-seizure medications 
● Allopurinol, or non -allopurinol alternatives 
● Rasburicase
● Immunoglobulin therapy
● Any medication given therapeutically for an SAE
● Vasopressors and cardiac inotropic agents (see below)
● Narcotics and sedatives (see below)
● Antineoplastic therapies (e.g. lymphodepeleting chemotherapy)
● Related to an AE or SAE defined as reportable for this period
Vasopressors and cardiac inotropic agents:
● For dose, record only maximum daily rate (e.g. ug/kg/hr, mg/hr, etc.) 
Narcotics and sedatives :
● For dose, r ecord only total daily dose 
Blood products (e.g. red cells, platelets, FFP, cry oprecipitate) :
● If administered ≤7 day s of a tumor response assessment :
● Record ALL blood products, including prophylaxis (to distinguish CR vs CRi)
● If NOT administered ≤7 days of a tumor response assessment :
● Only record blood products if given for bleeding (excludes prophylactic use)
Electroly te & vitamin replacement:
● Record all electrolyte replacement if given for a ≥ Grade 3 electrolyte disturbance and list 
these as an adverse event (AE). 
● Do notrecord  ≤ Grade 2 or prophylactic use of electrolyte or vitamin replacements
● Do not record total parenteral nutrition (TPN) on concomitant medication CRF
Fluids :
● Do notrecord fluid boluses and maintenance fluids All Modified:
● Related to an AE or SAE defined as 
reportable for this period
● Mutagenic agents (including cytotoxic 
drugs)
● Radiation & antineoplastic therapy 
(including SCT)
● Immunoglobulin therapy
● Immunosuppres ive agents (including 
dose of steroids higher than physiologic 
replacement therapy doses of steroids  
(6-12 mg/m2/day hydrocortisone or 
equivalent)
● Investigational therapy
 

Novartis Confidential Page 167
Oncology Amended Protocol Version 02 (Clean) Protocol No. C CTL019B2205J
Pre-treatment period
(ICF to LD chemo/pre -infusion visit)Post -treatment Period 
(Starting from LD chemo/pre -infusion visit, through Month 
12 )Post -treatment Period 
(After Month 12, through Month 60 )
Inpatient/ICU OR Outpatient Inpatient/ICU Outpatient Inpatient/ICU OR Outpatient
Laboratory 
dataModified:
● Record allscheduled labs (per Visit Evaluation Schedule)
● Record allresults (scheduled or unscheduled) for:  LDH, Uric acid, , and 
fibrinogen (related to CRS/TLS/MAS)
● Record all other laboratory values if they are ≥ Grade 3
● For laboratory abnormalities reportable as AE/SAE, record laboratory results that support 
the event (scheduled or unscheduled)
● For any AE/SAE that may be caused by a laboratory abnormality, the laboratory value(s) 
(any grade) must also be recorded (e.g. “muscle cramps ” potentially caused by hypokalemia)
● Laboratory abnormalities that are treated prophylactically are NOT to be recorded (e.g. 
maintenance electrolyte replacement, platelets given without clinical bleeding)All Modified:
● Record allscheduled labs (per V isit 
Evaluation Schedule)
● Record allresults (scheduled or 
unscheduled) for:  LDH, Uric acid,  
 and fibrinogen (related to 
CRS/TLS/MAS)
● Record all other laboratory values if 
they are ≥ Grade 3
● For laboratory abnormalities reportable 
as AE/SAE, record laboratory results that 
support the event (scheduled or 
unscheduled)
● For any AE/SAE that may be 
caused by a laboratory abnormality, the 
laboratory value(s) (any grade) must also 
be recorded (e.g. “muscle cramps” 
potentially caused by hypok alemia)
● Laboratory abnormalities that are 
treated prophylactically are NOT to be 
recorded (e.g. maintenance electrolyte 
replacement, platelets given without 
clinical bleeding)
 
